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SMALL VESSEL VASCULITIS
Since the Chapel Hill consensus conference vasculitides are classifi ed according to the size 
of the involved vessels, histopathology of the lesions, and clinical fi ndings [1]. Th e primary 
vasculitides aff ecting small vessels, that is small arteries, arterioles, capillaries, and venules, 
are Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA), necrotizing crescentic 
glomerulonephritis (NCGN), and Churg-Strauss syndrome (CSS). WG is hallmarked by the 
classic triad of small-vessel vasculitis, extravascular necrotizing granulomatous infl ammation, 
and necrotizing crescentic glomerulonephritis (NCGN). In NCGN vasculitis is limited 
to the kidney, and in MPA also extra-renal vessels are aff ected, but without the typical 
granulomatous infl ammation present in WG. Finally, CSS is characterized by the classic triad 
of astma, eosinophilia and small-vessel vasculitis. As CSS is clinically diff erent from the other 
small-vessel vasculitides it is beyond the scope of this thesis.
Th e Chapel Hill criteria were developed for research purposes, and in clinical practice 
application and classifi cation can be diffi  cult. It can be particularly challenging to distinguish 
WG from MPA as granulomas are oft en hard to detect. Several additional diff erences 
between WG and MPA in presentation and disease progression have been identifi ed. Among 
others MPA oft en presents with more chronic treatment resistant kidney damage [2], whereas 
patients with WG experience more relapses during follow-up than patients with MPA (over 
50% in WG versus 30% in MPA during a follow-up of 5 year) [3].
ANTI-NEUTROPHIL CYTOPLAMIC AUTOANTIBODIES (ANCA)
Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA) and necrotizing crescentic 
glomerulonephritis (NCGN) are associated with the presence of anti-neutrophil cytoplasmic 
autoantibodies (ANCA). Th erefore, these vasculitides are also called ANCA-associated 
vasculitis (AAV). ANCA were originally detected by indirect immunofl uorescence (IIF) 
on ethanol fi xed neutrophils. Th ree diff erent patterns of fl uorescence are distinguished: a 
cytoplasmic pattern (C-ANCA), a perinuclear pattern (P-ANCA), and a more diff use 
cytoplasmic staining pattern (atypical ANCA). Th e predominant antigens of ANCA in 
AAV are the constituents of neutrophilic granules proteinase 3 (PR3) and myeloperoxidase 
(MPO). Approximately 90% of sera that produce a C-ANCA pattern by IIF react with 
PR3, whereas a P-ANCA pattern is associated with MPO in approximately 70% of patients. 
Several lines of evidence suggest a pathogenetic role for ANCA in AAV. Key evidence is 
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provided by an animal model. In this mouse model introduction of anti-MPO IgG derived 
from MPO-immunized MPO defi cient mice, into wild type or Rag2-defi cient mice induces 
pauci-immune necrotizing cresecentic glomerulonephritis [4]. Th e following theory has been 
formulated defi ning ANCA pathogenecity. Priming of neutrophils by cytokines induces 
surface expression of PR3 and MPO. Primed neutrophils can adhere to activated endothelial 
cells. Th ese primed and adherent neutrophils, showing membrane expression of PR3 and 
MPO, can be stimulated by PR3- or MPO-specifi c ANCA, leading to full activation and 
thereby degranulation and formation of reactive oxygen species (ROS) which damages the 
vessel wall [5].
In clinical practice the presence of ANCA is of important diagnostic value. PR3-ANCA 
are predominantly associated with WG, whereas MPO-ANCA are more oft en associated 
with MPA and NCGN [6]. However, also in WG MPO-ANCA can be present, and PR3-
ANCA can be associated with MPA and NCGN. 
Data confl ict regarding the diagnostic and prognostic potential of ANCA during follow-
up. However, a rise in ANCA should caution a clinician that a relapse might be looming. As 
mentioned before, patients with WG are at increased risk to experience a relapse compared 
to patients with MPA. Th us, research eff orts to identify the predictive value of ANCA rises 
during follow-up have focused on patients with WG. In a prospective observational single-
centre study in 100 patients with WG (85 PR3-ANCA, 15 MPO-ANCA) with 2-monthly 
ANCA measurement, the predictive value of an increase in ANCA-titers for relapse was 
71% for PR3-ANCA and 100% for MPO-ANCA (both by ELISA) [7]. However, in a recent 
prospective clinical trial in 156 patients with WG measuring PR3-ANCA every 3 months by 
capture ELISA, no relation was found between increases of PR3-ANCA levels and occurrence 
of relapses (adjusted hazard ratio, 0.8 (95% CI, 0.4-1.9) [8]. A diff erent approach was used 
by Slot et al who measured ANCA at a fi xed time point. Th ey reported that in patients 
with PR3-ANCA associated vasculitis a positive C-ANCA titer by IIF aft er induction of 
remission was signifi cantly associated with relapse (RR 2.6, 95% confi dence interval 1.1-
8.0; P=0.04) [9]. In chapter 3 predictive value of serial measurements of C-ANCA by IIF
and PR3-ANCA by ELISA for the occurrence of clinical relapses in PR3-ANCA associated 
vasculitis are analyzed.
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T CELLS IN AAV
Several lines of evidence support T cell involvement in AAV, including the presence of T 
cells in granuloma of WG patients and the subclass distribution of ANCA which suggests a 
T cell dependent immune-response [10]. In recent years interesting data have been generated
about diff erent CD4-positive T cell populations and their role in ANCA-associated 
vasculitis. CD4-positive T cell responses can be divided in three groups. First, Th 1 responses, 
associated with cell-mediated eff ector immune-responses and hallmarked by production of 
IFN-gamma. Th 1 responses seem to dominate in localized WG and MPA [11, 12]. Secondly, 
Th 2 cells which are associated with humoral immune-responses and distinguished by the 
production of IL-4, IL-5, IL-10, and IL-13. Th 2 markers have been suggested to dominate in 
generalized disease, suggesting a shift  towards a Th 2 response [13]. Finally, Th 17 cells which 
have been recently identifi ed and produce IL-17; these cells are thought to be especially 
important in development of auto-immunity [14]. In WG, overproduction of IL-17 in 
response to a local infectious stimulus, for instance S. Aureus, might result in priming of 
neutrophils, promotion of granuloma formation, and possibly ANCA production [15]. In
chapter 4 we evaluated whether the T cell activation markers sIL-2R, sCD30, IL-10, and 
B cell activator of the TNF family (BAFF) at diagnosis and during initial follow-up are 
predictive for persistent or renewed ANCA-positivity and clinical relapse in PR3-ANCA 
associated vasculitis.
TREATMENT OF AAV
Th e foremost important development regarding therapy in AAV has been the introduction 
of cyclophosphamide [16]. Prior to this WG was a disease with oft en fatal outcome [17, 18]. 
Aft er the introduction of cyclophosphamide, in combination with corticosteroids, attention 
shift ed to reducing treatment intensity and thereby toxicity. Th e last ten years, since the 
CYCAZAREM study, a staged approach of immunosuppressive therapy is standard [19]. 
Patients receive induction therapy with cyclophosphamide and corticosteroids, and 
aft er remission therapy is switched to less toxic immunusuppressives, ie azathioprine or 
methotrexate. By this scheme remission is achieved in over 90% of patients. In chapter 5 
and 6 we retrospectively evaluated long-term disease-free survival in patients with AAV on 
cyclophosphamide maintenance therapy as compared to azathioprine maintenance.
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Th us, nowadays ANCA-associated vasculitides have become chronic relapsing diseases. 
Apart from long-term immunosuppression, life-long intensive follow-up is warranted. 
Th e French prospective multi-center randomized open-label WEGENT study compared 
maintenance with oral azathioprine versus methotrexate and did not fi nd diff erences 
regarding safety or relapses [20]. Several risk-factors for relapse have been identifi ed in
multiple studies [21, 22], these risk-factors include PR3-ANCA and lung involvement. 
However, up till now these risk-factors have not resulted in individualization of treatment.
PATHOGENESIS OF RENAL INVOLVEMENT IN AAV
Although blood vessels in all organ systems can be aff ected, the kidney is regularly involved 
in AAV. When renal involvement is present in AAV the glomeruli will show extracapillary 
proliferation. In this process extrarenal infl ammatory and epithelial cells proliferate into 
Bowman’s space forming so-called crescents. First these crescents predominantly exist out of 
cellular components. Subsequently, during disease progression fi broblasts and macrophages 
will be attracted and start to reorganize the crescent composition into a fi brous crescent, 
leading to loss of glomerular function [23]. However, it is thought that the cellular crescent
can also recover and regain normal function [24].
It is not well known what infl uences the typical organ distribution of AAV. Probably 
an interaction between the immune system and the vessel wall, that is endothelial cells, is 
essential. Th e endothelium in the kidney stands out because of its fenestrated nature, essential 
for its role as fi lter. In a pro-infl ammatory environment the endothelial cells will express 
adhesion molecules as selectins, intracellular adhesion molecule-1, and vascular cell adhesion 
molecule-1. Activated neutrophils and monocytes will be able to adhere and transmigrate 
through the vessel wall. As mentioned before, primed neutrophils will express the ANCA-
antigens MPO and PR3 on their surface and when adhered to endothelial cells binding by 
ANCA will result in a respiratory burst as well as degranulation and release of proteolytic 
enzymes. One class of these enzymes are the matrix metalloproteinases (MMPs). 
MMPS IN VASCULITIS
Th e MMPs are a family of over 25 proteases able to degrade extracellular matrix components 
[25]. One of fi ve subgroups is the basement membrane-degrading MMPs or gelatinases 
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(MMP-2 and -9). MMP activity is tightly regulated at three diff erent levels: gene expression,
activation and inactivation. Gene expression of MMP-2 is constitutive, while MMP-
9 production is induced by infl ammatory cytokines such as IL-1 and TNF-α. MMPs are
produced as inactive pro-enzymes, and activation involves multiple steps. Four endogenous
tissue inhibitors of matrix metalloproteinases (TIMPs) are present in excess and neutralize 
the detrimental actions of MMPs [26]. Th e balance between MMPs and their inhibitors
TIMPS will determine either net degradation or production of collagens, and might thereby 
discriminate infl ammation from fi brosis.
MMPs are essential in renal homeostasis and infl ammation [27]. By degrading extracellular 
matrix MMPs facilitate infl ux of infl ammatory cells and release of pro-infl ammatory products
from the extracellular matrix. Th ereby MMPs probably have an important pathogenetic 
role in the initial phase of crescentic glomerulonephritis. In Kawasaki disease patients, 
elevated expression, activity and protein levels of MMP-9 have been detected [28]. In giant
cell arteritis, MMP-9 participates in the degradation of elastic tissue and is associated with
intimal hyperplasia, subsequent luminal narrowing, and neoangiogenesis [29]. Chapter 
7 analyzes the presence of MMPs and TIMPs in kidney biopsies of patients with AAV in 
relation to renal disease activity and damage. Consecutively, in chapter 8 urinary and serum 
levels of MMP-2 and -9 and TIMP-1 are measured and related to renal levels and disease
activity.
AIM OF THE THESIS
Th is thesis focuses on monitoring disease activity in AAV. Part one focuses on prediction
and occurrence of relapses in AAV. First, in chapter 2 we review risk factors for relapse in
AAV, their potential pathogenic implications, and their possible role in preventive strategies 
and adaptations of current treatment policies. Th en, in chapter 3 the predictive value of 
serial measurements of C- and PR3-ANCA for clinical relapses in PR3-AAV are analyzed.
In chapter 4 we evaluated whether the T cell activation markers sIL-2R, sCD30, IL-10,
and B cell activator of the TNF family (BAFF) at diagnosis and during initial follow-up are 
predictive for persistent or renewed ANCA-positivity and clinical relapse in PR3-AAV. In 
chapter 5 and 6 we retrospectively evaluated long-term disease-free survival in patients with
AAV on cyclophosphamide maintenance therapy as compared to azathioprine maintenance.
Th en in part two of the thesis focus is on renal production of MMPs and TIMPs in AAV.
Chapter 7 analyzes the presence of MMPs and TIMPs in kidney biopsies of patients with
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AAV in relation to renal disease activity and damage. Consecutively, in chapter 8 urinary 
and serum levels of MMP-2 and -9 and TIMP-1 are measured and related to renal levels and 
disease activity. Finally, in chapter 9 the results of our studies are summarized and put into 
perspective.
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ABSTRACT
Current treatment based on the use of cyclophosphamide and corticosteroids has changed
anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides from highly fatal
into more chronic relapsing diseases. Relapses are a major problem in these diseases and cause
increased morbidity and mortality. Current clinical research mainly focuses on achieving 
control of active disease while minimizing treatment related toxicity. Risks for long-term
relapse and their sequelae are less clearly studied. It is noteworthy that, besides treatment, 
several other factors have been associated with the occurrence of relapses. Th us, compared 
to MPO-ANCA positive patients, patients with PR3-ANCA associated vasculitis have a 
signifi cantly increased risk to experience relapse. In addition, ANCA-status during follow-
up, levels of T cell activation, genetic background, and infectious and other exogenous factors
have been linked to relapse as well. With a few exceptions, these associations are merely 
descriptive and not pathophysiologically proven. Furthermore, data on adapting treatment
in accordance with risk factors for relapse are scarce. We review risk factors for relapse in
ANCA-associated vasculitis, their potential pathogenic implications, and their possible role 
in preventive strategies and adaptations of current treatment policies.
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INTRODUCTION
Th e antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are 
a group of primary vasculitides aff ecting small to medium-sized vessels and associated 
with autoantibodies against neutrophilic proteases, in particular proteinase 3 (PR3) and 
myeloperoxidase (MPO). In Wegener’s granulomatosis (WG) ANCA are mostly directed 
against PR3, whereas a large number of patients with microscopic polyangiitis (MPA), 
idiopathic necrotizing crescentic glomerulonephritis (iNCGN) and Churg-Strauss 
syndrome (CSS) are MPO-ANCA positive [1]. Th e introduction of cyclophosphamide and
prednisolone has dramatically improved patient-outcome, and, currently, most patients with 
AAV can be brought into remission [2-4]. However, when immunosuppression is tapered 
and eventually stopped, relapses frequently occur [3]. Long-term follow-up of patients with 
WG showed a relapse rate of 50% or more within 5 years aft er diagnosis, and active disease 
during relapses was the main cause of mortality beyond the fi rst year [3, 5-7]. Additionally, 
the number of relapses that had occurred was a strong predictor of damage during follow-up, 
as measured by the Vasculitis Damage Index [7]. Also for long-term renal survival in PR3-
ANCA-associated vasculitis, the number of renal relapses is the primary determinant [8]. 
Relapses in ANCA-associated vasculitis constitute a clinically relevant problem. Th ere-
fore, a major challenge in current long-term treatment is the identifi cation of patients at 
increased risk for relapse and the prevention of these relapses with minimal treatment related 
toxicity. Additionally, risk factors associated with the occurrence of relapses can provide 
insight into the pathogenic mechanisms underlying disease reactivation, and might lead to 
new, more individualized, risk-adapted treatment strategies. We will discuss the risk factors 
for relapse of disease and the potential preventive strategies identifi ed thus far. 
Treatment
Standard treatment for AAV consists of a combination of cyclophosphamide and 
prednisolone and is eff ective in inducing remission in the majority of patients. However, 
treatment related toxicity, both short- and long-term, occurs frequently, and relapses are 
encountered in many patients. In a meta-analysis of three randomized controlled trials 
continuous cyclophosphamide appeared to result in a lower relapse rate as compared to 
pulse cyclophosphamide, although the diff erence was not statistically signifi cant (RR 1.79; 
95% CI 0.85-3.75) [9]. In these trials patients on continuous treatment received signifi cantly 
higher cumulative dosages of cyclophosphamide than patients on pulse treatment. Recently, 
Koldingsnes et al showed that a cumulative dosage of less than 10 g cyclophosphamide 
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during the fi rst 6 months was associated with more relapses in patients with Wegener’s 
granulomatosis (WG) (RR 2.83, 95% CI 1.33-6.02) [7]. However, higher cumulative doses 
of cyclophosphamide have also been associated with more damage during follow-up, as 
measured by VDI [7].
Various alternative treatment strategies have been tested, with treatment related 
toxicity and relapse rate as primary outcome measures. Maintenance therapy with low 
dose methotrexate following remission induction with cyclophosphamide in an open-label 
prospective trial resulted in a high rate of, predominantly renal, relapses aft er a median follow-
up of 25 months (26 relapses in 71 patients) [10]. In addition, a randomised study of the 
European vasculitis study group (EUVAS) demonstrated that induction and maintenance 
therapy with cyclophosphamide therapy or methotrexate, both limited to an unusual short 
period of 12 months, resulted in a high number of relapses during 18 months follow-up [11].
However, the relapse rate was even greater in the methotrexate group as compared to the 
cyclophospamide group (70% vs. 45%, p=0.016).
Additional attempts have been made to reduce cyclophosphamide exposure by limiting 
the period of cyclophosphamide treatment to 3 months following remission. Th e European 
multicenter trial comparing cyclophosphamide to azathioprine during remission in AAV 
(CYCAZAREM) showed that aft er induction of remission with cyclophosphamide, patients
who switched to azathioprine did not experience more relapses aft er 18 months follow-
up in comparison to cyclophosphamide maintenance (disease-free survival 86.3% in the
cyclophosphamide group and 84.5% in the azathioprine group) [4]. Whether these results
persist on longer follow-up is, however, questionable. We analysed outcome aft er 5 years in 
newly treated patients at our center who were diagnosed between 1990 and 2000 and had 
been treated with cyclophosphamide only (1990-1996) or were switched to azathioprine 
following 3 months of stable remission (1997-2000). We found that, despite a relapse rate 
at 18 months that was not diff erent (disease-free survival 88.6% in the cyclophosphamide 
group and 89.6% in the azathioprine group), patients who switched to azathioprine (n=48) 
tended to have more relapses than those on cyclophosphamide maintenance (n=88) during 
long-term follow-up (RR 1.51; 95% CI 0.92-2.68, p=0.099), although this diff erence did 
not reach statistical signifi cance [12]. Relapses tended to occur especially in the third and 
fourth year of follow-up aft er immunosuppressive therapy was stopped. Th is suggests ongoing 
smouldering disease, which, upon stopping of immunosuppressive maintenance therapy, 
results in a clinically apparent relapse. Possible prevention by continued immunosuppressive 
maintenance therapy would be rational when subgroups at increased risk for relapse can be 
identifi ed during the initial period of follow-up.
Relapses in AAV | 21
Immune activation
ANCA specifi city and levels 
In WG about 85% of patients are PR3-ANCA positive, whereas patients with MPA and 
idiopathic NCGN are more frequently MPO-ANCA positive [1]. Apart from their specifi c 
clinical hallmarks, these diseases diff er in relapse rate; reported relapse rates in cohorts of 
patients with WG are 50% during a mean 8 years follow-up 3 and 44% within 3 years 6 
compared to 25-35% within 2.5 to 5 years in other ANCA-associated vasculitides [6, 1, 14]. 
Consequently, relapses are associated with ANCA specifi city and occur more frequently in 
PR3-ANCA-associated vasculitis compared to MPO-ANCA-associated vasculitis [15-20]. 
Also in our own cohort diagnosed between 1990 and 2002 PR3-ANCA positive patients 
were more likely to experience relapse than MPO-ANCA positive patients (with a relative 
relapse risk of around 3.7; 95%CI 1.6-4.1; p=0.002) (Figure 1). Th is diff erence in relapse 
rate based on ANCA specifi city seems to occur also within one disease entity. In our center 
patients with WG who were PR3-ANCA positive (n=137) experienced signifi cantly more 
relapses than the small group of WG patients with MPO-ANCA (n=13) (RR 4.4; 95% CI 
1.1-5.0) (Figure 2A) [21]. Likewise, within the group of patients with MPA and iNCGN,
those with PR3-ANCA (n=12) show a higher relapse rate as compared to those with MPO-
ANCA (n=36). Th e relative risk for relapse for PR3-ANCA positive patients as compared to 
MPO-ANCA positive patients within this group was comparable to that found in our group 
of WG patients (Figure 2B).
Many studies have been published on the usefulness of ANCA titration for prediction of 
relapses. During induction treatment, ANCA levels fall or become negative in 30% to more 
than 80% of the patients within the fi rst few months. Patients who subsequently remain 
ANCA negative during follow-up have a very low risk to develop a relapse. In contrast, 
persistence or reappearance of ANCA aft er induction of remission has been associated with 
the occurrence of relapses. A signifi cant association was found between C-ANCA positivity 
in the fi rst year aft er diagnosis and the subsequent occurrence of relapses [15-18, 22, 23], 
whereas this relation is less clear for patients positive for P-ANCA [14, 17, 18, 24]. Recently,
we showed that in patients with PR3-ANCA associated vasculitis, a positive C-ANCA-
titer at switch to azathioprine, aft er induction of stable remission by cyclophosphamide, 
was associated with an increased risk to experience relapse (RR 2.6, 95% CI 1.1-8.0), with a 
relapse-free survival of only 18% at 5 years [19].
With respect to the predictive value of ANCA rises for relapses, as measured by 
indirect immunofl uorescence (IIF) or ELISA, divergent results have been reported. Rises 
in C-ANCA titer were followed by a relapse in 57 to 82% of the patients; rises in PR3-
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Figure 1. Disease-free survival in 174 patients diagnosed with antineutrophil cytoplasmic 
antibody (ANCA)-associated vasculitis and treated with cyclophosphamide and prednisolone 
at the University Hospital Groningen from 1990 to 2002 according to ANCA specifi city. Th ere 
is a signifi cant diff erence in disease-free-survival between patients with MPO- (■) (n = 43) and
PR3-ANCA-associated vasculitis (▲) (n=131); RR 3.7 (95% CI 1.6-4.1); p=0.002.
ANCA and MPO-ANCA by ELISA were followed by relapses in 59 to 100%, and 79 to
100% of cases, respectively (reviewed in [21]). Several diffi  culties come up when interpreting 
studies on serial ANCA measurements. Many studies are retrospective and concern few 
patients, they do not standardise the interval between ANCA measurements, and do not 
defi ne a relapse. Additionally, the methodology of ANCA measurement diff ers widely. 
Using predefi ned criteria for a relapse and a standardised interval for sequential ANCA
measurement, and eliminating inter-assay variation by prospectively measuring sequential 
samples within the same assay, we found that 4-fold rises in C-ANCA titers by IIF or >75%
increase in PR3-ANCA levels as determined by direct ELISA predicted the occurrence of a 
relapse within a period of 12 months in 50% and 58% of cases, respectively [25]. Th is study 
showed rises in PR3-ANCA levels to be a slightly better predictor than rises in C-ANCA
titers (Figure 3) [25]. Attempts have been made to improve the association between changes
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Figure 2. A Disease-free survival during follow-up in patients diagnosed with Wegener’s
granulomatosis between 1990 and 2000 at the University Hospital Groningen according to 
ANCA specifi city (PR3-ANCA; n=124; ▲, and MPO-ANCA; n=13; ■). (Adapted with
permission from reference 21). B Disease-free survival during follow-up in patients diagnosed 
with microscopic polyangiitis and idiopathic necrotizing crescentic glomerulonephritis between 
1990 and 2000 at the University Hospital Groningen according to ANCA specifi city (PR3-
ANCA; n=12; ▲, and MPO-ANCA; n=36; ■).
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in ANCA-levels and vasculitic disease activity by analyzing IgG subclasses of ANCA or
specifi c functional aspects of the interaction of ANCA with their antigens, such as neutrophil 
activating capacity and interference with PR3 and MPO inhibition by α-1-antitrypsin and 
ceruloplasmin, respectively. So far, the results of these studies have been negative and analysis
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Figure 3. Percentage of patients with Wegener’s granulomatosis who did not experience disease 
relapses in the indicated time period aft er a rise in antineutrophil cytoplasmic antibodies as
measured by either indirect immunofl uorescence (IIF; n=30) or antigen-specifi c enzyme-linked 
immunosorbent assay (ELISA; n=38). Th e numbers above the horizontal axis indicate the 
number of patients who were still at risk for a relapse at 6, 12, 18, 24, and 30 months aft er the rise 
in antibody levels as detected by ELISA (upper numbers) or IIF (lower numbers). (Reprinted 
with permission from Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc., and the authors
[25]).
T cell activation and cytokines
At the moment of active disease, activation of T cells can be found in patients with AAV. 
Abundant presence of T cells in involved tissues and markers of T cell activation on
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circulating lymphocytes can be demonstrated. In addition, serum markers of T cell activity, 
notably sIL-2R (sCD25) and sCD30, are elevated in active disease and correlate with disease 
activity [26-29]. Moreover, activation of circulating T cells seems to persist during remission 
and may point to an ongoing immune stimulating process, which may predispose to renewed 
disease activity [30, 31]. Likewise, Ohlsson et al reported that low plasma levels of the 
immunosuppressive Th 2 cytokine IL-10 during remission were associated with an increased 
risk of subsequent relapse in AAV [32].
Disease activity has also been correlated with altered presence of specifi c T cell subsets. 
Both in CD4+- and CD8+ T cell subsets expansion of memory eff ector cells and reduction 
in naive T cell subpopulations have been described. Again, these alterations seem to persist 
during remission [33]. Whether individualized diff erences in these distributions may be
related to clinical disease activity is currently unresolved.
Genetic factors
Many polymorphic genetic factors, especially involving genes coding for immunologically 
functioning products, have been associated with AAV. For some of these factors hypotheses 
have been formulated regarding how they may infl uence the pathophysiology of AAV. 
However, only very few genetic factors have been found to relate to disease course and relapse.
mPR3 epression and neutrophil activation
Neutrophils store proteinase 3 (PR3) in specifi c and secretory vesicles, but PR3 is also 
constitutively present on the membrane of resting neutrophils [34, 35]. Between individuals 
the percentage of neutrophils with PR3 membrane expression diff ers from 0 to 100%, and 
also the level of expression may diff er. Th e percentage of neutrophils expressing membrane 
proteinase 3 (mPR3) within one person is stable, and probably genetically controlled [35], 
[36]. WG patients tend to have higher percentages of mPR3 expressing neutrophils compared 
to healthy individuals [34, 37]. Within patients with WG the level of mPR3 expression on 
neutrophils is associated with the incidence of relapse with a relative risk of around 0.5 for 
those with low mPR3 expression during a median 80 months follow-up [34]. In vitro data 
show that stimulation by PR3-ANCA of mPR3+ primed neutrophils results in higher degrees
of superoxide generation, and more degranulation than mPR3- primed neutrophils from
the same individual [38]. We found that stimulation of unprimed mPR3+ neutrophils with 
anti-PR3 antibodies could induce early activation, as detected by actin polymerization [39]. 
Moreover, the degree of actin polymerization upon stimulation with anti-PR3 antibodies 
correlated with the level of constitutive mPR3 expression on neutrophils. Th ese data suggest 
that the degree of mPR3 expression has functional and, possibly, pathogenic consequences.
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Fcγ Receptor polymorphisms
Fcγ receptors display genetic polymorphism, like the R/H131 polymorphism for
FcγRIIa, and the V/F158 polymorphism for FcγRIIIa. Functional consequences of these 
polymorphisms are diff erences between genotypes in ligand affi  nity and specifi city, as well 
as cell distribution [40]. Dijstelbloem et al showed that patients with WG were more prone
to experience relapses in the fi rst 5 years aft er diagnosis when they homozygously expressed 
both the R131 form of FcγRIIa and the F158 form of FcγRIIIa (n=12), both considered 
low affi  nity phenotypes, compared to all other FcγR phenotypes (n=79) (RR 3.3; 95% CI
1.6-6.8) [41]. Diff erences in affi  nity may aff ect clearance of immunecomplexes or opsonized 
micro-organisms. Otherwise, Fcγ-receptors may be involved in ANCA induced neutophil
acitvation.
HLA-DR
Only weak associations of AAV with HLA-antigens were observed, with a reduced frequency 
of HLA DR13 in patients with AAV [42, 43]. Spencer et al studied a cohort of 59 patients and 
reported an association between persistence of ANCA during follow-up and the presence of 
HLA DR2 [44]. Likewise, we recently found an increased relapse rate during follow-up in
HLA DR3 positive patients [45]. Whether these associations are primarily with class II genes 
or are due to linkage with other immunologically important polymorphisms located close to 
class II genes on chromosome 6, such as the gene encoding for TNF-α, is at present unclear 
[43].
Myeloperoxidase
Genetic polymorphisms in the promoter region of the MPO gene, which infl uence MPO 
expression, have been described. Th e MPO-463GG genotype was associated with two- to 
three-fold higher levels of MPO mRNA and protein expression than were GA/AA genotypes
in myeoloid leukemia cells [46]. In patients with MPO-ANCA-associated vasculitis the
MPO-463GG genotype was more frequently present in female, but not in male patients 
[20]. In addition, MPO-ANCA positive vasculitis patients with this GG genotype were older
at diagnosis and had a signifi cantly reduced risk to experience relapse of disease compared to
patients with GA/AA genotypes (RR 0.31; 95%CI 0.05-0.70). Th ese observations were not 
confi rmed in a recent study by Fiebeler et al, who did not fi nd diff erences in the frequencies
of MPO G-463A promoter polymorphisms between MPO-ANCA- and PR3-ANCA-
associated vasculitis patients and healthy controls [47]. Th e possible association of GA/AA 
genotypes with earlier onset of vasculitis and more frequent relapses suggests that higher 
MPO levels could somehow be protective.
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Other genetic infl uences
Polymorphisms in other immune-response genes have been studied in AAV. So far most of 
these polymorphisms have not been related to patient-outcome or relapse risk.
In the CTLA-4 gene, which is involved in T cell activation, both an (AT)n microsatellite 
and a single nucleotide polymorphism in the promoter region have been linked to WG 
[48, 49]. Regarding the IL-10 (-1082) polymorphism, a shift  towards the homozygous AA 
genotype was found in both WG and MPA [50, 51]. In vitro the IL-10 -1082AA homozygous 
genotype has been shown to correlate with low IL-10 secretion by ConA-stimulated 
peripheral blood mononuclear cells, which may be in line with the fi nding that low plasma 
levels of IL-10 during remission are associated with an increased risk of subsequent relapse 
[32, 52]. Patients with renal involvement of PR3-ANCA associated vasculitis had an increased 
risk of developing end-stage renal disease when carrying the proinfl ammatory IL-1β/IL-1Ra 
genotype characterized by high secretion of IL-1β and low secretion of its antagonist IL-1Ra 
[53].
Polymorphisms in the α-1-antitrypsin (a1-AT) gene, in particular the α1-AT PiZ allele 
which results in lower plasma concentrations of α1-AT, have been linked to AAV [54]. a1-AT 
is the natural inhibitor of the lytic activity of PR3. In a cohort of 99 patients with PR3-
ANCA associated vasculitis, the 18 PiZ-positive patients did not have a higher relapse rate 
but did have more disseminated disease and a higher risk of fatal outcome [55]. Finally, the 
PR3 gene itself shows polymorphisms, and in WG an association was demonstrated with the 
A-564G polymorphism in the PR3 promoter which aff ects a putative transcription factor 
binding site [56]. So far no functional or clinical consequences of this polymorphism have
been described.
Infection and microbiological factors
Given the fact that target antigens of ANCA are expressed and released by activated 
neutrophils and monocytes/macrophages, it is tempting to speculate on a relation between 
infection induced activation of these cells and subsequent development of disease activity in 
patients with AAV. Indeed, several cases of bacterial and other infections have been reported 
in which ANCA with specifi city for PR3 and MPO have been detected [57]. Especially in 
cases of bacterial endocarditis, in which also vasculitic symptoms may occur, fi nding of PR3-
ANCA may pose a diagnostic problem [58]. With respect to the occurrence of relapses, it has
been suggested that infections may lead to disease activity and the site of infection might even 
determine the location of active vasculitis [59]. In addition, a seasonal infl uence in disease 
onset, with a higher incidence of WG in winter months, has been described, suggesting the 
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possible infl uence of (viral) airways infection on disease activation [60]. However, other
studies, although documenting a high incidence of especially upper airways infection in WG, 
failed to provide a strong link between the occurrence of infections and relapse of active
disease in ANCA associated vasculitis [22, 61]. 
Staphylococcus aureus has been shown a frequent cause of secondary infections of the 
paranasal sinuses in patients with WG [62]. It has been shown that 60 to 70% of patients 
with WG, far exceeding the percentage seen in healthy individuals, are chronic nasal carriers
of S. aureus, which may explain the preponderance of this organism in causing infections. 
In addition, it was found that nasal carriage is a signifi cant risk factor (RR 7.2; 95%CI
1.6-31.5) for the occurrence of relapses in WG and that nasal carriage was associated with 
persistently positive C-ANCA titers during follow-up [22]. Th ese data suggest a role for 
S. aureus in disease activation in WG, although the pathophysiology of this association is
currently unclear. S. aureus has the ability to produce several immune activating proteins 
like superantigens which polyclonally stimulate T cells expressing particular Vβ patterns. 
We found, however, no clear association between T lymphocyte Vβ repertoire in patients 
with WG and the presence of particular S. aureus derived superantigens in S. aureus isolates 
from their nasal cavities [63]. We did fi nd, however, a relation between the occurrence of 
relapses in WG patients and the presence of TSST-1 superantigen in S. aureus isolates 
from the nasal cavity. For the other ANCA related vasculitic diseases associations between 
disease activity and infections or the presence of microbiological organisms are less clear. 
Cases of MPA (and WG) in association with parvovirus B19 infection have been described
[57, 64]. Likewise, cases of Churg-Strauss syndrome have been described in association with 
infestation/infection with Ascaris, Aspergillus sp., and HIV [65]. In the majority of patients
with active AAV, however, a clear precipitating event cannot be identifi ed. Finally, many 
cases have been published in which a temporal relation of vasculitic disease activity with 
vaccinations have been described. As many individuals receive vaccinations and large cohort 
studies or randomized trials on the eff ects of vaccination on vasculitic activity in patients
with AAV have not been performed, the role of vaccinations in precipitating disease activity 
is unclear [66, 67].
Th e potential role of infections in ANCA-associated vasculitis is supported by the fi nding 
described in case series that some patients with WG and limited disease activity can be
successfully treated with trimethoprim-sulfamethoxazole [68-70]. In addition, a prospective, 
placebo-controlled randomized trial has shown that treatment with trimethoprim-
sulfamethoxazole for 2 years in patients with WG who are in remission signifi cantly reduces 
the risk for relapse by 60% [61]. However, in another prospective study 42% of patients with
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generalized WG on co-trimoxazole maintenance relapsed aft er a median 13 months whereas 
29% of patients without co-tromoxazole relapsed aft er a median 22.5 months [70].
Whether the eff ect of trimethoprim-sulfamethoxazole is caused by its anti-microbial 
eff ects and suppression of S. aureus or by its immune modulating eff ects on infl ammatory 
cells as has been postulated based on in vitro data, is as yet unresolved [71]. Currently, data 
on the potential effi  cacy of other antibiotic agents in ANCA-associated vasculitis are not 
available.
Can treatment in ANCA-associated vasculitis be adapted to risk factors for relapse?
Th e morbidity and mortality associated with relapses combined with treatment related toxicity 
ask for prevention. Although their pathophysiological role is not always well understood, 
the identifi cation of several risk factors has made tailored intervention strategies feasible. 
First and foremost, patients with PR3-ANCA associated vasculitis have a more than 3-fold 
higher risk for relapse within 5 years following diagnosis than patients with MPO-ANCA-
associated vasculitis, an eff ect which seems to be independent from the specifi c diagnosis. 
Th e lower absolute risk for relapse in MPO-ANCA-associated vasculitis makes it probable 
that prolonged maintenance treatment in this group will not be eff ective, unless other 
specifi c risk factors with high predictive value can be identifi ed. In PR3-ANCA-associated 
vasculitis, patients who remain or again become C-ANCA positive during induction of 
remission have an increased relapse risk, which could indicate that these patients may benefi t 
from prolonged immunosuppressive maintenance therapy. However, the toxicity of long-
term immunosuppression could outweigh the benefi t of a potential reduction of relapses. We 
are currently evaluating in a randomized study whether long-term azathioprine maintenance 
treatment in PR3-ANCA positive patients who remain C-ANCA positive aft er induction 
of remission by cyclophosphamide for 3 months, indeed reduces the occurrence of relapse. 
Th is study will provide data that can demonstrate whether pre-emptive treatment with toxic 
agents is eff ective in this subgroup of patients with PR3-ANCA-associated vasculitis who 
have an increased risk to experience a relapse during long-term follow-up, and does not lead 
to increased toxicity.
Studies that evaluate soluble or cellular markers of immune activation at several points in 
time for their predictive value have to be performed in order to see whether they can improve 
the identifi cation of high and low risk groups additive to the predictive role of ANCA. 
Finally, patients who have previously experienced a relapse apparently have a relapse prone 
phenotype and may be in need for adapted treatment when disease activity occurs. Solid data 
supporting this view are, however, lacking.
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Several genetic factors, i.e. constitutive membrane PR3 expression, Fcγ Receptor-, HLA 
DR antigen- and MPO-polymorphisms, have been identifi ed as risk factors associated with
relapse. So far, the applicability of these factors in individual treatment strategies appears 
limited and data on treatment adaptations based on these factors are absent. Moreover,
suffi  ciently large size studies evaluating multiple polymorphisms and their interaction with 
relapses have not been undertaken. Exogenous factors, particularly chronic nasal carriage of 
S. aureus, have been identifi ed as a risk factor for relapses in WG. Since an association is by 
no means equivalent to a causative role, it still remains to be proven that eradication of S. 
aureus (if possible) will lead to a reduction in relapses. Whether or not caused by an eff ect on 
S. aureus, trimethoprim-sulfamethoxazole has been proven eff ective in preventing relapses in 
WG and maintenance therapy in patients with WG should be considered.
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ABSTRACT
Objective:We performed a retrospective evaluation of whether C-ANCA titers (indirect 
immunofl uorescence) and PR3-ANCA levels (ELISA) at diagnosis and following 
immunosuppressive treatment are predictive for relapse of ANCA-associated vasculitis. 
Methods: Patients diagnosed with PR3-ANCA associated vasculitis between 1991 and 2002,
with at least 2 years of follow-up, and treated with cyclophosphamide only (1991-1996) or 
switched to azathioprine aft er induction of remission with cyclophosphamide (1997-2002) 
were included in this retrospective study. ANCA were assessed by IIF and direct PR3-specifi c
ELISA at diagnosis, and at 3, 6, 12, 18, and 24 months aft er diagnosis. Actuarial relapse-free
survival was analysed by logrank test.
Results: We studied 87 patients positive for PR3-ANCA: 46 on cyclophosphamide
maintenance, 41 switched to azathioprine. Overall actuarial relapse-free survival was 72%
at 2 years and 34% at 5 years. Survival did not diff er between patients on cyclophosphamide
maintenance and patients switched to azathioprine maintenance (p=0.34). Patients who
became and stayed negative for C-ANCA (IIF) or PR3-ANCA (ELISA) until 24 months 
aft er diagnosis had a lower risk to experience relapse (p=0.01 and p=0.02, respectively).
Positive C-ANCA (IIF) titers at 3 (RR 2.0; 95% CI 1.2-3.8), 12 (RR 1.9; 95% CI 1.1-3.3), 
18 (RR 2.9; 95%CI 1.3-4.6), and 24 months (RR 2.6; 95% CI 1.2-5.0) were signifi cantly 
associated with relapse within 5 years aft er diagnosis. Also, PR3-ANCA levels >10 U/ml 
at 18 (RR 2.7, 95% CI 1.1-4.3) and 24 months (RR 4.6; 95% CI 1.2-6.3) were predictive 
for relapse within 5 years. In the azathioprine group a positive C-ANCA titer at switch to 
azathioprine (RR 2.2; 95% CI 1.0-5.4) was associated with relapse. 
Conclusion: Positive C-ANCA (IIF) and PR3-ANCA (ELISA) titers during early follow-up 
identify patients at increased risk for relapse.
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INTRODUCTION
Small vessel vasculitides predominantly aff ecting the respiratory tract and kidneys and 
associated with the presence of antineutrophil cytoplasmic autoantibodies (ANCA) can 
nowadays successfully be treated resulting in a 10-year survival of 60-90% [1-3]. Following 
induction of remission by immunosuppressive treatment a substantial number of patients 
experience relapses of disease, however. Relapses are associated with considerable morbidity 
and mortality. Th erefore, identifi cation of subgroups of patients with ANCA-associated 
vasculitis at increased risk of relapse and the subsequent adjustment of treatment are of major 
importance. 
ANCA-specifi city is an apparent risk factor for relapse, as anti-proteinase 3-ANCA (PR3-
ANCA)-positive patients are more prone to experience relapse than anti-myeloperoxidase-
ANCA (MPO-ANCA)-positive patients, with a relative relapse risk of around 3.7 [4, 5]. 
Traditionally, ANCA are detected by indirect immunofl uorescence (IIF) on ethanol 
fi xed granulocytes. A cytoplasmic-ANCA (C-ANCA) staining pattern by IIF is strongly 
associated with antibodies against PR3. Recently, we showed that a positive C-ANCA-titer 
in patients with PR3-ANCA associated vasculitis at the time of switch to azathioprine, aft er 
induction of stable remission for at least 3 months by cyclophosphamide, is associated with an 
increased risk for relapse [6]. As many relapses occur during tapering or shortly aft er stopping 
therapy, we hypothesize that persistent or reappearing ANCA titers following induction 
of remission and during tapering of immunosuppressive therapy may identify a subgroup 
of patients at increased risk for relapse. In order to test this hypothesis, we retrospectively 
analyzed serial C-ANCA titers (IIF) and PR3-ANCA levels (ELISA) until 24 months aft er 
diagnosis in patients with PR3-ANCA-associated vasculitis in relation to the occurrence 
of relapses during long-term follow-up. Th e results show that positive ANCA-tests during 
follow-up identify patients at increased risk for relapse.
PATIENTS AND METHODS
Patients and treatment
Eighty-seven patients diagnosed with PR3-ANCA-associated vasculitis who received 
induction treatment with cyclophosphamide and were followed for at least two years, were 
included in this retrospective study. Charts were reviewed from all patients diagnosed with 
PR3-ANCA associated vasculitis between January 1991 and March 2002. During this period 
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122 patients were newly diagnosed with PR3-ANCA-associated vasculitis at our center. 35 
patients could not be included: 18 patients with less than 2 years of follow-up (10 died, 8 were 
transferred to another center), 16 patients receiving a diff erent treatment regimen, and one 
patient because of missing samples. Charts of the included patients were reviewed for relapse 
up to 5 years aft er diagnosis (n=65) and for those diagnosed aft er March 1999 up to March 
2004 (n=22). Out of 87 patients, 68 had histologically proven granulomatous disease and 
consequently fulfi lled the Chapel Hill consensus criteria for Wegener’s granulomatosis. Of 
the other 19 patients, three were classifi ed as having necrotizing crescentic glomerulonephritis 
and 16 as having microscopic polyangiitis.
Induction treatment consisted of oral cyclophosphamide (2 mg/kg) and prednisolone 
(1 mg/kg; maximum dose 60 mg) daily. Doses of cyclophosphamide were adjusted to maintain
the white blood cell count above 4 x 109/l. Aft er 4 to 6 weeks, the daily prednisolone dose was 
tapered by 10 mg every 2 weeks until the dose reached 30 mg, and thereaft er by 5 mg every 2 
to 4 weeks. Once remission was achieved the daily dose of oral cyclophosphamide was tapered 
by 25 mg every 3 months. Patients were seen and evaluated for signs and symptoms of active 
disease at our outpatient clinic at least once a month during the fi rst year and once every three 
months thereaft er. From 1997 on, patients were increasingly switched to azathioprine (1.5-
2 mg/kg daily), following three months of stable remission, with tapering of azathioprine 
by 25 mg every 3 months. Cumulative dosages of cyclophosphamide, corticosteroids and 
azathioprine were calculated and corrected for weight. Additionally, cumulative dosages of 
cyclophosphamide at 3, 6, and 12 months aft er diagnosis were calculated.
At diagnosis, at 3, 6, 12, 18, and 24 months, and at relapse, serum ANCA titers were 
determined by indirect immunofl uorescence and EDTA-plasma was collected for testing 
ANCA levels by direct PR3-ANCA ELISA. Plasma samples were spun at 3000 rpm for 10
minutes, and supernatants were stored at -80°C until use. At all time points, disease activity 
was scored using the Birmingham Vasculitis Activity Score (BVAS) [7].
Defi nitions
Remission was defi ned as the absence of clinical signs and symptoms of active vasculitis
(BVAS=0) in combination with a normal C-reactive protein level (<3 mg/l). A relapse
was defi ned as clinical signs of vasculitic activity in combination with biopsy proven active 
vasculitis, or the occurrence of nodular pulmonary lesions aft er exclusion of infectious 
or malignant diseases. Renal vasculitic disease was defi ned as biopsy proven necrotizing 
glomerulonephritis or a combination of microscopic glomerular erythrocyturia, erythrocyte
cell casts, proteinuria, and a decrease in creatinine clearance [8].
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Detection of C-ANCA by IIF 
C-ANCA titers during follow-up were collected from the patient records. C-ANCA had 
been detected by indirect immunofl uorescence (IIF) as described previously [9]. ANCA 
titers had been analysed by serial dilution of sera starting at 1:20. When a cytoplamic staining 
pattern (C-ANCA) was present in at least a 1:40 dilution, sera were considered positive for 
C-ANCA. A perinuclear or atypical staining pattern was considered negative for C-ANCA.
Detection of PR3-ANCA 
In all patients, the presence of PR3-ANCA at diagnosis was confi rmed by antigen specifi c 
capture enzyme-linked immunosorbent assay (ELISA) [10]. PR3-ANCA levels in all stored 
plasma samples were quantitatively assessed by direct PR3-ANCA ELISA, as described 
previously with minor modifi cations [11]. Plasma samples from individual patients were
tested within one assay to prevent inter-assay variation. In short, Nunc Maxisorp 96-well 
microtiter plates were coated at 37°C for 1.5 hours with PR3 (1 μg/ml) in coating buff er 
(0.1 M sodium carbonate, pH 9.6) which was inactivated by 5 mM phenylmethylsulfonyl 
fl uoride. Blocking buff er (0.1 M Tris HCl, 0.3 M NaCl, 1% bovine serum albumin (BSA)) 
was subsequently added and left  for 1 hour. Plasma samples were diluted in incubation buff er 
(0.1 M Tris HCl, 0.3 M NaCl, 1% BSA, 0.05% Tween 20 (Sigma)) and subsequently applied 
at a dilution of 1:100 and 1:300. A standard curve was made using a reference plasma sample 
that was included in each test. Values were expressed as arbitrary units/ml. Values of ≥10 
units/ml (mean + 3 SD of 65 normal controls) were considered positive.
Statistical analysis
For comparison of paired data the Wilcoxon signed rank test was used, for unpaired data the 
Mann-Whitney U-test was used. Proportions between groups were compared with the χ2
test. For multiple comparisons the Kruskal-Wallis analysis of variance was used, followed by 
Dunn’s test to determine diff erences between groups. Correlation coeffi  cients were calculated 
by Spearman’s test. Relapse-free survival curves were calculated using Kaplan-Meier estimates 
for survival distribution. Diff erences in actuarial relapse-free survival between groups were 
analysed by log rank test with relapse free survival as dependent variable. Th e endpoint for 
survival analysis was the occurrence of relapse. Patients without relapse were censored at fi ve 
years aft er diagnosis, March 2004 or at death, whichever came fi rst. Positive and negative 
predictive values of ANCA-positivity to experience relapse were calculated. Analyses were 
performed with GraphPad Prism version 3.00 (GraphPad Soft ware Inc., San Diego, CA). A 
two-sided p-value <0.05 was considered to indicate statistical signifi cance.
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RESULTS
Clinical characteristics
In Table 1 clinical characteristics at diagnosis are given for the included patients. Apart from
age (median age in the group on cyclophosphamide maintenance 58 years versus 47 years 
in the group on azathioprine maintenance, p=0.003), there were no signifi cant diff erences 
in clinical characteristics at diagnosis between patients receiving cyclophosphamide
maintenance treatment and patients switched to azathioprine maintenance. Patients
on cyclophosphamide maintenance received a mean dosage of 0.46 ± 0.21 gram/kg 
cyclophosphamide during 16 ± 6 months; patients in the azathioprine group fi rst received
a mean dosage of 0.23 ± 0.13 gram/kg cyclophosphamide during 6±4 months, and
subsequently 0.51 ± 0.32 gram/kg azathioprine during 14 ± 9 months. 
Table 1. Clinical characteristics at diagnosis
All patients (n=87)
At diagnosis
male/female (n (%)) 55 (63%)/32 (37%)
age (years)# 55 (14-80)
C-ANCA titer (IIF)# 1:320
CRP (mg/l)* 126.3 ± 96.7
Creatinine (μmol/l)# 117 (40-918)
BVAS# 25 (7-48)
Organ Involvement
Ear, nose and throat: n (%) 77 (89%)
Lung: n (%) 46 (53%)
Kidney: n (%) 67 (77%)
* mean ± SD, # median (range)
In total, 52 patients (60%) experienced one or more relapses of disease within 60 
months; 26 patients (63%) in the group switched to azathioprine (n=41) and 26 patients 
(57%) in the cyclophosphamide group (n=46). Clinical characteristics at the time of relapse 
are shown in table 2. Clinical characteristics at relapse did not diff er between patients 
on cyclophosphamide maintenance and patients switched to azathioprine maintenance 
treatment. Four patients died within 5 years of follow-up, all aft er having reached stable 
remission, and experienced one or more relapses of disease. None of these patients died due 
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to disease exacerbation. Overall actuarial relapse free survival was 72% at 24 months and 
34% at 60 months aft er diagnosis. Relapse-free survival did not diff er between patients on 
cyclophosphamide maintenance and those switched to azathioprine (relative risk (RR) 1.4; 
95% confi dence interval (CI) 0.8-2.0, p=0.34).
Table 2. Clinical Characteristics at relapse
Patients experiencing relapse (n=52)
At relapse
C-ANCA titer (IIF)# 1:320
CRP (mg/l)* 50.8 ± 53.0
Creatinine (μmol/l)# 118 (71-1243)
BVAS# 12.5 (3-24)
Organ Involvement
Ear, nose and throat: n (%) 34 (65%)
Lung: n (%)  5 (10%)
Kidney: n (%) 33 (63%)
* mean ± SD, # median (range) 
Relapse-free survival did also not diff er between patients diagnosed as having Wegener’s 
granulomatosis (n=68) and those diagnosed as having microscopic polyangiitis (n=16). 
Clinical characteristics at diagnosis did not diff er between patients experiencing a relapse 
(n=52) and those not experiencing a relapse (n=35). 
Serial C-ANCA measurement by IIF
At diagnosis, all but 5 patients were positive for C-ANCA. Th ese 5 patients showed either a 
perinuclear (n=1) or an atypical staining pattern (n=4). All patients included were positive for 
PR3-ANCA by capture ELISA. C-ANCA titers at diagnosis and at relapse were signifi cantly 
higher than at 3, 6, 12, 18, and 24 months aft er diagnosis (p<0.001). Sixty-nine out of the 87 
included patients became at least once negative for C-ANCA during follow-up whereas 18 
patients were persistently positive for C-ANCA. At 3 months, 51 patients (59%) were already 
negative for C-ANCA increasing to 57 patients (66%) at six months aft er diagnosis (Figure 
1). Only 16 out of the 57 patients (28%) who were negative for C-ANCA at 6 months aft er 
diagnosis, stayed negative for C-ANCA until 24 months aft er diagnosis. At 12, 18, and 24 
months aft er diagnosis an increasing number of patients became again positive for C-ANCA 
(Figure 1), and C-ANCA titers at these time points were signifi cantly higher than at 3 and 
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6 months aft er diagnosis (C-ANCA titers at 12 months versus 3 months, p = 0.024; at all
other time points, p < 0.001). Patients switched to azathioprine did not diff er from those on 
cyclophosphamide maintenance treatment with respect to being positive for C-ANCA at
any time point. In addition, we found no correlation between cumulative cyclophosphamide
dosages at 3, 6 and 12 months aft er diagnosis on the one hand and ANCA-titers, changes in 
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Figure 1. Percentage of patients who were positive for C-ANCA by IIF (≥1:40) (solid squares) 
or positive for PR3-ANCA by direct ELISA (≥10 U/ml) (grey squares) at diagnosis (d) and
during follow-up 3, 6, 12, 18 and 24 months aft er diagnosis. At diagnosis all patients (n=87) were
positive by capture PR3-ANCA ELISA. Patients who experienced a relapse (n=24) during 24
months follow-up withdrew from the study group.
C-ANCA titers and risk of relapse
Compared to patients who stayed positive for C-ANCA from 6 months aft er diagnosis
onwards (n=22) or became positive for C-ANCA again within 24 months (n=41), the 16
patients who were negative for C-ANCA at 6 months aft er diagnosis and stayed negative
for C-ANCA had a signifi cantly reduced risk for relapse (p=0.012) (Figure 2). Only four
of these 16 patients (25%) experienced a relapse within 60 months aft er diagnosis. In 
contrast, 14 out of the 22 patients (64%) who were positive for C-ANCA from 6 months
aft er diagnosis onwards, experienced a relapse during follow-up (median time to relapse,
20 months). Twenty-nine out of the 41 (71%) patients who were negative for C-ANCA
6 months aft er diagnosis and became positive for C-ANCA during follow-up, experienced
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a relapse (median time to relapse:, 28 months). Th e time point of becoming positive for 
C-ANCA, either at 6, 12, 18, or 24 months, did not infl uence relapse rate.
Positive C-ANCA titers 3, 12, 18, and 24 months aft er diagnosis were associated with 
a signifi cantly increased risk for relapse (Figure 3a). A positive C-ANCA titer at switch to 
azathioprine was signifi cantly associated with increased risk for relapse (RR 2.2; 95% CI 
1.0-5.6). 
Diagnosis 
6 months 57 Negative for C-ANCA 29 Positive for C-ANCA 
1 relapse 
24 months follow-up 16 negative 7 negative41 positive 22 positive
60 months follow-up 4 relapses (25%) 4 relapses (57%) 29 relapses (71%) 14 relapses (64%) 
87 patients 
Figure 2. Relapse-rate within 60 months according to C-ANCA status at 6 months aft er diagnosis 
and during 24 months follow-up in the respective groups.
PR3-ANCA
At diagnosis PR3-ANCA levels as measured by direct ELISA were less than 10 units/ml in 
9 patients. One of these patients had an atypical ANCA staining pattern by IIF; the others 
all had strong cytoplasmic staining patterns. By defi nition, all were positive by PR3-capture 
ELISA. Like C-ANCA titers, PR3-ANCA levels were signifi cantly higher at diagnosis than 
at 3, 6, and 12 months aft er diagnosis. In total, 52 patients became negative for PR3-ANCA 
at some moment during 24 months of follow-up. At 3 months aft er diagnosis, 38 patients 
were negative for PR3-ANCA, and at 6 months aft er diagnosis 42 patients were negative for 
PR3-ANCA (Figure 1). An increasing number of patients was positive for PR3-ANCA at 
12, 18, and 24 months aft er diagnosis (Figure 1). PR3-ANCA levels were signifi cantly higher 
at these time points than 6 months aft er diagnosis (p<0.001). Cumulative cyclophosphamide 
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dosages 3, 6, and 12 months aft er diagnosis did not correlate with PR3-ANCA-titers and 
changes in titers. 
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Figure 3. (A) Relative risk of relapse of patients positive for C-ANCA at 3, 6, 12, 18, and 24 
months aft er diagnosis compared with patients negative for C-ANCA at these time points. (B) 
Relative risk of relapse of patients positive for PR3-ANCA at 3, 6, 12, 18, and 24 months as
compared with patients negative for PR3-ANCA at these time points. Lines indicate relative risk 
and 95% confi dence interval. Relative risk (95% confi dence interval). P, p-value; PPV, positive
predictive value; NPV, negative predictive value.
PR3-ANCA levels and risk of relapse
Patients who were negative for PR3-ANCA 6 months aft er diagnosis and stayed negative
for PR3-ANCA until 24 months aft er diagnosis (n=7) did not experience a relapse during 
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follow-up (p=0.021 compared with the remaining patients). Twenty-one of the 35 patients 
(60%) who stayed positive for PR3-ANCA during 24 months of follow-up, experienced a 
relapse compared to 32 (71%) of 45 patients who became positive for PR3-ANCA again 
within 24 months (p=0.38).
Patients who became positive for PR3-ANCA again 6 or 12 months aft er diagnosis 
(n=27) relapsed earlier (median time to relapse 27 months) than patients who became 
positive for PR3-ANCA at 18 or 24 months aft er diagnosis (n=18; median time to relapse 
40 months) (p=0.020).
At 3, 6, and 12 months aft er diagnosis PR3-ANCA positive patients did not have a 
signifi cantly increased risk to experience a relapse (Figure 3b). However, patients positive for 
PR3-ANCA 18 months and 24 months aft er diagnosis had a signifi cantly increased risk to 
experience relapse (Figure 3b).
DISCUSSION
Most patients with ANCA-asssociated vasculitis can be brought into remission with current 
immunosuppressive induction therapy. Following induction of remission immunosuppressive 
therapy is tapered with reductions in corticosteroid and cyclophosphamide dose, or 
cyclophosphamide is switched to azathioprine to reduce treatment related toxicity. Th is 
latter approach leads to rates of relapse-free survival during short and medium-term follow-
up of more than 85% at 18 months [12]. With longer follow-up, however, disease relapses
are frequent and occur in 50% or more of patients at least once within 5 years, especially 
in patients with ANCA with specifi city for proteinase 3 [2, 12, 13]. Th e data of the current 
study indicate that the course of C-ANCA- (IIF) and PR3-ANCA titers during follow-up 
contributes to identify patients at increased risk for relapse.
In our group of 87 patients with PR3-ANCA-associated vasculitis 48% became negative 
for PR3-ANCA and 66% negative for C-ANCA (IIF) within 6 months following start of 
treatment. In particular, the limited number of patients who were C-ANCA/PR3-ANCA 
negative at 18 and 24 months aft er diagnosis had a strongly reduced risk to experience 
relapse. Apparently, immunosuppressive therapy can be tapered safely in these patients. 
However, other studies with a limited follow-up and including both PR3- and MPO-
ANCA positive patients have also found a positive relation between disappearance of 
C-ANCA during the fi rst year aft er diagnosis and subsequent relapse-free survival [4, 14-17]. 
In our study, the majority of patients who initially became negative for C-ANCA and/or 
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PR3-ANCA, gradually became ANCA positive during the second year of follow-up when 
immunosuppressive therapy was tapered and stopped. Seventy-three per cent of patients 
from this latter group relapsed within 60 months, comparable to the group of patients who
were persistently positive for C-ANCA or PR3-ANCA. In addition, patients who became
positive for PR3-ANCA again within the fi rst year aft er diagnosis had a signifi cantly shorter
time to relapse than patients who became positive for PR3-ANCA at a later time point 
during follow-up.
It is not clear how ANCA infl uence the risk of relapse. Changes in levels of ANCA are 
frequently but not always related to the disease course. Binding of ANCA to their respective
surface antigens on primed leukocytes in vitro leads to activation and degranulation of these 
cells, and subsequent vascular damage. Th ese data imply that qualitative diff erences between 
ANCA such as epitope specifi city and immunoglobulin (sub)class characteristics, are also 
relevant. Th is might explain divergence between quantitative ANCA titers and clinical
outcome. However, patients who remain positive for C-ANCA might also have an ongoing 
smouldering immune activation. Th e latter hypothesis requires further investigation and
might be addressed by serially studying markers of immune activation, ANCA titers and
clinical status.
As most relapses occur during tapering or shortly aft er stopping immunosuppression, 
extension of treatment in high-risk patients might prevent relapses [17]. Unfortunately, in 
some patients the time interval between becoming positive for C-ANCA and the occurrence
of relapse was rather long, making it diffi  cult to individualize treatment. Long-term
immunosuppression is currently tested in an EUVAS study in which long-term (4 years) low-
dose immunosuppressive therapy is compared with standard treatment with azathioprine
maintenance for 18 months [18]. Although this study specifi cally aims at patients in whom
an additional renal relapse would severely threaten renal survival and does not incorporate
ANCA status, its outcome might indicate to what extent this strategy can be extrapolated
to other subgroups. Obviously, the adverse eff ects of extended immunosuppressive therapy 
should outweigh the damage due to increased relapse rate.
As our study is retrospective and we studied relapse risks in patients on sequential 
treatment regimens, a prospective study is needed to confi rm our data. Ideally, such a study 
should be combined with a clinical trial, stratifying treatment-groups according to C-ANCA
status. 
In conclusion, ANCA positivity at several time points during early follow-up identifi es 
patients with PR3-ANCA-associated vasculitis at increased risk of experiencing relapse.
ANCA-guided adjustment of immunosuppressive regimens may lead to a reduction in
relapses and should be explored in prospective, randomized, controlled trials.
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ABSTRACT
Objective: To evaluate whether T cell activation as refl ected by levels of sIL-2R, sCD30, IL-
10 and B cell activator of the TNF family (BAFF) at diagnosis and during initial follow-up
is predictive for persistent or renewed ANCA-positivity and clinical relapse in PR3-ANCA-
associated vasculitis.
Methods: Patients with PR3-ANCA associated vasculitis and at least 2 years of follow-up
were included (n=87). C-ANCA titers were detected by IIF; PR3-ANCA, sIL-2R, sCD30,
IL-10, and BAFF were assessed by ELISA, at diagnosis, and at 3, 6, 12, 18, and 24 months
aft er diagnosis. Healthy volunteers (n=31) provided plasma samples for comparison. Levels
of immune markers were related to ANCA-positivity and relapse during follow-up
Results: Plasma levels of sIL-2R, sCD30, and BAFF were higher in patients than in healthy 
controls at all time points. Plasma levels of sIL-2R, sCD30 and IL-10 were higher at
diagnosis and relapse than during remission. At 18 months, sCD30 (p<0.001) and sIL-
2R levels (p=0.01) were signifi cantly higher in patients positive for PR3-ANCA (ELISA)
than in PR3-ANCA negative patients. At 24 months, patients who were ANCA positive by 
ELISA or IIF had signifi cantly higher sCD30 plasma levels (p = 0.02; p = 0.03) as compared
to ANCA negative patients. 
Conclusion: Increased T cell activation in patients with ANCA-associated vasculitis in 
remission during and aft er immunosuppressive treatment is associated with persistent or
renewed ANCA positivity.
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INTRODUCTION
Antineutrophil cytoplasmic antibodies against myeloperoxidase (MPO-ANCA) and 
proteinase 3 (PR3-ANCA) are associated with primary vasculitides aff ecting small to 
medium sized vessels [1, 2]. With current immunosuppressive induction therapy most
patients with these diseases can be brought into stable remission. Patients positive for PR3-
ANCA, however, are particularly prone for relapse of disease during long-term follow-up 
when immunosuppressive therapy is tapered and fi nally stopped [3]. Recently, we showed 
that persistence of a positive ANCA-titer in these patients aft er induction of remission by 
cyclophosphamide, at the time treatment is switched to azathioprine, is associated with an 
increased risk for relapse [4]. 
Additionally we found positive c-ANCA and PR3-ANCA titres at 3, 12, 18 and 24 
months aft er diagnosis were also associated with relapse [5]. We concluded from these data 
that ANCA positivity refl ects smouldering immune-activation, and is, therefore, associated 
with an increased risk for disease relapse when immunosuppressive therapy is tapered and 
stopped. Serological markers of immune activation are, indeed, present in active ANCA-
associated vasculitis. Notably, serum levels of soluble IL-2 receptor (sIL-2R) and soluble 
CD30 (sCD30) are elevated during active disease refl ecting T cell activation [6-9]. Th ey 
have been proposed as markers of disease activity. Moreover, not only in active disease but 
also during remission activated T cells can be present [10]. Recently, Ohlsson et al reported 
that the presence of low plasma levels of the immunosuppressive Th 2 cytokine IL-10 during 
remission is associated with an increased risk of subsequent relapse in ANCA-associated 
vasculitis [11]. In addition to activated T cells, patients with active ANCA-associated
vasculitis have been shown to have increased numbers of activated B cells. In other 
autoimmune diseases elevated plasma levels of the polyclonal B cell stimulator BAFF (B cell 
activating factor of the TNF family) have been related to B cell activation [12-14]. BAFF
stimulates B cells promoting their survival and BAFF itself might be produced by activated 
T cells. As BAFF is produced by activated T cells it might link activated T cells to B cell 
activation. We hypothesize that patients with PR3-ANCA-associated vasculitis who remain 
positive for ANCA aft er induction of remission, might have ongoing smouldering immune-
activation with an associated increased risk for relapse. In this study, we measured serial levels 
of the immune-markers sIL2R, sCD30, IL-10 and BAFF in patients with PR3-ANCA-
associated vasculitis up to 24 months aft er diagnosis. We assessed their association with 
ANCA-status, disease activity, and relapse rate during long-term follow-up. We observed 
that patients positive for ANCA during remission had persisting increased T cell activation 
aft er tapering of immunosuppressives. 
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PATIENTS AND METHODS
Patients and ANCA assessment 
Eighty-seven patients diagnosed with PR3-ANCA-associated vasculitis at our center
between January 1991 and March 2002 and being followed for at least 2 years, were included
in this retrospective study. Data of the patients are given in table 1. Patients were followed
until March 2004. In all patients, the presence of PR3-ANCA was confi rmed by antigen 
specifi c enzyme-linked immunosorbent assay (ELISA) [1]. Induction treatment consisted of 
oral cyclophosphamide (2 mg/kg) and prednisolone (1 mg/kg; maximum dose of 60 mg/
day). Doses of cyclophosphamide were adjusted to maintain the white blood cell count above
4 x 109/L. Aft er 4 to 6 weeks, the daily prednisolone dose was tapered by 10 mg every 2 weeks 
until the dose reached 30 mg, and thereaft er by 5 mg every 2 to 4 weeks. Once remission 
was achieved the daily dose of oral cyclophosphamide was tapered by 25 mg every 3 months
during the period 1991-1996. From 1997 on, patients were switched to azathioprine (1.5-
2 mg/kg body weight daily) aft er three months of stable remission with tapering by 25 mg 
every 3 months.
Table 1. Patient characteristics 
All patients (n=87)
At diagnosis
male/female, n (%) 55 (63%)/32 (37%)
age (years)# 55 (14-80)
ANCA titer (IIF)# 1:320
CRP (mg/l)* 126.3 ± 96.7
Creatinine (μmol/l)* 219.4 ± 223.5
BVAS# 25 (7-48)
Organ Involvement
Ear, nose, throat: n (%) 77 (89%)
Lung: n (%) 46 (53%)
Kidney: n (%) 67 (77%)
#median (range), *mean ± SD
All patients received Pneumocystis carinii prevention with co-trimoxazole (three times 
per week 960 mg). An additional 13 patients received maintenance therapy with higher 
dosages of co-trimoxazole (960 mg twice daily). Fift een patients were treated additionally 
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with plasma exchange or methylprednisolone infusions (1000 mg on 3 consecutive days) due 
to the clinical severity of their disease. 
At diagnosis, during follow-up and at relapse, disease activity was scored using the 
Birmingham Vasculitis Activity Score (BVAS) [15]. At diagnosis and at 3, 6, 12, 18, 24 
months aft er diagnosis, and at relapse, serum ANCA titers were determined by indirect 
immunofl uorescence (IIF) as described previously [16], and EDTA plasma was collected from 
each patient. Sera were considered positive for ANCA when a cytoplasmic staining pattern 
(C-ANCA) was present at a dilution of at least 1:40. Plasma samples were spun at 3000 rpm 
for 10 minutes, and supernatants were stored at -80°C until use. In plasma samples PR3-
ANCA levels were determined by direct PR3-ANCA ELISA as described previously [17]. 
Values were expressed as arbitrary units/ml; values of ≥10 units/ml were considered positive. 
Th irty-one sex and age matched healthy laboratory workers (13 females, 18 males; median 
age 51; range: 44-67) volunteered and provided EDTA plasma specimens for comparison.
Defi nitions
Remission was defi ned as the absence of clinical signs and symptoms of active vasculitis 
(Birmingham Vasculitis Activity Score (BVAS)=0) in combination with a normal C-reactive 
protein (<10 mg/l). A relapse was defi ned as clinical signs of vasculitic activity in combination 
with biopsy proven vasculitic disease activity, or the occurrence of nodular pulmonary lesions 
aft er exclusion of infectious or malignant diseases. Renal vasculitic disease was defi ned as 
biopsy proven necrotizing glomerulonephritis or a combination of microscopic glomerular 
erythrocyturia, erythrocyte cell casts, proteinuria, and a decrease in creatinine clearance [18].
Detection of soluble IL-2R, soluble CD30, IL-10, and BAFF 
Soluble IL-2R (R&D systems; Oxon, UK), soluble CD30 (Bender MedSystems, Vienna, 
Austria) and IL-10 (Mabtech, Strand, Sweden) were detected by commercial sandwich 
enzyme-linked immunosorbent assays (ELISAs) according to the manufacturer’s instructions. 
Lowest levels of detection of the ELISAs were 32 pg/ml for sIL-2R, 0.5 U/ml for sCD30, and 
0.5 pg/ml for IL-10. Plasma levels of BAFF were measured by a sandwich ELISA, developed 
in our laboratory, using a monoclonal antibody as capturing and a biotinylated polyclonal 
antibody as detecting antibody. In brief, 96-wells plates (Nunc, Maxisorb) were coated 
overnight at 4°C with 4 mg/ml mouse anti-human BAFF (clone 36006.211; R&D systems). 
Aft er washing, plates were blocked with 2% bovine serum albumin (BSA), 0.05% Tween 
20 in PBS for 60 minutes. Human plasma samples and recombinant BAFF were diluted in 
High Performance ELISA (HPE) buff er (Sanquin, Amsterdam, Th e Netherlands), added to 
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the plate and incubated at room temperature for one hour. Aft er washing, bound BAFF was 
detected by a one hour incubation with biotinylated goat anti-human BAFF (PeproTech, 
NJ, USA). Aft er washing, samples were incubated with 0.125 mg/ml peroxidase conjugated
streptavidin (Sanquin, Amsterdam, Th e Netherlands) for 30 minutes, and the colour
reaction was performed with tetramethylbenzidin (TMB) (Roth, Karlsruhe, Germany).
Th e colorimetric reaction was stopped by the addition of 100 ml/well 0.5 M 2 N H2SO4.
Adsorption at 450/575 nm was measured with a microplate reader. Sensitivity of this ELISA
to detect BAFF was 0.15 ng/ml. Plasma concentrations were determined by interpolation
from a standard curve.
Statistical analysis
For comparison of paired data the Wilcoxon signed rank test was used, for unpaired data 
the Mann-Whitney U test was used. For multiple comparisons the non-parametric Kruskal-
Wallis test was used, followed by Dunn’s post-test. Correlation coeffi  cients were calculated
by Spearman’s test. For calculation of relapse free survival, survival curves were calculated
using Kaplan-Meier estimates for survival distribution. Diff erences between groups in
survival were analysed with log-rank test with disease free survival as dependent variable. 
Endpoint for survival analysis was the occurrence of relapse. A two-sided p-value <0.05 was
considered statistically signifi cant.
RESULTS
Clinical characteristics
Fift y-two out of the 87 included patients (60%) experienced one or more relapses of 
disease, 26 patients (63%) in the group switched to azathioprine maintenance (n=41) and
26 patients (57%) in the group on cyclophosphamide (n=46). Clinical characteristics at
diagnosis of the included patients are given in table 1. Overall actuarial relapse free survival 
was 72% at 24 months and 34% at 60 months aft er diagnosis. Baseline characteristics and 
overall relapse free survival did not diff er between the cyclophosphamide maintenance group
and the azathioprine maintenance group. Also, clinical characteristics at diagnosis did not
diff er between patients with (n=52) and without relapse (n=35) during follow-up. Clinical
characteristics at relapse are shown in table 2.
sIL-2R, sCD30, IL-10, BAFF in PR3-AAV | 55
Table 2. Clinical Characteristics at relapse
 Patients experiencing relapse (n=52)
At relapse
C-ANCA titer (IIF)# 1:320
CRP (mg/l)* 50.8 ± 53.0
Creatinine (mmol/l)# 118 (71-1243)
BVAS# 12.5 (3-24)
Organ Involvement
Ear, nose, throat: n (%) 34 (65%)
Lung: n (%)  5 (10%)
Kidney: n (%) 33 (63%)
* mean ± SD, # median (range) 
Aft er starting immunosuppressive therapy many patients became negative for ANCA: 
at 6 months, 49% was negative for ANCA by ELISA and 69% negative for ANCA by IIF 
(Figure 1). Subsequently, an increasing number became again positive for ANCA during 
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Figure 1. ANCA-status during follow-up. Percentage of patients at risk for relapse who are 
positive for C-ANCA by IIF (≥1:40) (dark gray squares) or for PR3-ANCA by direct ELISA 
(≥10 U/ml) (light gray squares) during follow up, at 3, 6, 12, 18, and 24 months aft er diagnosis.
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Soluble IL-2R
W e measured levels of the T cell activation marker sIL-2R during follow-up in PR3-ANCA-
associated vasculitis. Plasma sIL-2R levels in patients with PR3-ANCA-associated vasculitis 
at diagnosis and during follow-up were signifi cantly higher than in healthy controls (p<0.01),
except at 6 months aft er diagnosis (Figure 2a). At diagnosis and at relapse, plasma sIL-2R 
levels correlated signifi cantly with BVAS (r=0.46, p < 0.001; r=0.40, p<0.01, respectively)
(table 3). Plasma sIL-2R levels at diagnosis were signifi cantly higher than at all time points
during follow-up (p<0.05), apart from 24 months aft er diagnosis when levels did not
signifi cantly diff er from sIL-2R levels at diagnosis (p=0.31) (Figure 2a). Levels of sIL-2R fell
aft er starting immunosuppressive therapy, but, subsequently, rose again. Accordingly, at 12,
18, and 24 months aft er diagnosis sIL-2R levels were signifi cantly higher than at 6 months 
aft er diagnosis (p=0.03; p=0.006; p=0.007, respectively). 
Soluble IL-2R levels as measured at several time points during the fi rst 24 months of 
follow-up did not diff er between patients with a relapse within 5 years aft er diagnosis and
those who did not relapse. 
We analysed whether sIL-2R levels diff ered between patients positive for ANCA and 
patients negative for ANCA during follow-up. Only at 18 months aft er diagnosis, sIL-2R 
levels were signifi cantly higher in patients positive for PR3-ANCA by ELISA as compared to
PR3-ANCA negative patients (p=0.022) (Figure 3a). At all other time-points during follow-
up, that is at 3, 6, 12, and 24 months aft er diagnosis, patients positive for ANCA did not have 
signifi cantly higher levels of sIL-2R as compared to patients negative for ANCA
Plasma levels of sIL-2R correlated signifi cantly (p<0.01) with levels of sCD30 but not 
with CRP levels at diagnosis and at all time points during follow up. 
Soluble CD30
Like sIL-2R, sCD30 is a marker of T cell activation. We evaluated sCD30 levels during 
follow-up in patients with PR3-ANCA-associated vasculitis. Plasma levels of sCD30 were
signifi cantly higher in patients with PR3-ANCA associated vasculitis, both at diagnosis and
during follow-up, than in controls (p<0.001) (Figure 2b). Soluble CD30 could be detected in
only 3 out of 31 control samples. Patients with PR3-ANCA associated vasculitis had higher
sCD30 levels at diagnosis than at all time points during follow-up (p<0.05), apart from 24
months aft er diagnosis when this diff erence was not statistically signifi cant (p=0.054). At
diagnosis, sCD30 levels correlated signifi cantly with BVAS (r=0.40, p = 0.003) (table 3). In 
contrast, sCD30 levels were not signifi cantly higher at relapse than during follow-up, and
did not correlate with BVAS (r=0.09, p= 0.56). sCD30 levels during follow-up did not diff er
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between patients with a relapse and those who did not relapse. sCD30 levels at diagnosis 
were, however, signifi cantly higher in patients who later experienced a relapse (median 56.6 
U/ml, range 9.5-310.7) compared to patients who did not relapse (median 32.0 U/ml, range 
7.4-106.0). Consequently, patients with a sCD30 level higher than median (39.3 U/ml) 
had a signifi cantly higher risk to experience relapse than patients with sCD30 levels lower 
than median (RR 3.3, 95% CI 1.1-4.6; p=0.01). Additionally, we analysed whether sCD30 
levels were associated with ANCA status. Plasma levels of sCD30 did not diff er signifi cantly 
between patients positive for C-ANCA by IIF or PR3-ANCA by ELISA and patients who 
were ANCA negative at 3, 6, and 12 months aft er diagnosis (Figure 3b). Patients who were 
positive for PR3-ANCA at 18 or 24 months had signifi cantly elevated sCD30 plasma levels 
compared to patients negative for PR3-ANCA (p<0.001; p=0.031) (Figure 3b). Patients 
who were positive for PR3-ANCA by ELISA at 18 months, already had signifi cantly higher 
sCD30 levels at 12 months aft er diagnosis (p = 0.034). At 24 months aft er diagnosis patients 
positive for C-ANCA (IIF) had signifi cantly higher sCD30 plasma levels compared to 
C-ANCA negative patients (p=0.025).
Levels of sCD30 during follow-up correlated signifi cantly with sIL-2R and CRP. At 
diagnosis and relapse sCD30 also correlated signifi cantly with sIL-2R but not with CRP.
IL-10
IL-10 is a Th 2-cytokine with immunosuppressive qualities. We studied IL-10 levels 
longitudinally, and evaluated to what extent increased levels during follow-up might protect 
against disease relapse in PR3-ANCA-associated vasculitis.
At diagnosis, patients’ IL-10 levels were signifi cantly higher than at 3 and 6 months aft er 
diagnosis (both p < 0.01). In patients with PR3-ANCA-associated vasculitis IL-10 levels 
were signifi cantly lower 6 months aft er diagnosis than in healthy controls (p<0.05) (Figure 
2c). IL-10 levels at relapse were signifi cantly higher than at all time points during follow-
up (p<0.01). Plasma IL-10 levels increased during follow-up; at 24 months aft er diagnosis, 
when immunosuppressive treatment had been stopped, IL-10 levels were signifi cantly higher 
than at 3, 6, 12 and 18 months aft er diagnosis (p<0.05) (Figure 2c).
Patients experiencing a relapse within a period of 60 months of follow-up had signifi cantly 
lower IL-10 levels at 3 months aft er diagnosis than patients who did not relapse. At 3 
months aft er diagnosis IL-10 levels higher than median (61 pg/ml) were associated with a 
signifi cantly reduced risk to experience relapse compared to IL-10 levels lower than median 
(RR 0.56, 95% CI 0.31-0.98; p=0.044).
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Figure 2. Plasma levels of sIL-2R, sCD30, IL-10, and BAFF. Box plots indicating 5-95% range
(error bars), 25-75% range (boxes), and median value (horizontal lines) of plasma levels of 
soluble IL-2R (A), soluble CD30 (B), IL-10 (C) and BAFF (D) in 87 patients with PR3-ANCA-
associated vasculitis at diagnosis (d), and during follow-up at 3, 6, 12, 18, and 24 months aft er
diagnosis for patients who had not yet experienced a relapse. In addition, levels are depicted
at relapse (r) (n=52) and in 31 healthy controls (c). * p<0.05 as compared to healthy controls 
(Kruskal Wallis, Dunn’s post-test).
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Figure 3. Plasma levels of sIL-2R, sCD30, IL-10, and BAFF in patients positive and negative for 
C-ANCA and PR3-ANCA at 18 and 24 months of follow-up. Box plots indicating 5-95% range 
(error bars), 25-75% range (boxes) and median value (horizontal lines) of plasma levels of soluble 
IL-2R (A), soluble CD30 (B), IL-10 (C), and BAFF (D) in patients positive for C-ANCA by IIF 
and PR3-ANCA by ELISA as compared to ANCA-negative patients at 18 and 24 months aft er 
diagnosis. * p<0.05 (Mann-Whitney U test).
Plasma IL-10 levels at all time points during follow-up did not diff er between patients 
who were either positive or negative for ANCA as determined by ELISA and IIF.
BAFF
Th e polyclonal B cell stimulator BAFF has been associated with autoimmunity. We measured 
plasma levels of BAFF in PR3-ANCA-associated vasculitis and assessed the relation between 
BAFF and disease-activity, as well as between BAFF and ANCA levels. 
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Table 3. Correlations between plasma levels of immune markers and disease-activity (BVAS) at
diagnosis and relapse.






* p<0.05, ** p<0.01, *** p<0.001
Plasma levels of BAFF were signifi cantly higher at all time points in patients than in 
controls (p<0.001) (Figure 2d). In patients with ANCA-associated vasculitis BAFF levels
tended to be higher at diagnosis than at 12 months aft er diagnosis (p=0.051). BAFF levels
were signifi cantly higher at 18 months than at 12 months aft er diagnosis (p=0.030) (Figure
2d). BAFF levels of patients with a relapse did not diff er signifi cantly from levels in patients
without a relapse. Plasma levels of BAFF did not diff er between patients positive and negative
for ANCA, as determined by ELISA or IIF.
DISCUSSION 
Several observations suggest T cell involvement in ANCA-associated vasculitis. Activated
T cells are present in lesions and T cell help is necessary to produce high affi  nity ANCA.
Additionally, elevated plasma levels of the T cell activation markers sIL-2R and sCD30 have
been reported in ANCA-associated vasculitis, and levels correlated with disease activity [6, 8,
9]. Both sIL-2R and sCD30 plasma levels diff ered between limited and generalized disease,
as well as between active and inactive disease [6, 8, 9]. Also in this study, sIL-2R- and sCD30
levels at diagnosis correlated with disease activity. Plasma levels of sIL-2R and sCD30 were
higher at diagnosis than during follow-up. Although immunosuppressive therapy thus
resulted in a decrease, plasma levels remained elevated as compared to healthy controls. Both
sIL-2R and sCD30 levels subsequently increased while tapering and eventually stopping 
immunosuppressive treatment, refl ecting increased T cell activity in patients in remission
that is not completely suppressed or abrogated by treatment. Th ese fi ndings are in line with
the observation that increased percentages of activated T cells are present in patients with
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AAV in remission [10]. Levels of sIL-2R and sCD30, but not of the B cell activator BAFF,
were associated with positive ANCA serology during follow-up. At 18 and at 24 months aft er 
diagnosis, both patients positive for C-ANCA (IIF) and PR3-ANCA (ELISA) had higher 
levels of sIL-2R and sCD30 than ANCA negative patients. Th erefore, ANCA-positivity 
seems part of a broader, possibly T cell driven, immune-activation present in patients with 
AAV. 
Obviously, clinical interpretation of levels of immune markers can be complicated 
by intercurrent infections. Additionally, our study is limited by its retrospective nature. 
Nevertheless, the association of T cell activation with the PR3-ANCA autoantibody 
response suggests an initiating role for T cell activation in PR3-ANCA-associated vasculitis. 
However, levels of sIL-2R and sCD30 did not diff er between patients with PR3-ANCA-
associated vasculitis who experienced a relapse and those who did not relapse during follow-
up. In contrast, Schmitt et al found that patients with WG who relapsed had signifi cantly 
higher sIL-2R levels before disease exacerbation than patients who did not relapse. [6]
As current immunosuppressive regimens are insuffi  cient to maintain long lasting 
remission in a major part of patients with PR3-ANCA-associated vasculitis, identifi cation 
of patients at risk for relapse is important. Our data suggest that the persistent presence of 
elevated levels of markers for T cell activation, although related with ANCA status, does not 
identify patients at risk for relapse.
In contrast to sIL-2R and sCD30, IL-10 is a cytokine with immunosuppressive and anti-
infl ammatory properties. Regulatory T cell subsets among other cells produce IL-10 [19]. 
Additionally, IL-10 is associated with type 2 T helper cells (Th 2) and can promote polyclonal 
hypergammaglobulinemia [20]. In Systemic Lupus Erythematosus (SLE), IL-10 levels refl ect
disease activity [21]. We found that IL-10 levels in patients with ANCA-associated vasculitis
were elevated at diagnosis and subsequently decreased. At 6 months aft er diagnosis IL-10 
levels were signifi cantly lower as compared to healthy controls. Additionally, low levels of 
IL-10 3 months aft er diagnosis were associated with increased relapse rate during 60 months 
of follow-up. Recently, Ohlsson et al reported on the same association between low IL-10 
levels in patients with AAV 3-months prior to relapse [11]. In addition, both in WG and 
MPA, a shift  towards the homozygous AA genotype has been found in the IL-10 (-1082) 
polymorphism [22]. In vitro this genotype correlates with low IL-10 secretion by ConA-
stimulated peripheral blood mononuclear cells of healthy individuals [23]. Th ese data and
our clinical fi ndings suggest that low plasma levels of IL-10 infl uence disease development 
and exacerbation.
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Whereas T cells are operative in production of ANCA, other factors, e.g. BAFF, may be 
involved as well. BAFF is a member of the tumor necrosis factor (TNF) ligand superfamily 
and is expressed by monocytes, macrophages, dendritic cells, and, possibly, activated T
cells [24-26]. Since BAFF stimulates all B cells and thereby promotes their survival [27], it is
thought to contribute to autoimmunity by stimulating autoreactive B cells. In patients with
SLE, Rheumatoid Arthritis (RA) and Sjögren syndrome, elevated serum levels of BAFF have
been found. Levels correlated with serum IgG levels and anti-double standed DNA antibody 
titers among SLE patients and with rheumatoid factor (RF) titers among seropositive RA
patients [12, 28]. Moreover, in Sjögren syndrome, levels of BAFF correlated with both anti-
SSA and anti-SSB antibodies and RF. Recently, two groups reported, on elevated levels of 
BAFF in Wegener’s Granulomatosis [29, 30]. We found that levels of BAFF were elevated in
patients with PR3-ANCA-associated vasculitis as compared to healthy controls. However,
BAFF levels did not correlate with ANCA titers, and ANCA positive patients did not have
higher BAFF levels than ANCA negative patients. Also in previous studies, no correlation
was found in patients with WG between B cell activation and serum levels of ANCA, RF,
IgM and IgG, the latter being markers of polyclonal B cell activation [10]. Th e data, therefore,
suggest that elevated BAFF levels are rather a result of a stimulated immune-system than a 
factor related to the PR3-ANCA response or to disease activity.
In summary, in PR3-ANCA-associated vasculitis, markers of T cell activation are 
increased at diagnosis and correlate with disease activity. Although immunosuppressive
therapy results in a decrease, T cell activity does not normalize. Upon tapering and stopping 
immunosuppression levels of T cell activation markers rise again, refl ecting increased T cell
activity. Th is increased T cell activity is associated with ANCA positivity, and should be
viewed as a result of a T cell driven immune-response which could be at the basis of this
disease.
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In their report on maintenance therapy for vasculitis associated with autoantibodies to
neutrophil cytoplasmic antibodies (ANCA) ( July 3 issue), Jayne et al. conclude that the level
of exposure to cyclophosphamide can be safely reduced in patients with ANCA-associated 
vasculitis by switching to azathioprine once remission has been achieved [1]. As the authors
point out, and as is noted in the accompanying Perspective article by Langford, follow-up
was limited to 18 months [1, 2]. It was thought unlikely that extended follow-up would
reveal signifi cant diff erences in rates of relapse. We present some data, that may challenge
this assumption.
From 1990 through 1996 new patients at our center were treated with oral 
cyclophosphamide (2 mg/kg/day, tapered every 3 months by 25 mg), whereas from 1997 to
2001, patients were increasingly switched to azathioprine (1.5-2.0 mg/kg/day, tapered every 3
months by 25 mg), aft er three months of remission achieved with cyclophosphamide therapy.
In both schemes treatment is discontinued aft er 18 to 24 months. Overall, 88 patients received
cyclophosphamide only, and 48 were switched to azathioprine. Treatment with prednisolone
was similar in both cohorts. Th e mean age at diagnosis was 53 years (mean, range 14-83);
there was renal involvement in 104 patients (76%); the mean (±SD) Birmingham Vasculitis
Activity Score was 23 ± 9; ANCA against proteinase 3 and myeloperoxidase were detected in
102 (75%) and 34 (25%) patients, respectively. Th ese characteristics did not diff er between
both cohorts and are similar to the clinical characteristics in the study by Jayne et al.
We analyzed the actuarial rates of relapse-free survival among patients treated with 
cyclophosphamide only and among those who were switched to azathioprine (Figure 1).
Data of patients who did not have a relapse were censored on May 1st 2003, or at the time
of death. In the cyclophosphamide-group three patients died, without experiencing relapse
or fi ndings compatible with active vasculitis (one died of myocardial infarction and two of 
disseminated carcinoma of the colon). At 18 months, the rate of relapse-free survival was
88.6 percent in the cyclophosphamide group and 89.6 percent in the azathioprine group,
results that are similar to those reported by Jayne et al (86.3 percent and 84.5 percent,
respectively). However, at fi ve years of follow-up, relapse-free survival was 42.3 percent in
the azathioprine group as compared with 57.4 percent in the cyclophosphamide group. Th e
diff erence between the curves nearly reached statistical signifi cance (log-rank test: RR 1.51,
95% CI 0.92-2.68; p=0.099).
Th ese data indicate that relapses in ANCA-associated vasculitis predominantly occur 
aft er therapy has been discontinued, as reported by Hoff man et al [3]. Moreover, our data 
challenge the conclusion by Jayne et al. that switching cyclophosphamide to azathioprine
aft er three months of remission does not lead to an increase in the rate of relapse, since their
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follow-up may have been too short. We recently found that the persistence of ANCA at 
the time when a patient is switched to azathioprine is a risk factor for relapse [4]. Whether
extending treatment with azathioprine in some or all patients might reduce the number of 
relapses without increasing treatment-related toxicity should be studied.
Numbers at risk
cyclophosphamide only 88 86 68  60  47 36
switch to azathioprine 48 46 37 25 17 9




















Figure 1. Disease-free survival among 136 patients with ANCA-associated vasculitis, according 
to treatment with cyclophosphamide only (■) or switched to azathioprine aft er 3 months of 
remission on cyclophosphamide (▲). Logrank test: RR 1.51, 95% CI 0.92-2.68; p=0.099.
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ABSTRACT
Objective: We retrospectively evaluated long-term disease-free survival in patients with 
ANCA-associated vasculitis (AAV) on cyclophosphamide maintenance treatment as
compared to azathioprine maintenance treatment.
Methods: Patients diagnosed with AAV between January 1990 and December 2007 were
included (n=247). All patients received induction with cyclophosphamide. From 1990 to
1996 patients were treated with cyclophosphamide maintenance aft er induction of remission
(n=113). From 1996 on patients were switched to azathioprine (n=34). Disease-free survival
was analysed by logrank test.
Results: 176 patients were diagnosed Wegener’s Granulomatosis, 52 Microscopic Polyangiitis,
and 19 idiopathic Necrotizing Crescentic Glomerulonephritis. ANCA were directed against
proteinase 3 (n=180) and myeloperoxidase (n=59), and their distribution did not diff er
signifi cantly between the two groups. In the cyclophosphamide group mean follow up was
111 months and in the azathioprine group 68 months (p<0.001).
At 18 months and 60 months aft er diagnosis relapse-free survival was 85% and 54%,
respectively, in the cyclophosphamide group, and 89% and 44%, respectively, in the
azathioprine group (at fi ve years, RR 1.22; 95% confi dence interval 0.83-1.81; p=0.32).
Leukopenia, incidence of infections, VDI-scores, and mortality did not diff er signifi cantly 
between the two cohorts.
Conclusion: Th is single center retrospective study shows that azathioprine maintenance is 
not inferior to cyclophosphamide maintenance during long-term follow-up in patients with
AAV.
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INTRODUCTION
Antineutrophil cytoplasmic auto-antibodies against myeloperoxidase (MPO-ANCA) and 
proteinase 3 (PR3-ANCA) are associated with primary vasculitides aff ecting small to medium 
sized blood vessels. Multiple organs can be involved, but the kidney and respiratory tract 
are predominantly aff ected. Th e introduction of cyclophosphamide has resulted in marked 
improvement of survival in these life-threatening diseases [1]. However, both short and long-
term cyclophosphamide maintenance therapy is toxic. In the short term cyclophosphamide 
is associated with frequent infectious complications. In the long-term especially bladder 
and bone marrow toxicity and carcinogenesis are feared complications. Recently, 
potential improvement in outcome has been realized by a staged treatment approach with 
cyclophosphamide induction during a limited treatment period, followed by azathioprine 
or methotrexate maintenance therapy [2, 3]. Th e CYCAZAREM trial previously showed 
equivalence in relapse rate of cyclophosphamide maintenance versus maintenance with 
azathioprine aft er induction of remission. However, this study was limited by a follow-up of 
18 months only, and failed to show diff erences in short-term therapy associated toxicity. Th us, 
whether these regimens diff er during long-term follow-up has not been studied. Meanwhile, 
most relapses in ANCA-associated vasculitis occur aft er tapering and discontinuation of 
immunosuppressive therapy. During fi ve year follow-up approximately 50% of patients 
experience a relapse [4-6]. We previously reported that azathioprine maintenance compared 
to cyclophospamide maintenance therapy might be associated with an increased relapse 
risk in ANCA-associated vasculitis [7]. Additionally, in ANCA-associated vasculitis long-
term data of outcome and toxicity of prolonged cyclophosphamide therapy compared with 
azathioprine maintenance is absent [4, 8, 9]. 
In this single center study we compared the outcome of cyclophosphamide and 
azathioprine maintenance regimens in two historic cohorts during extended follow-up. We 
studied potential diff erences of the regimens regarding prevention of disease activity and 
compared damage infl icted by treatment modality.
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PATIENTS AND METHODS
Patients 
All two hundred forty-seven consecutive patients diagnosed with ANCA-associated
vasculitis and treated with induction therapy with cyclophosphamide and corticosteroids
at our center between January 1990 and December 2007 were included in this retrospective 
study. Data of the patients are given in table 1. Patients were followed until death (n=73),
loss to follow-up (n=17) or December 31st 2008 (n=157), whichever came fi rst. Patients
were classifi ed as Wegener’s Granulomatosis (WG), Microscopic Polyangiitis (MPA) and
Necrotizing Crescentic Glomerulonephritis (NCGN) according to Chapel-Hill criteria 
[10]. In all patients a positive ANCA in indirect immunofl uorescence (IIF) was confi rmed
by antigen specifi c enzyme-linked immunosorbent assay (ELISA). Induction treatment
consisted of oral cyclophosphamide (2 mg/kg) and prednisolone (1 mg/kg; maximal dose 
of 60 mg/day). Doses of cyclophosphamide were adjusted to maintain the white blood
cell count above 4 x 109/L. Aft er 4 to 6 weeks, the daily prednisolone dose was tapered 
by 10 mg every 2 weeks until the dose reached 30 mg, and thereaft er by 5 mg every 2 to 4
weeks. In patients diagnosed before 2000 reductions of daily prednisolone from 10 mg to
discontinuation were oft en made over an extended time interval. 
During the period 1990-1996 once remission was achieved the daily dose of oral 
cyclophosphamide was tapered by 25 mg every 3 months. Patients treated solely with
cyclophosphamide for maintenance were included in the cyclophosphamide cohort
(CYC, n=113). From 1997 on, patients were switched to azathioprine (1.5-2 mg/kg body 
weight daily) aft er three months of stable remission following induction treatment with
cyclophosphamide (AZA, n=134). From one year aft er diagnosis azathioprine was tapered
by 25 mg every 3 months. Patients who died within six months aft er diagnosis (n=22) were
included in the cyclophosphamide group when diagnosed before 1997 (n=6), and in the
azathioprine group when diagnosed aft er 1997 (n=16). All patients received Pneumocystis 
jirovecii prophylaxis with co-trimoxazole (three times per week 800/160 mg) during therapy 
with cyclophosphamide and/or azathioprine.
At diagnosis, during follow-up and at relapse, disease activity was scored using the 
Birmingham Vasculitis Activity Score (BVAS) [11]. At 6, 12 months aft er diagnosis and 
subsequently at 2, 3 and 5 years aft er diagnosis damage was assessed by the Vasculitis Damage
Index (VDI) [12]. VDI-scores were subdivided according to critical damage (16 items) and
treatment related damage (9 items). Additionally, VDI was scored the year before and aft er
the occurrence of a relapse.
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Table 1. Patient Characteristics at baseline
Characteristic Cyc Aza p (cyc vs aza)
Patients, n 113 134
Men, n (%) 67 (59%) 76 (57%) 0.68
Mean age at diagnosis (SD), years 59 (13) 55 (18) 0.07
Mean follow-up (SD), months 111 (58) 68 (49) < 0.001
ANCA-status, n (%)
PR3 ANCA 84 (74%) 96 (72%) 0.64
MPO ANCA 24 (21%) 35 (26%) 0.37
HNE ANCA 2 (2%) 2 (2%) 0.86
None 6 (5%) 3 (2%) 0.20
Diagnosis, n (%)
WG 84 (74%) 92 (69%) 0.33
MPA 21 (19%) 31 (23%) 0.38
NCGN 8 (7%) 11 (8%) 0.74
Organ involvement, n (%)
Ear, nose, throat 90 (80%) 82 (61%) 0.002
Pulmonary 54 (48%) 72 (54%) 0.35
Renal 85 (75%) 108 (81%) 0.31
BVAS at diagnosis, mean (SD) 20 (8) 22 (8) 0.24
CRP, mean (SD), mg/l 86 (79) 112 (98) 0.04
Creatinine, mean (SD), μmol/l 296 (301) 239 (263) 0.13
Hemodialysis, n (%) 17 (15%) 15 (11%) 0.37
Cyc, cyclophosphamide maintenance; Aza, azathioprine maintenance
Defi nitions
Remission was defi ned as the absence of clinical signs and symptoms of active vasculitis 
(Birmingham Vasculitis Activity Score (BVAS)=0) in combination with a normal C-reactive 
protein level (<10 mg/l). A relapse was defi ned as clinical signs of vasculitic activity in 
combination with biopsy proven vasculitic disease activity, or the occurrence of nodular 
pulmonary lesions aft er exclusion of infectious or malignant diseases. Renal vasculitic 
disease was defi ned as biopsy proven necrotizing glomerulonephritis or a combination of 
microscopic glomerular erythrocyturia, erythrocyte cell casts, proteinuria, and a decrease in 
creatinine clearance [13]. Th e time point of relapse was the fi rst day of renewed or intensifi ed 
therapy for disease activity.
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Statistical analysis
Groups were compared using the t test or the chi-square test. For comparison of non-
continuous data the Mann Whitney U test was used. For paired data the Wilcoxon signed
rank test was used. Relapse free survival was assessed by actuarial survival curves calculated 
using Kaplan-Meier estimates for survival distribution. Diff erences between groups in survival
were analysed with log-rank test. Patients lost to follow-up or who died before December 31st
2008 without relapse were censored. A two-sided p-value <0.05 was considered statistically 
signifi cant.
RESULTS
Patient and treatment characteristics
In table 1 clinical characteristics of patients in the cyclophosphamide (n=113) and
azathioprine cohort (n=134) at the time of diagnosis are presented. Patients in the
cyclophosphamide cohort tended to be older than patients in the azathioprine cohort (59
versus 55 years, p=0.07). No diff erences in diagnosis or ANCA status were present. In 
both the cyclophosphamide and azathioprine group one patient was simultaneously PR3-,
MPO-, and HNE-ANCA positive. In the cyclophosphamide group one additional patient
was simultaneously MPO- and HNE-ANCA positive. In the cyclophosphamide cohort
signifi cantly more patients presented with ENT involvement (p=0.002) while there was
no diff erence in ANCA specifi city or classifi cation as WG, MPA or NCGN. Mean follow-
up was more than 9 years in the cyclophosphamide group and more than 5.5 years in the
azathioprine group.
As expected patients in the cyclophosphamide cohort were treated signifi cantly longer 
with cyclophosphamide than patients in the azathioprine cohort (22.6 versus 5.4 months,
p<0.001). However, in addition to cyclophosphamide, patients in this cohort received 
prednisolone during an extended period compared to patients switched to azathioprine (22.2
versus 13.3 months, p<0.001). A major proportion of patients in the cyclophosphamide 
group received low dose steroids during long-term follow-up. As shown in table 2 mean
dosages of prednisolone at 3 and 12 months did not diff er signifi cantly. However, at 6 months
aft er diagnosis mean prednisolone dosage in the cyclophosphamide group was signifi cantly 
higher than in the azathioprine group (p<0.001). In contrast, in the azathioprine group
at diagnosis more patients were treated by high-dose methylprednisolone (p=0.014), and
plasma exchange (p=0.005) than in the cyclophosphamide group.
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Table 2. Treatment characteristics
Treatment Cyc Aza p (cyc vs aza)
Plasmaferesis, n (%) 11 (10%) 31 (23%) 0.005
Methylprednisolone, n (%) 20 (18%) 42 (31%) 0.014
Co-trimoxazole therapeutic, n (%) 13 (12%) 12 (9%) 0.51
Duration of cyclophosphamide (SD), months 21.4 (19.8) 5.2 (3.1) < 0.001
Duration of cyclophosphamide, 
median (25%-75%), months
17.4 (11.4-24.4) 4.6 (3.4-6.0)
Duration of prednisolone (SD), months 21.2 (19.9) 11.9 (9.1) < 0.001
Duration of prednisolone,
median (25%-75%), months
12.1 (9.7-25.3) 9.1 (5.9-13.9)
Prednisolone dosage at, mean (SD), mg 
3 months 26.8 (13.5) 25.6 (12.5) 0.54
6 months 11.9 (6.3) 7.9 (5.6) < 0.001
12 months 5.0 (6.9) 3.6 (9.6) 0.27
Duration of azathioprine (SD), months 20.1 (14.8)




Cyc, cyclophosphamide maintenance; Aza, azathioprine maintenance
Co-trimoxazole therapeutic stands for a dosage of 960 mg twice daily
Table 3 shows clinical characteristics of the fi rst relapse patients experienced. Again more
patients in the cyclophosphamide group had ENT involvement (p=0.023). Also creatinine 
levels at the time of relapse were signifi cantly higher in the cyclophosphamide group 
compared to the azathioprine group (p = 0.002).
Table 3. Patient Characteristics at fi rst relapse
Cyc Aza p (cyc vs aza)
1st relapse 51 (45%) 59 (44%)
Organ involvement, n (%)
Ear, nose, throat 36 (71%) 29 (49%) 0.023
Pulmonary 9 (18%) 10 (17%) 0.92
Renal 29 (57%) 25 (42%) 0.13
BVAS, mean (SD) 12 (6) 11 (5)
CRP, mean (SD), mg/l 57 (57) 51 (56) 0.84
Creatinine, mean (SD), μmol/l 228 (251) 151 (122) 0.002
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Relapse rate
Relapse rate of patients on azathioprine maintenance was not signifi cantly higher as 
compared to patients on cyclophosphamide maintenance (RR 1.22; 95% confi dence interval 
0.83-1.81; p=0.32) (fi gure 1). Relapse free survival in the cyclophosphamide group was 85% 
at 18 months, and 54% at 60 months. Relapse free survival in the azathioprine group was 
89% at 18 months, and 44% at 60 months.



























Time 0 24 48 60 72 96 120
Cyc (N) 113 78 56 47 44 39 27
Aza (N) 134 85 47 26 17 11 7
Figure 1. Relapse free survival of cyclophosphamide and azathioprine cohort
PR3-ANCA positive patients experienced signifi cantly more relapses than MPO-
ANCA positive patients (RR 2.90; 95% CI 1.93-4.36; p<0.0001). Also, patients classifi ed as 
WG who were PR3-ANCA positive (n=161) experienced signifi cantly more relapses at fi ve 
years than MPO-ANCA positive or ANCA negative patients diagnosed WG (n=15) (RR 
2.80; 95% CI 1.44-5.40; p=0.002). Finally, patients diagnosed MPA who were PR3-ANCA 
positive (n=14) were at increased risk to experience a relapse in comparison to MPO-ANCA 
positive MPA patients (n=33) (RR 4.53; 95% CI 1.57-27.94; p=0.01).
As for the whole group, the relapse rate was not signifi cantly diff erent in PR3-ANCA 
positive patients (RR 1.16; 95% CI 0.78-1.73; p=0.46), or MPO-ANCA positive patients 
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(RR 1.83; 95% CI 0.47-7.11; p=0.39) between patients on cyclophosphamide as compared 
to azathioprine maintenance therapy. 
Mortality
In total 73 (29.5%) patients died during follow-up, 47 patients in the cyclophosphamide 
and 26 in the azathioprine cohort. Actuarial survival was not diff erent between the CYC 
and AZA group and 5 year mortality did not diff er signifi cantly (fi gure 2). Table 4 shows 
causes of death in the cyclophosphamide and azathioprine cohort. In both cohorts infectious 
diseases were a primary cause of death (10 CYC; 14 AZA). In the cyclophosphamide group 
two patients died of active vasculitis, in the azathioprine group none. Of 12 patients the 
cause of death was unknown (7 CYC, 5 AZA). In total 7 patients died of a malignancy (6 
CYC, 1 AZA). As aforementioned, patients in the cyclophosphamide group tended to be 
older and were followed for a longer period of time in comparison to the azathioprine group. 




















Time 0 24 48 60 72 96 120
Cyc (N) 113 104 96 47 83 74 53
Aza (N) 134 105 86 26 53 36 24
Figure 2. Survival of cyclophosphamide and azathioprine cohort
VDI
VDI at 6, 12, 24, 36, and 60 months aft er diagnosis was compared between the 
cyclophosphamide and azathioprine group. Aft er correction for multiple comparisons VDI-
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scores did not diff er between the cyclophosphamide group as compared to the azathioprine 
group. Both critical and treatment related damage items were absent in most patients, and 
did not diff er between the cyclophosphamide group and the azathioprine group. Finally, 
in all patients there was a signifi cant increase in VDI aft er fi rst (n=110, p<0.0001), second 
(n=51, p<0.0001), and third relapse (n=19, p=0.03).
Table 4. Causes of death
n Cyc n Aza
10 infectious disease 14 infectious disease
pneumonia (5), mediastinitis, septicaemia 
(2),
pneumonia (8), septicaemia (4), diverticu-
litis, 
endocarditis and Aspergillus infection meningo-encephalitis
6 malignancy 1 malignancy 
B-CLL, sarcoma, unknown primary, unknown primary
adenoid-, colonic, and pancreatic cancer
3 cerebrovascular disease 2 pulmonary embolism
7 cardiac disease 2 cardiac disease
6 renal insuffi  ciency 1 respiratory insuffi  ciency following aspiration




1 diff use intravascular coagulation
2 no specifi c cause
7 unknown cause 5 unknown cause
Leukopenia and infections
In the fi rst two years aft er diagnosis 26 patients in the cyclophosphamide cohort (23%) and 
29 patients (22%) in the azathioprine group experienced at least one leukopenic episode 
(Leukocytes <4.0). Most of these episodes occurred within 6 months aft er diagnosis (71%, 
n=39). Twenty-four of these thirty-nine leukopenic episodes were associated with the 
occurrence of infections (12 CYC, 12 AZA). Leukopenia within 6 months aft er diagnosis 
was signifi cantly associated with the occurrence of infection (RR 3.53; 95% CI 1.97-6.35; 
p<0.001). 
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Most infectious episodes occurred within 6 (100), and 24 months aft er diagnosis (130). 
Characteristics of infectious episodes in the fi rst two years aft er diagnosis are depicted in 
table 5. In total 100 infections (49 CYC, 51 AZA) occurred within 6 months aft er diagnosis 
in 77 patietns (37 patients in CYC and 40 patients in the AZA (p=0.62)). From 6 months 
aft er diagnosis, when patients in the AZA group were switched to azathioprine, the number 
of patients experiencing an infectious episode did not diff er between the cyclophosphamide 
and the azathioprine group (17 versus 11, p=0.14) (table 5).
Malignancies
Malignancies are depicted in table 6. At diagnosis 15 patients had a history of malignancy 
which was considered to be cured (8 CYC, 7 AZA). In the cyclophosphamide group 
one patient eventually died of recurrence of malignancy present at diagnosis of AAV 
(adenocarcinoma), the patient with T cell lymphoma died of a secondary radiation 
sarcoma. None of the patients in the azathioprine group died of their previously diagnosed 
malignancies, or had progressive disease. 
Table 5. Infectious episodes
0-6 months CYC Leukopenia admission AZA Leukopenia admission
Viral 24 10 16 15 4 8
 CMV 12  9 11 10 4  7
 varicella zoster 5  0  2  5 0  1
Fungal 7 7 3 3 0 3
Bacterial 12 3 10 27 6 18
PCP 2 2 2 1 1 1
Unknown 4 1 1 5 1 3
Patients, n (%) 37 (33%) 12 18 40 (30%) 12 23 p=0.62
6-24 months CYC Leukopenia admission AZA Leukopenia admission
Viral 7 1 4 1 0 0
 CMV  2  1  2 0
 varicella zoster  5  0  2 1  0 0
Fungal 2 0 0 1 0 0
bacterial 4 0 4 5 0 5
PCP 1 0 1 0
Unknown 5 0 2 1 3
Patients, n (%) 17 (16%) 1 11 11 (9%) 1 6 p=0.14
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Table 6. Malignancies
n Cyc n Aza
before diagnosis
2 Prostate cancer 2 Breast cancer 
2 Lymphoma (T cell (died), NHL) 2 Urothelial cell carcinoma
1 Planocellular carcinoma lung 1 Colonic cancer 
1 Adenocarcinoma (died) 1 Melanoma
1 Paraganglioma 1 Basocellular carcinoma 
1 Meningeoma
aft er diagnosis
4 Basocellular carcinoma 2 Basocellular carcinoma (+ recurrence) 
2 Prostate cancer 2 Planocellular carcinoma 
2 Breast cancer 1 Urothelial cell carcinoma (+ recurrence)
1 Planocellular carcinoma 1
Liver metastases with unknown primary 
(died)
1 Sarcoma (died)
1 Colonic cancer (died)
1 Pancreatic cancer (died),
1 Unknown primary with liver metastases 
(died)
1 B cell lymphoma (died) and urothelial cell
carcinoma
In the CYC group 15 malignancies developed in 14 patients during 1046 person years 
of follow-up. One patient developed a B cell lymphoma, and subsequently a urothelial cell 
carcinoma. Five patients died of active cancer (B cell lymphoma, colonic cancer, pancreatic 
cancer, sarcoma, unknow primary). In the azathioprine group, during 762 person years 
follow-up, 6 patients developed a malignancy. One of these patients died of active cancer 
(unknown primary). At 5 years aft er diagnosis the incidence of malignancy did not diff er 
signifi cantly between the cyclophosphamide and azathioprine group (RR 1.34; 95% CI 
0.30-5.91; p=0.69)
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DISCUSSION
Our retrospective single center study shows azathioprine maintenance is not inferior to 
cyclophosphamide maintenance in sustaining remission of AAV during long-term follow-
up. In 2003 we found a trend towards an increased relapse rate during fi ve years follow-up 
in the azathioprine group (88 CYC vs 48 AZA; RR 1.51; 95% CI, 0.92 to 2.68; p=0.099) 
[7]. Now, with extended follow-up and more patients in both cohorts no diff erence appeared 
between the two treatment strategies. Relapse rates in the cyclophosphamide group at 18, 
36 and 60 months were 85%, 68%, and 54%, and in the azathioprine group 89%, 65%, and 
44%, respectively. So far, in two randomized controlled trials azathioprine maintenance 
has been compared with cyclophosphamide (CYCAZAREM) or MTX (WEGENT), 
respectively. In the CYCAZAREM study, at 18 months relapse-free survival was 86.3% in 
the cyclophosphamide group and 84.5% in the azathioprine group, respectively [2]. In the
WEGENT study, which compared adverse events of azathioprine and MTX, aft er 18 months 
relapse-free survival was 88.9%, and aft er 36 months 64.1% in the azathioprine group [14]. 
Th us the results of our study are comparable with the randomized controlled trials that have 
addressed maintenance therapy up to 18 and 36 months aft er diagnosis. Additionally, our 
retrospective study is unique in the number of patients included, the length of follow-up, the 
low number of patients lost to follow-up and the small number of physicians taking care of 
the patients over the years.
Obviously, a randomized controlled trial is superior to a cohort study. A number 
of limitations should be addressed when considering the results of the current study. 
First, possible identifi ed confounders in this study include age, aff ected organ systems at 
diagnosis, additional treatment at diagnosis, and length of steroid treatment. Patients in the 
cyclophosphamide group tended to be older, more frequently had ENT involvement, and 
received steroids for a longer period during follow-up. We can not explain the age diff erence 
between the two groups, however this diff erence did not reach statistical signifi cance. 
Secondly, more patients in the cyclophosphamide group had ENT involvement. Th is 
diff erence was not related to a diff erence in ANCA-status or diagnosis. Neither did disease 
severity as assessed by BVAS diff er at diagnosis. In a previous study form the USA ENT 
involvement was associated with increased relapse risk, in contrast to a large French cohort 
of patients with ANCA-associated vasculitis in which it was not [3, 15]. Most relevant when 
comparing relapse rate in the two cohorts are additional diff erences in treatment regimens. 
Patients in the azathioprine group were more oft en treated with plasma exchange and 
methylprednisolone at diagnosis. Some patients in the azathioprine cohort were included 
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in the MEPEX study [16]. Th is study demonstrated that plasma exchange when compared
with methylpednisolone increased the rate of renal recovery at one year aft er diagnosis 
in ANCA-associated vasculitis that presented with renal failure. It is unknown what the 
impact of plasma exchange and methylprednisolone therapy is on long-term outcome and 
relapse-rate. Further analysis of subgroups and long-term MEPEX data might provide more 
data. Furthermore, long-term steroid therapy diff ered between the two groups. Although 
steroid dosages did not diff er at 3 and 12 months aft er diagnosis, more patients in the 
cyclophosphamide group were treated with long-term low dose steroid therapy. To what 
extent this strategy prevented relapses cannot be ascertained. Increased exposure to steroids 
would explain a reduced relapse rate, more infectious complications and more treatment 
related damage in the cyclophosphamide group. Obviously, these diff erences are of concern 
when interpreting the results of our study. Ideally long-term follow-up of a randomized study 
would exclude these factors. Regarding vasculitis and treatment related damage the VDI 
has been established as a reliable instrument. We did not fi nd diff erences in VDI between 
the cyclophosphamide and azathioprine group. Also when comparing critical damage and 
treatment related damage items no diff erences were detected between the two cohorts. 
Th us, although the cyclophosphamide cohort was exposed to both cyclophosphamide and 
prednisolone for a longer period this did not result in diff erences in treatment related damage 
items of the VDI score.
Th e majority of infections occurred within 6 months aft er diagnosis, when both groups 
were treated with cyclophosphamide and most leukopenic episodes occurred. Aft er six 
months the incidence of infectious complications diminished in both groups, and did not 
diff er signifi cantly between the groups. Also, in the CYCAZAREM study incidence of 
leukopenia and infection did not diff er between the cyclophosphamide and azathioprine 
group [2]. In the CYCAZAREM study, during 18 months follow-up, 33 infections were
documented in 144 patients, 17 (55%) were associated with concurrent leukopenia. In 
our study we documented considerably more infectious episodes within 24 months (136 
in 247 patients versus 33 in 144 patients). Th is diff erence was mainly attributable to the 
fi rst 3 months aft er diagnosis, when in the CYCAZAREM study only 7 infectious episodes 
were reported, whereas in our cohort 81 infectious episodes were documented. In the 
WEGENT study, aft er induction with cyclophosphamide, during a mean follow-up of 29 
months 19 infectious episodes were reported in 63 patients on azathioprine maintenance 
and only 2 patients on azathioprine maintenance experienced neutropenia [14]. Th us,
our data on infectious complications on azathioprine maintenance are comparable with 
data from CYCAZAREM and WEGENT. However, our study shows that the risk of 
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infectious complications is mainly related to induction therapy with the combination of 
cyclophosphamide and high-dose corticosteroids. Addition of more intensive therapy with 
plasma exchange and methylprednisolone will further augment this risk. Previously, in the 
MEPEX trial in 137 patients, 61 infectious complications were documented of which 37 life-
threatening [16]. Eventually, 19 patients died within one year of an infectious complication.
Only 3 patients in our cohort experienced Pneumocysitis Jirovecii infection, stressing 
the eff ectiveness of prophylactic co-trimoxazole treatment. Th is compares favourably with 
earlier studies [17]. In the cyclophosphamide group more fungal infections were detected. In
addition to diff erences in immunosuppressive therapy more rigid use of anti-fungal agents in 
later years might explain this diff erence. However, in the azathioprine group more bacterial 
infections were documented within 6 months aft er diagnosis. Th is diff erence might be 
explained by the more intensive immunosuppressive regimens with methylprednisolone and 
plasma exchange that were off ered to patients diagnosed aft er 1997. 
A variety of malignancies developed during follow-up of both cohorts. Th e incidence of 
malignancies did not diff er between the cyclophosphamide and azathioprine group at 5 years 
aft er diagnosis. Only one patient in the cyclophosphamide group developed a urothelial cell 
carcinoma. Also, only one of 15 patients with a history of malignancy had recurrent disease. 
Finally, mortality did not diff er signifi cantly between the groups. In both cohorts 
infectious diseases were major causes of death. A variety of other causes was identifi ed, with 
only 2 patients in the cyclophosphamide group dying of active vasculitis.
Our data confi rm the success of a staged immunosuppressive approach. Starting with more 
aggressive therapy, i.e. cyclophosphamide with potential addition of methylprednisolone 
or plasma exchange, then down staging to azathioprine. However, in contrast to what we 
had expected, we did not fi nd an advantage regarding treatment toxicity with azathioprine 
maintenance as compared to cyclophosphamide maintenance in the largest documented 
cohort of AAV patients. Th erefore, preference for azathioprine over cyclophosphamide 
maintenance is not supported by head to head comparisons in ANCA-associated vasculitis.
In this study we also showed that both PR3-ANCA positive WG and MPA patients have 
a higher relapse risk than MPO-ANCA positive or ANCA negative patients. Previously, 
we showed that every relapse is associated with an irreversible loss of renal function [18]. 
Additionally, we found a signifi cant increase of VDI aft er every consecutive relapse. 
Th erefore, for a subgroup of PR3-ANCA positive patients prevention of relapses by adapting 
immunosuppressive therapy according to risk factors for relapse might be benefi cial. 
In conclusion, the past decades have shown major progress of evidence-based treatment 
strategies for AAV, leading to limited exposure of patients to cyclophosphamide. In our 
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retrospective study this reduction in cyclophosphamide duration by switching maintenance 
therapy to azathioprine is not associated with more relapses.
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ABSTRACT
Background: Expression of matrix metalloproteinases (MMPs) by infi ltrating and intrinsic 
renal cells is increased in infl ammatory conditions, and may correlate with disease 
activity of glomerulonephritis. We analysed renal expression of MMPs, tissue inhibitor of 
metalloproteinase-1 (TIMP-1) and markers of neutrophil and monocyte infi ltration in renal 
biopsies of patients with active ANCA-associated glomerulonephritis.
Methods: Immunohistochemical expression of MMP-2, -3, -9, TIMP-1, the neutrophil and
monocyte derived MMP activators cathepsin G, neutrophil elastase, and myeloperoxidase, 
and the monocyte marker CD14 was determined in renal biopsies of active PR3-ANCA 
(n=7) and MPO-ANCA (n=6) associated glomerulonephritis, and in normal renal tissue 
(n=4). Double-labelling experiments of MMPs and TIMP-1 were performed with MPO 
and CD68, labelling neutrophils and macrophages.
Results: MMP-2, -3, -9, and TIMP-1 positive cells were detected in ANCA-associated
glomerulonephritis in glomeruli with active infl ammation (cellular crescents or fi brinoid 
necrosis), only occasionally in normal appearing glomeruli, and not in sclerotic glomeruli 
and in the tubulo-interstitium. MMPs and TIMP-1 were predominantly expressed by 
MPO and CD68 positive cells. In normal renal tissue no expression was detected with the 
exception of weak mesangial staining for MMP-2. In ANCA-associated glomerulonephritis 
glomerular MMP-2, -9, and TIMP-1 correlated with glomerular cathepsin G expression, 
while the number of MMP-9 expressing cells per glomerulus correlated with the percentage 
of crescentic glomeruli. Tubulo-interstitial expression of MMPs correlated with all markers 
of neutrophil and monocyte infi ltration, and interstitial MMP-9 and TIMP-1 expression 
correlated with renal function at the time of renal biopsy.
Conclusion: Expression of glomerular and interstitial MMP-2, -3, -9, and TIMP-1 is increased 
in active ANCA-associated glomerulonephritis and correlates with infl ammatory activity.
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INTRODUCTION
Anti-neutrophil cytoplasm antibodies (ANCA) directed against proteinase 3 and 
myeloperoxidase are the hallmark of a group of auto-immune small-vessel vasculitic disorders, 
such as Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA) and renal limited 
vasculitis [1, 2]. Many patients with these vasculitic disorders develop renal involvement with
necrotizing crescentic glomerulonephritis, characterized by fi brinoid capillary necrosis and 
cellular crescents. Subsequently these cellular, infl ammatory crescents evolve and become 
acellular and fi brotic leading to permanent loss of functional glomerular volume. Th e 
development of crescents is the result of interaction between infi ltrating leukocytes, local 
proliferating cells and changes in the extracellular matrix.
Matrix metalloproteinases (MMPs), the main matrix degrading enzymes, have been 
implicated in both the infl ammatory and fi brotic phase of crescent formation and are 
upregulated during infl ammation and physiological remodelling processes [3]. MMP 
gene-expression and subsequent production as pro-enzymes is tightly regulated by various 
controlling mechanisms [4]. Th e extracellular activation of pro-MMPs is predominantly a 
two-step process with initial cleavage by a protease, followed by a fi nal cleavage, usually by 
another MMP [5, 6]. Specialised tissue inhibitors of matrix metalloproteinases (TIMPs) and 
various other molecules, including α2-macroglobulin, are able to inhibit activated MMPs 
[7]. During infl ammation activated MMPs degrade the extracellular matrix hence promoting 
trans-basement membrane migration of leukocytes and release of pro-infl ammatory products 
from the extra-cellular matrix. Th us MMPs are likely to have an important pathogenic role 
in the acute phase of human crescentic glomerulonephritis. To study whether MMPs refl ect 
renal infl ammation in active renal ANCA-associated vasculitis we determined intra-renal 
expression of MMPs, their activators and a specifi c MMP inhibitor, TIMP-1, and correlated 
this with histological and functional markers of renal disease.
PATIENTS AND METHODS
Renal biopsy specimens
Renal biopsy specimens were studied from 13 patients with active renal ANCA-associated 
vasculitis. Samples of normal kidney tissue from patients with renal cell carcinoma (n=4) 
were used as control specimens. Blinded to the clinical status and renal function of the 
patient at the time of biopsy, renal biopsies were evaluated by light microscopy. Normal, 
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sclerosed, crescentic, and glomeruli with fi brinoid necrosis were counted. Results were 
expressed as percentage of the total number of glomeruli. Interstitial fi brosis, tubulo-
interstitial infl ammation, and atrophy were scored semi-quantitatively from 0 to 4 (0=no 
interstitial fi brosis/infl ammation/atrophy; 1=<10%; 2=10-25%; 3=25-50%; 4>50%). Age, 
ANCA-status, serum creatinine, proteinuria and CRP were recorded from all patients at the 
time of biopsy. Additionally, data on creatinine-clearance at biopsy, and 1, 3 and 12 months 
aft er renal biopsy were collected.
Immunohistochemistry
Frozen 4 mm sections were fi xed at room temperature (RT) for 10 minutes in 100% acetone 
and washed for 5 minutes in phophate buff ered saline (PBS, pH 7.4). Th e sections were 
incubated for one hour at RT with the primary antibody diluted in 1% Bovine Serum 
Albumin (BSA) in PBS (the source, specifi city and dilution of the primary antibodies are 
given in table 1). Next, the slides were rinsed with PBS for 5 minutes. Endogenous peroxidase 
activity was blocked by incubating the slides in 0.075% hydrogen peroxide/PBS for 30 
minutes. Following three washes with PBS the slides were incubated for 30 minutes with 
peroxidase conjugated secondary antibodies (all from Dako, Glosstrup, Denmark; specifi c 
combinations are given in table 1), supplemented with 1% human AB serum. Th e sections 
were washed in PBS and peroxidase activity was developed in a freshly prepared solution 
of 3-amino-9-ethylcarbazol (AEC), containing 0.03% hydrogen peroxide for 10 minutes. 
Counterstaining was performed using Mayer's hematoxylin. Control slides, which were 
incubated in PBS in the absence of the primary antibody, were consistently negative.
Positively stained cells in the glomeruli were manually counted, and interstitial staining 
was scored semi-quantitatively from 0-4 (0=no staining; 1=occasional positive cells in <10% 
of interstitium; 2=positive cells in 10-25% of interstitium; 3=positive cells in 25-50% of 
interstitium; 4=positive cells in >50% of interstitium). 
Additional double-labelling experiments were performed on cryostat sections. Briefl y, 
aft er blocking of endogenous peroxidase, sections were incubated with primary antibodies, 
monoclonal mouse anti-human CD68, polyclonal rabbit anti-human MPO, and mouse 
anti-human α-smooth muscle actin (α-SMA) respectively. In contrast to CD14, which 
predominantly labels monocytes, CD68 is a pan-macrophage marker. 
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Peroxidase conjugated goat anti-mouse IgG3, IgG2a (SBA, Birmingham, USA) or swine 
anti-rabbit (DAKO, Glosstrup, Denmark) antibodies were added and peroxidase activity 
was developed in diaminobendizine (DAB). Subsequently, monoclonal mouse anti-human 
MMP-2, monoclonal mouse anti-human MMP-9 or monoclonal mouse anti-human TIMP-
1, respectively, were added. Th en, secondary FITC labelled goat anti-mouse IgG1 (Southern 
Biotechnical Associates) was added. Finally, sections were stained using Mayer’s hematoxylin. 
In all double-labelling experiments appropriate isotype controls were included, these were 
consistently negative.
Statistical Analysis
Th e non-parametric Mann-Whitney test was used to compare clinical and histological data 
between PR3- and MPO-ANCA positive patients. Using this test renal expression of MMPs, 
TIMP-1 and markers of neutrophil and monocyte infi ltration were compared. Correlations 
were tested using Spearman’s correlation coeffi  cient. Statistical signifi cance was defi ned as a 
two-sided p<0.05. 
RESULTS
Clinical and histological characteristics
Clinical and histological features of the included patients are shown in table 2. Th e median 
age in the patient group was 63 years (range: 26-86), six patients were MPO-ANCA positive 
and seven were PR3-ANCA positive, at presentation six patients required dialysis. MPO- 
and PR3-ANCA positive patients did not diff er regarding clinical data. However, the 
fraction of glomeruli with fi brinoid necrosis diff ered signifi cantly: the median fraction in 
PR3-ANCA positive patients was 0.20 (range: 0.11-0.58), whereas in MPO-ANCA positive 
patients this fraction was 0.07 (range: 0.00-0.56) (p=0.035). Additionally, the fraction of 
crescentic glomeruli tended to be higher in PR3-ANCA positive patients (0.43 (range: 0.25- 
1.00)) compared to MPO-ANCA positive patients (0.19 (range: 0.06-0.78)) (p=0.051). 
Tubulo-interstitial infl ammation did not diff er between the two groups.
Immunolocalization of MMP-2, -3, -9 and TIMP-1 in normal and nephritic glomeruli
Immunohistochemical staining in renal biopsies of patients with ANCA-associated 
glomerulonephritis revealed MMP-2 and -3 positive cells in cellular crescents. In addition, 
MMP-2 and -3 were detected in interstitial, glomerular and periglomerular cells (fi gure 1). 
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MMP-9 positive cells, in contrast to MMP-2 and MMP-3, were only present in glomeruli with
active crescents, and in the interstitium. In control specimens only weak MMP-2 staining was
found in some mesangial cells, whereas MMP-3 and MMP-9 were absent. TIMP-1 protein
was expressed in glomeruli with active crescents and in smooth muscle cells of larger arteries.
Th e latter was also seen in control kidneys (fi gure 1). Cathepsin G, neutrophil elastase and
MPO were found in active crescents and were also present in interstitial infl ammatory cells.
Cathepsin G, neutrophil elastase and MPO were absent in control kidneys (fi gure 1). In
fi brous crescents staining for MMPs, TIMP-1, cathepsin G, neutrophil elastase, and MPO
were virtually absent.
Double-labelling experiments were performed to clarify which cells produced MMP-
2, MMP-9 and TIMP-1 in the crescentic glomeruli. MMP-9 and TIMP-1 expressing cells
were predominantly MPO-positive, while only a fraction of MMP-2 expressing cells were
MPO-positive (fi gure 2). Additionally, some CD68 positive macrophages produced MMP-
2, MMP-9 and TIMP-1 (fi gure 2). Part of the MMP-2 positive cells were neither MPO,
nor CD68 positive, and these cells had the morphological characteristics of glomerular
mesangial cells (not shown). In additional double-labelling experiments a substantial part of 
the MMP-2 positive cells were found to be α-SMA-positive (fi gure 2).
In general, expression of all enzymes tended to be higher in PR3- as compared to MPO-
ANCA associated cases. Th e diff erences did, however, only reach statistical signifi cance
for glomerular neutrophil elastase and MMP-9 (table 3). Th e number of positive cells per
glomerulus and the interstitial scores for MMP-2, -3, -9 and TIMP-1 are shown in table 3 for
controls and patients, categorised according to their ANCA-specifi city.
Correlation between MMPs and TIMP-1 versus cathepsin G, neutrophil elastase,
MPO and CD14
Th e relation between expression of MMPs and their neutrophil derived activators,
cathepsin G, neutrophil elastase and MPO, was studied. Th e interstitial expression of 
MMP-3 and MMP-9 correlated signifi cantly (p<0.01) with CD14 as marker of monocyte-
infi ltration and all neutrophil derived proteinases (table 4). Th e interstitial expression of 
MMP-2 correlated with MPO (p<0.01), cathepsin G (p<0.05), and CD14 (p<0.01), but
not with the number of cells expressing neutrophil elastase. In the glomeruli, the number
of MMP expressing cells did not correlate with neutrophil elastase and MPO (see table 4),
CD14 was not detected in the glomeruli. Only MMP-2 correlated signifi cantly (p<0.05)
with the glomerular expression of cathepsin G. In contrast, the number of TIMP-1 expressing 
cells in the glomeruli correlated with all markers of neutrophil infi ltration in the glomerulus
(p<0.01). 
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Figure 1. Immunohistochemical 
staining for Cathepsin G (A,B),
MMP-2 (C,D), MMP-3 (E,F),
MMP-9 (g,h) and TIMP-1 (I,J)
on control (A,C,E,G,I) renal tisssue
and tissue from patients with necro-
tizing crescentic glomerulonephritis
(B,D,F,H,J). Cathepsin G staining 
was absent in control kidneys (A)
and abundantly present in solitary 
cells (arrow) in glomeruli and in-
terstitium in necrotizing glomerul-
nephritis (B). MMP-2 was weakly 
stained in the glomerular mesan-
gium from control kidneys (C).
Increased expression was observed
in glomerular crescents (outlined),
interstitial and glomerular cells
from patients with necrotizing glo-
merulonephritis (D). MMP-3 and
MMP-9 were absent in control kid-
neys (E,G) and markedly upregulat-
ed in glomerular cresents (arrows)
from patients with necrotizing 
glomerulonephritis (F,H). TIMP-
1 was expressed in smooth muscle
cells (arrows), but not in glomeruli
and in the interstitium from control
kidneys (I), whereas TIMP-1 was expressed in glomeruli (arrows) and in the interstitium from 
patients with necrotizing glomerulonephritis ( J). 
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Figure 2. Double immunostaining for MMP-
2 (B,H,N), MMP-9 (D,J) and TIMP-1 (F,L) 
with MPO (A,C,E), CD68 (G,I,K), and a-SMA 
(M) respectively. Arrows in the fi gures indicate 
double-labelled cells. A minority of MMP-
2 producing cells were MPO-positive (A,B). 
MMP-9 (C,D) and TIMP-1 producing cells (E, 
F) were predominantly MPO-positive. Some, 
but not all, glomerular and peri-glomerular 
CD68-positive cells co-localised with MMP-
2 (G,H), MMP-9 (I,J) and TIMP-1 (K,L). A 
considerable number of MMP-2 producing cells 
were a SMA positive (M,N).- -
MMPs in renal vasculitis | 97
Table 3. Glomerular and tubulo-interstitial expression of matrix metalloproteinase (MMP)-2, -3, 
-9, tissue inhibitor of metalloproteinases (TIMP)-1, cathepsin G, myeloperoxidase, neutrophil 
elastase in renal biopsies of 13 patients with active ANCA-associated glomerulonephritis.









MMP-2 2.3 (0.9-3.8) 3.6 (2.6-4.0) 2 (1-4) 3 (1-4)
MMP-3 2.0 ( 1.0-2.8) 1.8 (1.0-3.4) 1.5 (1-3) 3 (1-4)
MMP-9 0.0 (0.0-0.3) 0.3 (0.0-5.4)a 0 (0-1) 1 (0-2)
TIMP-1 0.8 (0.0-1.4) 1.6 (0.1-3.5) 0.5 (0.0-2.0) 1 (0-3)
Cathepsin-G 2.1 (1.0-3.5) 3.5 (1.3-13.0) 2.5 (1-3) 3 (1-4)
Myeloperoxidase 4.6 (0.6-6.8) 3.9 (0.8-21.3) 1 (1-2) 2 (1-3)
Neutrophil elastase 0.3 (0.0-1.5) 5.0 (0.4-14.4)b 1 (0-1) 2 (0-3)
Data given as median value (range) for the group of the mean values per biopsy (glomerular) or the score (tubulo-
interstitium)
a p=0.007 compared to MPO-ANCA
b p=0.03 compared to MPO-ANCA
Table 4. Correlation coeffi  cients of the relation between matrixmetalloproteinase (MMP)-2, 
-3, -9, and tissue inhibitor of metalloproteinases (TIMP)-1 expression in glomeruli and tubulo-
interstitium with cathepsin G (Cath G), myeloperoxidase (MPO), neutrophil elastase (HNE),
and CD14 as markers of infl ammatory cell infi ltration in renal biopsies of 13 patients with active 
ANCA-associated glomerulonephritis.
Glomerular expression* Tubulo-interstitial expression**
Cath G MPO HNE Cath G MPO HNE CD14
MMP-2 0.59a 0.39 0.52 0.62a 0.79b 0.54 0.80b
MMP-3 0.38 0.51 0.15 0.84b 0.80b 0.81b 0.85b
MMP-9 0.65a 0.46 0.51 0.73b 0.83b 0.84b 0.78b
TIMP-1 0.74b 0.85b 0.72b 0.48 0.50 0.77b 0.51
* expression scored as the mean number of positive cells per glomerulus
** expression scored as semi-quantative score
a p<0.05
b p<0.01
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Correlation between MMPs, TIMP-1 and renal histology
To study whether expression of MMPs and TIMP-1 refl ected active infl ammation, correlation 
with renal histology was tested. Th e number of MMP-9 positive cells in the glomeruli 
correlated signifi cantly (r=0.60; p < 0.05) with the percentage crescentic glomeruli. In PR3-
ANCA positive patients the number of crescentic glomeruli tended to be higher (p=0.051), 
and signifi cantly more MMP-9 positive cells were present (p=0.007) than in MPO-ANCA 
positive patients. Th ere were no correlations between numbers of positive cells for MMP-2, 
-3 and TIMP-1 in the glomeruli and glomerular damage, as refl ected by the percentage of 
normal, sclerosed, crescentic glomeruli and glomeruli with fi brinoid necrosis. Th e interstitial 
expression of MMP-2, -3, -9 and TIMP-1 did not correlate with the histologically classifi ed 
grades of interstitial fi brosis, and tubular atrophy (data not shown). In contrast, interstitial 
expression of MMP-9 (r=0.87, p<0.0001) and TIMP-1 (r=0.66, p<0.05) correlated 
signifi cantly with tubulo-interstitial infl ammation, whereas interstitial expression of MMP-
2 (r=0.43, p=0.17) and MMP-3 (r=0.57, p=0.06) did not.
Correlation with renal function
Th e interstitial expression of MMP-9 (r=-0.59, p<0.05) and TIMP-1 (r=-0.60, p<0.05) 
correlated with the creatinine clearance at the moment of biopsy. Also interstitial neutrophil 
elastase (r=-0.62, p<0.05), tubular atrophy (r=-0.59, p<0.05) and the percentage of normal 
glomeruli (r=0.68, p<0.05) correlated with the clearance, while the percentage of sclerosed 
glomeruli (r=-0.50, p=0.08) and tubulo-interstitial infl ammation (r=-0.54, p=0.06) did not 
correlate signifi cantly with the clearance at the moment of biopsy. Th e glomerular expression 
of MMP-2, -3, -9 and TIMP-1 did not correlate with the clearance. During follow-up clearance 
was recorded at 1, 3 and 12 months. Th e renal expression of matrix metalloproteinases and 
TIMP-1 did not correlate with clearance during follow-up. In contrast, the percentage of 
normal glomeruli (r=0.64; p<0.05) and sclerosed glomeruli (r=-0.71; p<0.01) correlated 
with the creatinine clearance at 12 months aft er biopsy.
DISCUSSION
In the present study, MMP-2, MMP-3, MMP-9, and TIMP-1 were detected in glomeruli and 
tubulo-interstitium in renal biopsies of patients with active ANCA-associated necrotising 
crescentic glomerulonephritis, while expression was virtually absent in controls. In addition, 
expression of MMPs and TIMP-1 was mainly found in glomeruli with cellular crescents and/
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or fi brinoid necrosis, but not in unaff ected or sclerotic glomeruli, and expression correlated 
with markers of neutrophil and monocyte infi ltration. Also, tubulo-interstitial expression of 
MMPs and TIMP-1 correlated with markers of neutrophil and monocyte infi ltration, and 
correlated with renal function at the moment of renal biopsy. Th ese fi ndings suggest that 
expression of these MMPs and TIMP-1 represents active infl ammation in ANCA-associated 
necrotising crescentic glomerulonephritis and can potentially be useful in assessing activity 
of the infl ammatory process. Especially as double staining experiments showed that MPO-
positive infi ltrated neutrophils produced MMP-2, MMP-9 and TIMP-1; in contrast, fewer 
CD68-positive macrophages were found to produce MMPs and TIMP-1. Th ese results 
correspond with the fi ndings of Urushihara et al who also showed that many neutrophils, 
but not macrophages, produced MMP-9 in various glomerulonephritides [8].
Th e MMPs have been fi rmly linked to infl ammation. Pro-infl ammatory cytokines such as 
IL-1 and TNF-α have been shown to induce transcription and expression of several MMPs 
in both infl ammatory cells such as neutrophils, monocytes and intrinsic renal cells, while 
the anti-infl ammatory and profi brotic cytokine TGF-β is an important downregulator of 
MMP expression and enhances expression of MMP-inhibitors such as TIMP-1 [4, 9, 10]. 
In addition, an essential step in the activation of MMPs, which are secreted as inactive pro-
enzymes, is the cleavage by proteases derived from activated infl ammatory cells, especially 
neutrophils and monocytes. In experimental glomerulonephritis increased expression of 
MMPs is associated with disease activity and infi ltration by infl ammatory cells. Recently, 
gene expression of MMP-2 and the membrane bound MT1-MMP, which is an important 
activator of MMPs, was shown to correlate in diff erent stages with infl ammation and renal 
damage in a longitudinal murine anti-GBM glomerulonephritis model [11]. Moreover, in 
another model treatment with an MMP-inhibitor targeting elevated levels of MMP-2 and 
MMP-9 expression in anti-Th y1.1 nephritis diminished histological damage and proteinuria 
[12]. However, in an accelerated model of anti-GBM nephritis MMP-9-defi cient mice 
showed more severe disease than control mice [13]. Th is suggests that MMP-9 not only causes 
glomerular damage, but might also protect glomeruli against injury, or promote glomerular 
recovery, aft er initial damage.
In human renal disease increased glomerular expression of MMP-9, but not of MMP-
2, has been reported in IgA nephropathy, mesangial proliferative glomerulonephritis and 
lupus nephritis [8]. In addition, elevated plasma levels of MMP-2, MMP-3, MMP-9 and of 
TIMP-1 have been found in some of these diseases, while elevated urinary levels of MMP-
2 and MMP-9 have been found in diabetic nephropathy [14-16]. In human rheumatoid
arthritis elevated plasma levels of diff erent MMPs, most oft en MMP-3, have been found and 
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correlated with disease activity [17]. Data on expression of MMPs and TIMP-1 in human
crescentic glomerulonephritis have, to our knowledge, not been published. As our study 
involved only a limited number of patients, all with active glomerulonephritis at the time 
of renal biopsy, but none with previous, but currently inactive, renal disease we can not be 
certain that expression is not increased in the latter situation. However, expression of MMPs 
and TIMP-1 clearly co-localised with histological markers of active glomerulonephritis, i.e. 
in crescentic glomeruli and within the tubulo-interstitial infi ltrates, while normal or sclerotic 
glomeruli were negative. 
As has been suggested by others based on morphological data, our data, despite the limited 
number of biopsies, do suggest a diff erence in infl ammation according to ANCA antigenic 
specifi city [18]. In line with these morphological data, higher expression of infl ammation
associated proteins in PR3- as compared to MPO-ANCA associated glomerulonephritis was 
found, although only for glomerular neutrophil elastase and MMP-9 this diff erence reached 
statistical signifi cance. Since our data suggest that MMPs and TIMP-1 expression is limited 
to active lesions of ANCA-associated glomerulonephritis and may refl ect infl ammatory 
activity, determination of plasma or urinary levels may be of potential value in assessing renal 
disease activity in these diseases and should be studied. Whether expression of MMPs or
TIMPs in the acute or recovery stage of active ANCA-associated glomerulonephritis or other 
forms of glomerulonephritis also may have prognostic signifi cance on long term follow up has 
to be studied. Given the important role of TGF-β, and probably other pro-fi brotic cytokines 
such as CTGF in regulating expression and activation of MMPs and TIMPs, longitudinal 
assessment may be of value in predicting long term outcome in glomerulonephritis and other 
progressive renal diseases. Increased serum and urinary levels of TIMP-1 and the matrix 
protein tenascin have been described in patients with renal function impairment due to 
diff erent diseases, but have not been correlated to renal infl ammation and fi brosis or changes 
of renal function during follow up [19]. Likewise, cross-sectional data in patients with a 
kidney transplant have correlated renal TIMP-1 mRNA expression with interstitial fi brosis 
6 months post transplant, but not to serum and urinary levels of TIMP-1 or renal function 
during follow up [8, 20].
In conclusion, increased renal MMP-2, -3, -9 and TIMP-1 expression refl ected the 
infl ammatory process in ANCA-associated glomerulonephritis, in particular MMP-9 
expression correlated with active glomerular lesions and tubulo-interstitial infl ammation. 
Establishing a link between the increased infl ammation related renal expression and elevated 
serum or urinary levels of MMPs and TIMP-1 will be a fi rst step required to test whether 
monitoring of MMP and TIMP-1 levels has potential value as non-invasive marker of renal 
disease activity in ANCA-associated and other forms of glomerulonephritis.
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ABSTRACT
Renal expression of MMP-2, -9, and Tissue Inhibitor of MMP-1 (TIMP-1) correlates with 
histological disease activity in ANCA-associated vasculitis (AAV). We studied whether 
urinary and plasma levels of MMP-2, -9, and TIMP-1 refl ect renal expression of these 
proteins and renal disease-activity in ANCA-associated vasculitis.
Urine and plasma samples of patients with AAV who underwent a renal biopsy were 
collected (n=32). Urinary activity of MMP-2, and -9 was measured by activity assays. 
Urinary and plasma levels of MMP-2, MMP-9 and TIMP-1 proteins were measured by 
ELISA. Healthy controls provided plasma and urine for comparison (n=31). In patients, the 
relationship of urinary and plasma levels with renal expression of MMP-2 and MMP-9 and 
clinical and histological disease activity was studied. Renal MMP expression was compared 
between patients and controls (n=8).
Urinary MMP-2 and MMP-9 activity and urinary and plasma TIMP-1 levels were 
signifi cantly higher in patients than in controls. In glomeruli of patients both MMP-2 and 
MMP-9 expression refl ected active glomerular infl ammation. Urinary activity of MMP-
2, and MMP-9 did not correlate with renal MMP expression or plasma levels. Urinary 
MMP activity correlated negatively with glomerular infl ammation, but positively with 
fi brous crescents. Urinary MMP-2 and TIMP-1 levels showed a positive correlation with 
tubulointerstitial damage and a negative correlation with creatinine clearance.
Urinary MMP-2, MMP-9, and TIMP-1 are elevated in AAV but do not refl ect renal 
MMP expression and glomerular infl ammation. However, urinary MMP-2 activity and 
TIMP-1 levels refl ect tubulo-interstitial damage, and correlate negatively with creatinine 
clearance at biopsy.
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INTRODUCTION
Many patients with vasculitis associated with anti-neutrophil cytoplasmic autoantibodies 
(ANCA) develop pauci-immune necrotizing crescentic glomerulonephritis (NCGN), 
which is frequently associated with rapidly progressive deterioration of renal function [1]. 
Although the pathogenesis of this glomerulonephritis is not precisely known, leukocyte 
infi ltration, matrix degradation and necrosis are essential steps in disease development. 
Following institution of immunosuppressive treatment some glomeruli with active crescentic 
lesions resolve with improvement of glomerular function, whereas others become acellular 
and fi brotic leading to permanent loss of glomerular function [2].
Th e role of matrix metalloproteinases (MMPs) in glomerular disease is increasingly 
appreciated. MMPs mediate both degradation of extracellular matrix components and cell 
proliferation, and facilitate leukocyte function [3, 4]. Th e balance between MMPs and their 
specifi c inhibitors, tissue inhibitors of MMPs (TIMPs), might direct the long-term disease 
course. Th is balance could either lead to glomerular recovery or, alternatively, to development 
of fi brosis.
Recently, we have found that renal immunohistochemical expression of MMP-2, -3 and 
-9 and Tissue Inhibitor of MMPs-1 (TIMP-1) correlates with histological renal disease-
activity in ANCA-associated vasculitis [5]. To assess whether urinary and plasma levels of 
MMP-2, -9, and TIMP-1 refl ect local renal MMP-production and disease-activity in ANCA-
associated vasculitis, we measured urinary MMP-activity, and urinary and plasma levels of 
MMP-2, MMP-9 and TIMP-1, and compared these to renal disease activity, damage, and 
immunohistochemical expression of MMP-2 and MMP-9.
PATIENTS AND METHODS
Patients
Patients with ANCA-associated vasculitis (AAV) (n=29) who underwent a renal biopsy at 
the University Medical Center Groningen between 1995 and 2004 were included in the 
study.
One patient underwent two biopsies, one other patient underwent three renal biopsies. 
In total, 32 renal biopsies were evaluated. Ten biopsies were performed in patients newly 
presenting with AAV, 13 biopsies were performed at the time of relapse, and 9 biopsies 
were performed some weeks aft er immunosuppressive therapy had been started to evaluate 
remaining renal infl ammation as recovery of renal function was considered unsatisfactory.
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Age, anti-neutrophil cytoplasmic antibody (ANCA)-status, serum creatinine, 
proteinuria, and C-reactive protein (CRP) were recorded at biopsy, disease activity was 
assessed by Birmingham Vasculitis Activity Score (BVAS). For the patients who underwent 
a biopsy aft er starting immunosuppressive therapy BVAS was recorded at the start of the 
disease episode. Additionally serum creatinine was recorded one year aft er diagnosis. Th irty-
one healthy volunteers (13 females, 18 males; median age 51, range: 44-67) provided plasma 
and urine specimens for comparison. Th e study was approved by the local medical ethical 
committee.
Histopathology
Sections of formalin-fi xed, paraffi  n-embedded renal biopsy tissue (5 mm) were stained 
with hematoxylin and eosin, periodic acid Schiff  (PAS), and methenamine silver. Biopsies 
were evaluated by light microscopy blinded to clinical status and renal function. Normal-, 
crescentic-, sclerosed glomeruli and glomeruli with fi brinoid necrosis were counted in all 
glomerular cross sections (gcs) per biopsy (median 12.5 gcs; range 6-50). Results were 
expressed as percentage of the total number of gcs. Interstitial fi brosis, tubulo-interstitial 
infl ammation, and atrophy were scored semi-quantitatively from 0-4 (0=no interstitial 
fi brosis/infl ammation/atrophy; 1=<10%; 2=10-25%; 3=25-50%; 4>50%). Th e interstitial 
scores were calculated as the mean score of at least 10 adjacent cortical fi elds individually 
scored at 400x magnifi cation. 
Urine and serum samples
Before biopsy, freshly voided urine and EDTA blood samples were collected from each 
patient. Urine samples were spun at 3000 rpm for 10 minutes to remove debris; supernatants 
were stored at -80°C until use. In alliquots of urine specimens creatinine and protein were 
measured. EDTA blood samples were spun at 3000 rpm for 10 minutes, supernatants were 
stored at -80°C until use. All specimens underwent a minimum of freeze-thaw cycles.
MMP Activity Assays
Endogenous urinary activity of MMP-2 and MMP-9 was determined by specifi c activity 
assays (Amersham Biosciences, Piscataway, USA ) [6]. In brief, MMP-2, and MMP-9 were
captured by MMP-specifi c antibodies. Endogenous MMP activity was measured by adding 
MMP substrate (modifi ed pro-urokinase; UKcol), and a chromogenic urokinase peptide 
substrate S-2444, and colour development was recorded. Results were expressed in U/umol 
creatinine (unit is defi ned as 1000*delta A405/t2).
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ELISA
Urinary and plasma levels of MMP-2, MMP-9 and TIMP-1 were determined by Enzyme-
linked Immunosorbent Assays (ELISA). In brief, for MMP-9 and TIMP-1 ELISA, 96 well 
plates (Greiner, M129A) were precoated with F(ab)2 fragments of goat-anti-mouse IgG-Fc 
( Jackson, West Grove, PA) in 0.1 M carbonated buff er (pH=9.6) for at least 48 hours. Aft er 
washing, plates were coated with 100 ng/ml mouse anti-human MMP-9 (clone 36020.111, 
R&D Systems, Oxon, UK) or 500 ng/ml mouse anti-human TIMP-1 (clone 63515.111, 
R&D Systems, Oxon, UK), respectively. Human urine samples and recombinant MMP-9 
and TIMP-1 were diluted in 1% BSA, 0.05% Tween-20 in 50 mM Tris-HCl (pH = 8.0) 
and 300 mM NaCl, plasma samples were diluted in HPE buff er (Sanquin, Amsterdam, Th e 
Netherlands). For MMP-2 ELISA, 96-well plates (Nunc, MaxiSorp) were coated overnight 
with 2 mg/ml mouse anti-human MMP-2 (clone 36006.211, R&D Systems, Oxon, UK), and, 
aft er washing, blocked with 1% bovine serum albumin (BSA) in PBS for 60 minutes. Human 
urine samples, plasma samples and recombinant MMP-2 were diluted in 0.1% BSA, 0.05% 
Tween 20 in PBS. In MMP-2, MMP-9 and TIMP-1 ELISAs both urine and plasma samples 
were added in duplicate and incubated at room temperature for one hour. Aft er washing, 
bound MMP-2, MMP-9, or TIMP-1 were detected by a 1-h incubation with respectively 
biotinylated rabbit anti-human MMP-2, rabbit anti-human MMP-9, or rabbit anti-human 
TIMP-1 (all R&D Systems, Oxon, UK). Aft er washing, samples were incubated with 0.125 
μg/ml peroxidase conjugated streptavidin (Sanquin, Amsterdam, Th e Netherlands) for 
30 min, and the colour reaction was performed with tetramethylbenzidin (TMB) (Roth, 
Karlsruhe, Germany). Th e colorimetric reaction was stopped by the addition of 100 μl/well 
0.5 M 2 N H2SO4, and adsorption at 450/575 nm was measured with a microplate reader.
Sensitivity of the ELISAs was 3.9 ng/ml for MMP-2, 0.039 ng/ml for MMP-9 and 
0.39 ng/ml for TIMP-1. Urine and plasma concentrations were determined by interpolation 
from a standard curve. Urinary concentrations were adjusted for the creatinine concentration 
and expressed in pg/mmol creatinine. 
Immunohistochemistry
Paraffi  n sections of 26 renal biopsies were available for immunohistochemistry. For the 
remaining 6 biopsies, insuffi  cient material was available for immunohistochemistry. Samples 
of normal kidney tissue from patients with renal cell carcinoma (n=8) were used as control 
specimens. For immunohistochemistry paraffi  n-embedded sections (5 μm thickness) were 
deparaffi  nized, microwaved for 10 minutes in 10 mM citrate pH 6.0. Sections were then 
(and aft er all subsequent steps) washed in Tris-buff ered saline (TBS). Aft er blocking of 
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endogenous peroxidase, sections were incubated for one hour with the following primary 
antibodies diluted in TBS: monoclonal mouse anti-human MMP-2 (Calbiochem, La Jolla, 
USA), polyclonal goat anti-human MMP-9 (R&D Systems, Oxon, UK), and monoclonal 
mouse anti-human CD68 (DAKO, Glosstrup, Denmark), respectively. Peroxidase conjugated 
secondary and, subsequently, tertiary antibodies were added and peroxidase activity was 
developed in a freshly prepared solution of 3-amino-9-ethylcarbazol (AEC), containing 
0.03% hydrogen peroxide for 10 minutes. Sections were counterstained using hematoxylin. 
Control slides, which were incubated in PBS in the absence of the primary antibody, were 
consistently negative. Histology slides were analyzed and scored by two observers. For each 
biopsy positively staining cells in glomeruli were manually counted and expressed as cells 
per glomerular cross section (gcs). Interstitial staining was scored semi-quantitatively from 
0-4 (0=no staining; 1=occasional positive cells in <10% of interstitium; 2=positive cells in 
10-25% of interstitium; 3=positive cells in 25-50% of interstitium; 4=positive cells in >50% 
of interstitium).
Statistics
Th e non-parametric Mann-Whitney test was used to compare data between various patient 
groups. Correlations were tested using Spearman’s correlation coeffi  cient. Statistical analysis 
was performed with the GraphPad Prism Soft ware version 4.0 for Windows (Graphpad 
Soft ware, San Diego, CA). Statistical signifi cance was defi ned as a two-sided p<0.05.
RESULTS
Clinical and histological characteristics
Clinical characteristics of 29 patients at renal biopsy are shown in table 1; median age in 
the patient group was 67 years (range 23-86), median BVAS was 19 (range 0-36), serum 
creatinine 233 mmol/l (range 99-1033) and proteinuria 1.5 g/l (range 0.1-14.1). In total 
18 patients were PR3-ANCA positive (including one patient who underwent 2 biopsies), 
and 11 MPO-ANCA positive (including one patient who underwent three biopsies). Ten 
renal biopsies were performed at diagnosis. Th irteen renal biopsies were taken because renal 
relapse was suspected. In the renal biopsy of one of the latter patients (#19) no active lesions 
were found. Nine renal biopsies were performed in patients with an unsatisfactory response 
to treatment to evaluate remaining renal disease activity several weeks (median 5, range 3-8) 
aft er starting immunosuppressive treatment. In six of these renal biopsies persistent activity 
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with cellular crescents was found. Table 2 shows histological damage in biopsies of all 
patients, and PR3- and MPO-ANCA positive patients, respectively. Histological parameters 
did not diff er between biopsies of PR3- and MPO-ANCA positive patients.
Urinary MMP- and TIMP-1 levels
In urine samples of healthy controls both endogenous MMP-2- (median 0.002 U/mmol 
creatinine; range 0.00-0.032) and MMP-9 activity (median 0.010 U/mmol creatinine; 
range 0.00-0.964) could be detected (Figure 1A). However, urinary MMP-2 activity was 
signifi cantly higher in patients with ANCA-associated vasculitis (median 0.005 U/μmol 
creatinine; range 0.00-0.052) (p=0.02) (Figure 1A). By ELISA urinary MMP-2 was detected 
in none of the controls and in only 2 urine samples from patients (6.6 ng/mmol creatinine 
and 7.5 ng/mmol creatinine, respectively). Urinary MMP-9 activity was signifi cantly 
elevated in patients (median 0.088 U/μmol creatinine; range 0.002-1.791) compared to 
controls (p=0.0002) (Figure 1A). Urinary MMP-9 levels, as measured by ELISA, were not 
signifi cantly higher in patients (median 0.07 pg/mmol creatinine; range 0.00-6.77) than in 
controls (median 0.00 pg/mmol creatinine; range 0.00-3.77) (p=0.15) (Figure 1B). Urinary 
MMP-9 activity (activity assay) and MMP-9 levels (ELISA) correlated signifi cantly (r=0.73, 
p<0.001). TIMP-1 levels in urine samples of patients (median 2.86 pg/mmol creatinine; 
range 0.00-23.50) were signifi cantly higher than in urine samples of healthy controls (median 
1.10 pg/mmol creatinine; range 0.30-5.20) (p=0.001) (Figure 1B). 
Plasma MMP- and TIMP-1 levels
Plasma MMP-2 levels (median 85 ng/ml; range 0-1340) were not signifi cantly elevated in 
patients with ANCA-associated vasculitis as compared to healthy controls (median 93 ng/
ml; range 0-723) (p=0.31) (Figure 2A). Also, plasma MMP-9 levels in patients (median 53.1 
ng/ml; range 4.8-410.0) were not higher than in healthy controls (median 65.2 ng/ml; range 
30.1-376.3) (Figure 2B). Plasma TIMP-1 levels were signifi cantly higher in patients with 
ANCA-associated vasculitis (median 649 ng/ml, range 86-1253) than in healthy controls 
(median 380 ng/ml; range 50-620) (p<0.0001) (Figure 2C). Plasma levels of MMP-2, -9 
and TIMP-1 did not correlate signifi cantly with urinary MMP-activity or levels, and TIMP-
1 levels, respectively. Plasma levels of MMP-2, -9, and TIMP-1 did not correlate with CRP, 
or BVAS.
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1 M 44 PR3 25 E, P, K, A 82 606 1.5
2 M 55 MPO 23 E, O, K, A 3 125 1.1
3 F 86 MPO 15 K 24 205 2.5
4 F 70 MPO 19 P, K 15 258 0.7
5 M 45 MPO 13 K 9 196 4.9
6 M 71 PR3 29 E, O, K, N 191 243 4.1
7 M 68 PR3 15 K 168 521 0.9
8 M 69 PR3 25 O, K, N, A 102 99 1.1
9 F 56 PR3 30 O, K, N, D 82 155 0.6
10 F 51 MPO 22 E, K, D, A 22 117 4.2
relapse
11a F 72 MPO 11 K 2 159 3.2
11b F 73 MPO 13 K 40 223 1.1 P
11c F 77 MPO 12 K 19 262 1.8
12 M 62 PR3 20 E, K 55 129 0.9 P, A
13 M 53 PR3 20 P, K 11 189 0.9 P
14 M 77 PR3 14 K 147 736 1.3 P
15 F 63 MPO 14 K 60 476 0.5 CS, HD
16 M 56 PR3 15 E, K 3 688 2.8
17 F 35 PR3 11 K 20 203 14.1 P
18 M 74 PR3 20 E, K 5 695 5.5
19 M 66 MPO 0 51 451 4.7
20 F 73 PR3 5 E, K, N, D, A 2 348 4 C, P, MP, 
PF, HD
21 M 58 PR3 19 E, O, P, K 12 177 1.6
evaluation
14b M 77 PR3 14 K 3 549 5.3 C, P, PF,
HD
22 M 69 PR3 25 E, P, K, N, D 8 169 0.1 C, P, HD
23 M 75 MPO 33 E, P, K, N 3 384 0.5 C, P, PF,
HD



















24 M 80 PR3 36 E, P, K, N,
D, A
9 120 0.3 C, P
25 F 56 MPO 21 K, D 3 187 1.7 C, P
26 F 23 MPO 19 P, K 4 704 0.7 C, P, PF, 
HD
27 M 57 PR3 20 E, K, D, A 9 1033 4.5 C, P, MP, 
PF
28 M 47 PR3 16 E, K 3 105 1.4 C, P
29 M 74 PR3 19 P, K, A 3 373 1.1 C, P, MP, 
PF
Clinical characteristics of 29 patients who underwent 32 renal biopsies; 10 at diagnosis, 13 at relapse, and 9 
to evaluate remaining disease activity; For patients who underwent a biopsy aft er starting immunosuppressive 
therapy BVAS was recorded at the start of the disease episode. M = male, F = female, E = ear/nose/throat, O = 
Ophthalmologic, P = Pulmonary, K = Kidney, D = Dermatologic, N = Nervous System, A = Rheumatologic 
symptoms; C = cyclophosphamide, P = Prednisone, A = Azathioprine, MP = Methylprednisolone; CS = 
Ciclosporin, PF = plasmaphoresis, HD = hemodialysis.
Table 2. Histological damage in biopsies of all patients, and according to ANCA-specifi city for 
proteinase 3 (PR3) or myeloperoxidase (MPO).
all biopsies (n=32) MPO (n=13) PR3 (n=19)
glomeruli (n) 13 (6-50) 16 (8-50) 11 (6-23)
normal (%) 19 (0-90) 17 (0-89) 20 (0-83)
fi brinoid necrosis (%) 7 (0-54) 4 (0-54) 13 (0-46)
cellullar crescents (%) 19 (0-92) 19 (0-92) 20 (0-62)
fi brous crescents (%) 24 (0-71) 20 (0-71) 25 (0-71)
global sclerosis (%) 8 (0-79) 13 (0-79) 0 (0-75)
TI atrophy (score) 2 (0-3) 1.5 (0-3) 2 (0-3)
TI fi brosis (score) 1.5 (0-3) 1.5 (0-3) 1 (0-3)
TI infl ammation (score) 1 (0-3) 1 (1-3) 1 (0-3)
Data are expressed as median (range)
TI, tubulo-interstitial. 













































































Figure 1. Box plo ts indicating range (error bars), 25-75% range (boxes) and median values 
(horizontal lines) of urinary MMP-2- and MMP-9 activity in patients and controls (A), and 
urinary MMP-9 and TIMP-1 levels in patients and controls (B). *p < 0.05 compared with controls 
MMP-2 and MMP-9 expression in renal biopsies
MMP-2 expressing cells were present in many glomeruli, particularly in active lesions, 
and to a lesser extent in normal appearing glomeruli (median 15.6 cells/gcs; range 0-52.5) 
(Figure 3A, Figure 4). In the interstitium MMP-2 expressing cells were present as well 
(median score 2; range 0-4), a major part of the tubulointerstitial MMP-2 expression was 
located in tubuloepithelial cells (Figure 5). In control sections signifi cantly fewer MMP-2 
expressing cells were present, both per glomerular cross section (2.5 cells/gcs; range 1.3-16.7) 
(p=0.003) (Figure 3A, Figure 4), and in the interstitium (median score 1; range 0-1) (p=0.01) 
(Figure 5). Compared with MMP-2, fewer cells expressed MMP-9 in glomeruli from patients 
with ANCA-associated vasculitis (median 0.8 cells/gcs; range (0.0-12.2)) (Figure 3, Figure 
4). In sections from controls signifi cantly more glomerular cells expressed MMP-9 (median






































































Figure 2. Box plots indicating range (error bars), 25-75% range (boxes) and median values 
(horizontal lines) of plasma levels of MMP-2 (A), MMP-9 (B) and TIMP-1 (C) in patients and 
controls. *p<0.05 compared with controls.
2.3 cells/gcs; range 0.8-3.8) than in patients with crescentic glomerulonephritis (p=0.04) 
(Figure 4). However, in some severely infl amed glomeruli many cells expressed MMP-
9 (Figure 3D). Both in controls and patients hardly any interstitial expression of MMP-9 
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was present (Figure 5). In glomeruli from patients signifi cantly more CD68 positive cells
were present than in control renal biopsy sections (p=0.0017) (Figure 4). Similarly, CD68
was expressed by signifi cantly more cells in the interstitium in patients than in controls
(p=0.0016).
Figure 3A-D. Immunohistology of glomeruli stained for MMP-2 (A, B), MMP-9 (C, D) in a 
renal biopsy of a patient with crescentic glomerulonephritis (B, D) and control tissue from a 
nephrectomy specimen (A, C). In normal glomeruli from controls MMP-2 expressing cells were
present (A). In crescentic glomeruli from patients MMP-2 expressing cells were present in both
glomeruli and crescentic lesions (B). Some MMP-9 expressing cells were present in controls
(C). In a patient with crescentic glomerulonephritis cells in the infi ltrate surrounding a severely 
damaged glomerulus expressed MMP-9 abundantly (D). Magnifi cation, X400.
Glomerular expression of both MMP-2 (r=0.044, p=0.83) and MMP-9 (r=0.33,
p=0.11) did not correlate signifi cantly with the number of CD68 positive cells per
glomerulus. Neither correlated glomerular MMP-2 and MMP-9 expression signifi cantly 
(r=0.32, p=0.11). Interstitial expression of MMP-2 correlated signifi cantly with interstitial
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expression of CD68 (r=0.59, p=0.002). Neither glomerular, nor interstitial MMP-2 
and MMP-9 expression correlated with urinary and plasma levels of these MMPs. Also, 
glomerular and interstitial expression of CD68 did not correlate with urinary and plasma 
levels of MMPs and TIMP-1.





















Figure 4. Box plots indicating range (error bars), 25-75% range (boxes) and median values 
(horizontal lines) of the number of positive cells per glomerular cross section (gcs) expressing 
MMP-2, MMP-9, and CD68 in patients with crescentic glomerulonephritis (GN) and control 
sections (controls). *p<0.05 compared with controls. 
Correlation of urinary MMP- and TIMP-1 levels with histological, and clinical 
characteristics
Urinary MMP-2 activity correlated negatively with the percentage of glomeruli with 
fi brinoid necrosis (r=-0.39, p=0.029) and cellular crescents (r=-0.42, p=0.017), and tended 
to correlate positively with the percentage of fi brous crescents (r=0.35, p=0.051) (Table 
3). Urinary MMP-9 activity also correlated negatively with the percentage of glomeruli 
with fi brinoid necrosis (r=-0.46, p=0.009), and cellular crescents (r=-0.41, p=0.02), and 
positively with the percentage of fi brous crescents (r=0.42, p=0.017) (Table 3). Urinary levels 
of TIMP-1 did not correlate with glomerular damage (Table 3). However, urinary TIMP-
1 correlated signifi cantly with tubulo-interstitial atrophy (r=0.41, p=0.022), and tubulo-
interstitial fi brosis (r=0.35, p=0.050) (Table 3). Urinary MMP-2 activity also correlated 
with tubulo-interstitial atrophy (r=0.49, p=0.005), and tubulo-interstitial fi brosis (r=0.41, 
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p=0.019) (Table 3). Urinary MMP-9 activity did not correlate with tubulo-intersitial
damage (Table 3). Plasma levels of MMPs and TIMP-1 did not correlate with glomerular
and tubulo-interstitial damage. 
Figure 5A-D. Immunohistology of tubulointerstitium stained for MMP-2 (A, B), MMP-9 (C,
D) in a renal biopsy of a patient with crescentic glomerulonephritis (B, D) and control tissue
from a nephrectomy specimen (A, C). In normal tubulointerstitium from controls some MMP-2
expressing cells were present (A). In patients with crescentic glomerulonephritis massive tubular
MMP-2 staining is seen (B). Few MMP-9 positive cells were detected in the tubulo-interstitium of 
controls (C). In a patient with crescentic glomerulonephritis some cells in the tubulointerstitium
expressed MMP-9 (D). Magnifi cation X200.
Urinary MMP-2 activity (activity assay) correlated negatively with creatinine clearance at
biopsy (r=-0.41, p=0.019) and one year aft er diagnosis (r=-0.40, p=0.042). Urinary MMP-
9 activity (activity assay) (r=-0.30, p=0.098) and urinary MMP-9 levels (ELISA) (r=-0.30,
p=0.10) tended to correlate negatively with creatinine clearance at diagnosis. At one year
aft er diagnosis no correlation was found between creatinine clearance and urinary MMP-
9 activity (r=-0.21, p=0.30). Urine levels of TIMP-1 correlated negatively with creatinine
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clearance at biopsy (r=-0.49, p=0.006), and urinary TIMP-1 levels tended to correlate with 
creatinine clearance one year aft er diagnosis (r=-0.35, p=0.08). Plasma levels of MMP-2, -9, 
and TIMP-1 (ELISA) did not correlate with creatinine clearance at biopsy or one year aft er 
diagnosis.
Correlation of renal MMP-2 and MMP-9 expression with histological and clinical 
characteristics
Glomerular MMP-2 expression correlated positively with the percentage of glomeruli with 
fi brinoid necrosis (r=0.55, p=0.004), and negatively with the percentage of glomeruli with 
fi brous crescents (r=-0.42, p=0.035) (Table 3). Glomerular MMP-9 expression correlated 
signifi cantly with the percentage of glomeruli with fi brinoid necrosis (r=0.68, p<0.001), and 
with cellular crescents (r=0.66, p<0.001) (Table 3). Glomerular number of CD68-positive 
cells correlated negatively with the percentage of normal glomeruli (r=-0.42, p=0.032), but 
not with glomerular damage (Table 3). 
Table 3. Correlation coeffi  cients of urinary MMP-2,-9 activity, MMP-9-, TIMP-1 levels, and 




























-0.06 -0.39a -0.42a 0.35 0.21 0.49b 0.41a 0.08
MMP-9 activity 
(U/μmol Cr)
0.00 -0.46b -0.41a 0.42a 0.10 0.21 0.14 -0.13
MMP-9
(ng/mmol Cr)
-0.06 -0.32 -0.25 0.30 0.12 0.22 0.29 0.06
TIMP-1 
(ng/mmol Cr)




0.31 0.55b 0.32 -0.42a -0.23
MMP-9
(positive cells/gcs)
0.17 0.68c 0.66c -0.39 -0.39
CD68 
(positive cells/gcs)
-0.42a 0.15 0.25 0.27 -0.05
Cr Creatinine, gcs glomerular cross section.
a p<0.05, b p<0.01, c p<0.001
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Interstitial expression of MMP-2 and CD68 correlated signifi cantly with tubulo-
interstitial infl ammation (r=0.51, p=0.009; r=0.59, p=0.002), but not with tubulo-
interstitial atrophy and fi brosis.
Glomerular MMP-2 and MMP-9 expression did not correlate with creatinine clearance 
at biopsy. In contrast, glomerular expression of CD68 correlated signifi cantly with creatinine 
clearance at biopsy (r=-0.41, p=0.036). Interstitial expression of MMP-2 did not correlate 
signifi cantly with creatinine clearance at biopsy, and one year aft er diagnosis. Interstitial 
expression of CD68 correlated negatively with creatinine clearance at biopsy (r=-0.43, 
p=0.028).
DISCUSSION
Renal lesions in ANCA-associated vasculitis are characterised by a wide variation in activity 
and chronicity. As histological characteristics are signifi cantly related to clinical outcome, 
clinical assessment in many cases warrants a renal biopsy [2]. However, a renal biopsy is not 
without risk and repeat biopsies to evaluate treatment response are usually not performed. 
Th erefore, other means of monitoring renal disease activity would facilitate and improve 
patient care. Urinary measurement of MMPs off ers a potential alternative as the presence and 
function of MMPs have been associated with disease activity and severity in both human- 
and animal models of glomerulonephritis. Recently we found that renal expression of MMP-
2, and -9 and TIMP-1 correlates with renal histological disease-activity in ANCA-associated 
vasculitis, a fi nding that was confi rmed in the current study [5]. In the current study we 
measured urinary levels and activity of MMP-2, MMP-9 and TIMP-1 and correlated these 
with renal protein expression, renal damage, plasma levels of MMPs and clinical disease 
activity. 
Both urinary MMP-2 and MMP-9 protein levels and/or activity were signifi cantly 
elevated in patients with active crescentic glomerulonephritis. In contrast, plasma MMP 
levels were not elevated in patients as compared to healthy controls and did not correlate 
with urinary MMPs or with measures of disease activity. Th us, urinary MMP excretion is not 
a refl ection of increased systemic infl ammation and MMP expression. Previously, in systemic 
lupus erythematosus, giant cell arteritis and Takayasu arteritis elevated protein levels and 
activity of MMP-9 were found, whereas MMP-2 was elevated in Takayasu arteritis [7-9]. 
In Wegener’s granulomatosis Bjerkeli found that increased plasma MMP levels, including 
MMP-2 [10]. Additionaly, Bjerkeli found TIMP-1 levels were increased and correlated
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with CRP. In line with these latter fi ndings, we found both elevated urinary and plasma 
levels of TIMP-1 in patients with ANCA-associated vasculitis. However, we did not fi nd 
a correlation between plasma TIMP-1 levels and disease activity as measured by BVAS and 
CRP. Th us plasma levels of MMP-2, MMP-9 and TIMP-1 do not refl ect disease activity in 
ANCA-associated vasculitis.
Additionally, we studied whether urinary MMP-9 levels refl ected histological MMP-9 
expression and consequently glomerular infl ammation. We observed that in patients with 
active crescentic glomerulonephritis a smaller number of glomerular cells expressed MMP-
9 than in normal appearing control renal sections. Although glomeruli were extensively 
damaged in most patients, only a few glomerular lesions contained an accumulation of MMP-
9 expressing cells. Nevertheless, glomerular MMP-9 expression correlated strongly with 
active glomerular infl ammation. In contrast to local renal expression, urine MMP-9 levels 
and activity were higher in patients than in healthy controls. Apparently, MMP-9 present 
in glomeruli from control sections is not excreted. MMP-9 excretion in patients might be 
the consequence of infl ammation and damage. However, neither urine MMP-9 levels nor 
activity refl ected renal damage. Th us from our study we cannot advocate the clinical use of 
MMP-9 in urine as a disease marker in ANCA-associated renal vasculitis.
In contrast to MMP-9 expression, signifi cantly more glomerular cells expressed MMP-
2 in patients with crescentic glomerulonephritis than in control sections. In our previous 
study, in a smaller number of patients, we also found only a small number of MMP-9-, but 
more MMP-2 positive cells in glomeruli of patients with crescentic glomerulonephritis [5]. 
In contrast to the previous study we now found more MMP-9 in control sections. Th is might 
be due to technical diff erences as we used formalin-fi xed paraffi  n embedded sections instead 
of frozen biopsy sections. Additionally, in the current study we used a diff erent polyclonal 
MMP-9 antibody as compared to the previous study. In concordance with our current fi ndings 
Lods et al previously found lower glomerular MMP-9 expression, and increased MMP-2 
expression in kidney biopsy specimens of patients with glomerulonephritis as compared to 
normal appearing glomeruli from tumor nephrectomy specimens [11]. However, both in the 
study of Lods et al and our study renal malignancy and related immunological responses 
might explain the increased glomerular MMP-9 expression in control sections. Animal and 
in vitro data suggest that MMP-2 is not only proteolytic but also involved in remodelling 
during fi brosis. MMP-2 was able to induce transformation of normal rat tubular epithelium 
into a myofi broblastic phenotype [12]. Our data could to some extent be interpreted in 
support of epithelial mesenchymal transition. We detected strong MMP-2 expression in 
tubuloepithelial cells of severely aff ected kidneys. Additionally, urinary MMP-2 activity 
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correlated with tubulo-interstitial damage and creatinine clearance at biopsy and one year 
aft er diagnosis. However, urinary MMP-2 activity did not refl ect renal MMP-2 expression. 
And, regarding immunohistochemical fi ndings no correlation was found between tubulo-
interstitial MMP-2 expression and fi brosis. 
From our study we can not conclude from what cellular sources the urinary MMPs were 
derived. However, the absence of a correlation with glomerular expression and the negative 
correlation with glomerular infl ammatory activity, when immunohistochemical expression 
is most pronounced, preclude a glomerular origin. Meanwhile urinary MMP activity and 
TIMP-1 refl ected tubulo-interstitial damage. Th us, although MMP-9 expression was only 
present in small amounts in the interstitium, urine MMPs might originate from the major 
renal compartment, the tubulo-interstitium. For MMP-2 this is supported by the strong 
expression we detected in tubuloepithelial cells.
In our study we measured both MMP activity and protein levels by activity assays and 
ELISA. Activity assays have been suggested to be superior as results refl ect proteolytic 
amounts. We did not fi nd major diff erences between the two techniques, and MMP-activity 
and protein levels correlated signifi cantly Because sensitivity of the MMP-2 ELISA was 
insuffi  cient regarding MMP-2 we cannot compare activity assay and ELISA results. 
In ANCA-associated vasculitis several serum markers are clinically used as indicators of 
disease-activity, in particular ANCA and CRP. However, these are not specifi c regarding 
renal disease-activity. Urinary levels of infl ammatory mediators could be more sensitive and 
specifi c markers of renal disease. We are the fi rst to report on urinary MMPs as a marker 
of glomerular and tubulo-interstitial disease in ANCA-associated glomerulonephritis. We 
did not fi nd a relationship between urinary levels or activity of MMPs, glomerular damage, 
and renal expression. No diff erence in renal expression of MMPs and levels in urine and 
plasma were found in patients who used immunosuppressive agents compared to patients 
who did not. We found elevated urinary levels of MMP-2, MMP-9 and TIMP-1. Moreover, 
urinary MMP-2 correlated negatively with creatinine clearance at biopsy and one year aft er 
diagnosis, whereas urinary TIMP-1 levels correlated negatively with creatinine clearance at 
biopsy. Other studies have found urinary markers refl ecting renal disease severity in ANCA-
associated glomerulonephritis, in particular macrophage migration inhibitory factor (MIF) 
and monocyte chemoattractant protein-1 (MCP-1) [13, 14]. Th ese studies stress the role of 
macrophages in glomerular disease induction and development. Macrophages play diff erent 
roles in both acute and chronic disease, resulting in diff erent phenothypes. MMP-expression 
is a defi ning feature of these diff erent macrophage phenotypes. In vitro IFN-gamma and 
TNF-α induced so called classical activation of macrophages result in a pro-infl ammatory 
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state [15]. Th ese macrophages predominantly express MMP-9 [16], corresponding with
the high MMP-9 expression that we found in what might be acute stages of glomerular 
injury. Whereas high expression of MMP-2 as detected in chronic lesions corresponds 
with a deactivated, dampened macrophage state induced by TGF-beta [17, 18]. Ultimately, 
more insight in this heterogeneity could lead to better disease monitoring and eventually 
manipulation of macrophage function.
In conclusion we found that urinary MMP-2 and MMP-9 activity and TIMP-1 levels 
were elevated in ANCA-associated glomerulonephritis. Urinary levels of MMP did not 
refl ect renal MMP expression and infl ammation. However, urinary MMP-2 activity and 
TIMP-1 levels correlated with tubulo-interstitial damage and creatinine clearance at biopsy.
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SUMMARY 
In this thesis disease activity in ANCA-associated vasculitis (AAV) was explored. Part I
focused on prediction and occurrence of relapses in AAV. Subsequently, part II of the thesis
studied renal production of matrix metalloproteinases (MMPs) and tissue inhibitors of 
MMPs (TIMPs) in AAV in relation to disease activity and damage.
In chapter 2 risk factors for relapse in AAV were reviewed. Several factors have been
associated with the occurrence of relapses. First, relapses occur more oft en in patients 
diagnosed WG than MPA or NCGN [1]. Additional identifi ed factors related to the 
occurrence of relapses are ANCA-status, level of T cell activation, therapy related factors, 
renal function, genetic factors, and microbiological factors. ANCA status, T cell activation 
and therapy related factors have been subjects of studies described in this thesis.
In chapter 3 we studied the relation between ANCA-status during follow-up and relapse.
We assessed whether C-ANCA titers as measured by IIF and PR3-ANCA levels measured by 
ELISA, at diagnosis and following immunosuppressive treatment, are predictive for relapse 
of AAV. In this retrospective analysis we evaluated 87 PR3-ANCA positive patients during 
fi ve years follow-up. Patients who became and stayed negative for C-ANCA (IIF) (n=16) or 
PR3-ANCA (ELISA) (n=7) had a lower risk to experience relapse. Positive C-ANCA (IIF) 
titers at 3, 12, 18 and 24 months aft er diagnosis and increased PR3-ANCA levels at 12, 18 
and 24 months aft er diagnosis were signifi cantly associated with relapse within 5 years aft er 
diagnosis.
In chapter 4 we evaluated whether T cell activation as refl ected by levels of sIL-2R, 
sCD30, IL-10 and B cell activator of the TNF family (BAFF) at diagnosis and during 
follow-up is predictive for ANCA-positivity and clinical relapse in PR3-AAV. Plasma levels 
of sIL-2R, sCD30, and BAFF were higher in patients than in healthy controls at all time 
points. Plasma levels of sIL-2R, sCD30 and IL-10 were higher at diagnosis and relapse 
than during remission. At 18 months, sCD30 and sIL-2R levels were signifi cantly higher 
in patients positive for PR3-ANCA than in PR3-ANCA negative patients. Th us we found 
indications for increased T cell activation in patients with ANCA-associated vasculitis in 
remission during and aft er immunosuppressive treatment. T cell activation was associated 
with persistent or renewed ANCA positivity. However, we did not fi nd a signifi cant relation 
between levels of T cell activation markers and the occurrence of relapse.
Previously, the CYCAZAREM study showed that cyclophosphamide can be safely 
replaced by azathioprine aft er induction of remission without increased relapse rate [2]. 
However, this study was limited by follow-up up to 18 months and did not show any 
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short-term signifi cant diff erences between cyclophosphamide and azathioprine toxicity. 
We retrospectively studied outcome of all patients diagnosed with AAV from 1990 at our 
center. Initially, from 1990 until 1996, these patients were treated with cyclophosphamide 
both for induction and maintenance. From 1996, aft er induction of stable remission on 
cyclophosphamide, treatment was switched to azathioprine maintenance. In 2003, studying 
136 patients, we found a trend towards increased relapses in the azathioprine maintenance 
cohort (chapter 5). However, as described in chapter 6, with longer follow-up including 247
patients, we did not fi nd a diff erence in relapse rate between patients on cyclophosphamide 
versus azathioprine maintenance treatment. Additionally, we did not fi nd diff erences in 
infectious complications. Th ese infectious complications primarily occurred in the fi rst three 
months aft er diagnosis, when both groups were treated with cyclophosphamide and most 
leukopenic episodes occurred. We did not detect a diff erence in damage scores between the 
cyclophosphamide and azathioprine group. In conclusion, also during long-term follow-up 
azathioprine maintenance is not inferior to cyclophosphamide maintenance in prevention 
of relapses. 
In part 2 of the thesis we focused on renal markers of disease activity and damage. In 
chapter 7 we analysed renal expression of MMPs, tissue inhibitor of metalloproteinase-1 
(TIMP-1) and markers of neutrophil and monocyte infi ltration in renal biopsies of patients 
with active ANCA-associated glomerulonephritis. MMP-2, -3, -9, and TIMP-1 positive 
cells were detected in ANCA-associated glomerulonephritis in glomeruli with active 
infl ammation (cellular crescents or fi brinoid necrosis), only occasionally in normal appearing 
glomeruli, and not in sclerotic glomeruli and in the tubulo-interstitium. MMPs and TIMP-
1 were predominantly expressed by infi ltrating neutrophils and monocytes. So, we detected 
increased glomerular and interstitial expression of MMP-2, -3, -9, and TIMP-1 in active 
ANCA-associated glomerulonephritis and this expression co-localized and correlated with 
infl ammatory activity. Th is supports the hypothesis that MMP-2, -3 and -9 have a role in 
the pathogenesis of ANCA-associated vasculitis. Subsequently, we questioned whether local 
expression of these infl ammatory markers might be refl ected by plasma and urine levels. In 
chapter 8 we studied whether urinary and plasma levels of MMP-2, -9, and TIMP-1 refl ect 
renal expression of these proteins and renal disease-activity in ANCA-associated vasculitis. 
However, urinary activity of MMP-2 and MMP-9 did not correlate with renal MMP 
expression or plasma levels. Urinary MMP activity correlated negatively with glomerular 
infl ammation, but positively with fi brous crescents. Urinary MMP-2 and TIMP-1 levels 
showed a positive correlation with tubulointerstitial damage and a negative correlation with 
creatinine clearance. 
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DISCUSSION
With the introduction of cyclophosphamide AAV have become chronic relapsing diseases, 
although still with considerable early mortality [1]. Nowadays, relapses of disease activity 
are a major problem associated with increased morbidity and mortality, and subsequent 
increased exposure to cytotoxic therapy. Active disease and treatment during relapse is 
directly associated with mortality [3-6]. Additionally, active disease and treatment during 
relapse lead to increased damage [5, 7], and increased damage is associated with mortality. 
Finally, the number of relapses is the primary predictor of long-term renal survival in 
proteinase-3 ANCA-associated vasculitis (PR3-AAV) [8]. So identifi cation of patients at 
risk and, if possible, prevention of relapses is of major importance.
Risk factors for relapse
Increased relapse risk in patients with WG is in part associated with chronic nasal carriage of S. 
Aureus [9]. Furthermore, a proportion of patients with limited WG can be successfully treated
with monotherapy with trimethoprim-sulfamethoxazole only. Additionally, maintenance 
treatment with trimethoprim-sulfamethoxazole upon standard treatment during two years 
reduced relapse risk by 60% [10]. However, most of the associations between infection and 
relapse have been descriptive and causality has not been proven. Recently, new evidence was 
provided of a mechanism by which infection could induce autoantibody mediated vasculitis. 
An immune response against adhesin FimH present on Gram-negative bacteria induced a 
cross-reactive auto-immune response towards lysosomal-associated membrane protein-2 
(LAMP-2) [11]. Auto-antibodies against LAMP-2 were present in almost all studied patients 
with AAV. When injected into rats these antibodies to LAMP-2 induced pauci-immune 
focal necrotizing glomerlonephritis. Th us, auto-immunity might be induced by an immune 
response against an exogenous, bacterial antigen.
Previously, it was feared that vaccination against infl uenza might be able to induce 
immune activation and subsequent relapses of disease. However, in a recent retrospective 
study of 230 patients with AAV we did not fi nd an increase of relapses aft er vaccination 
against infl uenza [12].
ANCA-status and relapse
In particular PR3-ANCA positive patients have, compared to MPO-ANCA positive 
patients, a signifi cantly increased risk to experience relapse (RR 3.7; 95% CI 1.6-4.1) [13]. 
Th is increased relapse risk based on ANCA specifi city can also be found within the diff erent 
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disease entities composing AAV. In addition, ANCA-status during follow-up has been linked 
to relapse. Previously, Slot et al showed that C-ANCA positivity aft er induction of remission 
is associated with the occurrence of relapse [14]. Also other smaller previous studies showed 
a relationship between disappearance of C-ANCA and relapse-free survival [9, 15-18]. In this
thesis we confi rmed the relation between persistence of C-ANCA positivity, during and 
aft er induction of remission, and the occurrence of relapse in patients with PR3-AAV. For 
a defi nitive answer regarding the clinical value of C-ANCA status at stable remission we 
will have to await the results of a multicenter prospective clinical trial that we are currently 
undertaking. In this trial therapy is adapted according to C-ANCA status at switch from 
azathioprine to cyclophosphamide in PR3-ANCA positive patients. Patients who are 
C-ANCA positive at stable remission are randomized to standard azathioprine therapy, 
with tapering from 12 months aft er diagnosis, and long-term azathioprine therapy which 
is continued until 48 months aft er diagnosis. Patients who are C-ANCA negative receive 
standard azathioprine therapy with tapering from 12 months aft er diagnosis. In this trial 
C-ANCA titers are measured centrally by IIF in the laboratory of clinical immunology of 
the University Medical Center Groningen in order to avoid the assumed inter-laboratory 
variation in ANCA-titers which is a disadvantage of this method when compared with 
quantitative measurements by ELISA. However, the study described in this thesis showed a 
better predictive value of C-ANCA by IIF as compared to levels of PR3-ANCA measured 
by ELISA. Additionally, a recent multicenter study from the USA did not fi nd a relationship 
between PR3-ANCA levels and the occurrence of relapse in WG [19]. In this study PR3-
ANCA levels from 156 patients collected approximately every 3 months were measured 
centrally by capture ELISA. Limitations of the study included diff erences in follow-up 
duration and long intervals between PR3-ANCA mesasurement in some patients, in 17 
patients more than 6 months.
Th us, there is an imperfect relation between persistent ANCA positivity or re-occurrence 
of ANCA and occurrence of relapse. Apparently, more is needed in a chain of immunologic 
events to induce relapse. Data suggest qualitive diff erences between ANCA in addition 
to quantitative diff erences. For instance, epitope specifi city and subclass of ANCA might 
explain discrepancies between ANCA levels and clinical status [20]. We assume that ANCA 
positive patients have a persistent state of immune activation and an ongoing smouldering 
autoimmune response. 
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T cells and disease activity
Patients with WG are lymphopenic which might result from a combined eff ect of therapy 
and disease [21]. Th is lymphopenia has been associated with a lower incidence of relapse [22]. 
Previously, in WG increased surface expression of T cell activation markers was detected 
in patients with active disease as compared to healthy controls, and this fi nding persists 
during remission [23]. In this thesis we confi rmed increased T cell activation in patients with
ANCA-associated vasculitis in remission during and aft er immunosuppressive treatment. 
Additionally, T cell activation was associated with persistent or renewed ANCA positivity. 
However, we did not fi nd a signifi cant relation between levels of T cell activation markers 
and the occurrence of relapse.
Th e role of T cells has been more appreciated and elucidated in recent years [24]. It was
shown that the distribution of T cell populations in patients with AAV diff ers from normal. 
Persistent T cell stimulation leads to a decrease in circulating naïve T cells and expansion of 
CD4+ T-eff ector memory cells during remission [25]. Subsequently, during active disease a 
signifi cant decrease in circulating CD4+ T-eff ector memory cells was observed as compared
to remission, suggesting migration of these cells to sites of infl ammation [25]. Additionally, 
increased numbers of T-eff ector memory cells have been found in urine sediments of 
patients with active WG [26]. Th is might thus be a new marker for active renal vasculitis. 
Furthermore, a new class of T cells has been identifi ed. Th ese Th 17 cells produce IL-17 and 
are thought to be pivotal in a range of human auto-immune disorders [27-29]. In line with 
these fi ndings, a signifi cant increase in percentages of Th 17 cells was found in WG patients 
as compared to healthy controls when peripheral blood cells were stimulated in vitro [30]
In ANCA-positive patients an increased frequency of PR3-specifi c Th 17 cells was found as 
compared to ANCA-negative patients. Although data in AAV are scarce, Th 17 cells might 
be important eff ector cells in AAV [26].
Th erapy and relapse
Several studies have shown a relation between type, dosage and duration of induction and 
maintenance therapy and risk the for relapse. Up till now no alternative for induction with 
cyclophosphamide has been proven to have similar effi  cacy with reduced toxicity. Toxicity of 
cyclophosphamide is well known and includes myelosuppression, infectious complications, 
and carcinogenesis, in particular bladder cancer. However, a dosage of <10 gram of 
cyclophosphamide in the fi rst 6 months was associated with an increased relapse rate [31]. 
Recently, the multicenter EUVAS CYCLOPS study found that pulse cyclophsophamide 
induced remission of AAV as eff ective as the oral regimen at a reduced cumulative 
Summary and discussion | 129
cyclophosphamide dose (8.18 versus 15.75 gram) and at a reduced incidence of leukopenia 
[32]. Within a median follow-up of 18 months 14.5% of patients experienced a relapse, with 
13 relapses in the pulse group and 6 in the daily oral group (HR 2.01 (95% CI 0.77-5.30)). 
Although not signifi cant, this fi nding confi rms an earlier meta-analysis of 3 randomized 
controlled trials by De Groot et al which also suggested a trend towards increased relapses 
in groups treated with three diff erent pulse regimens as compared to the oral group (RR 
1.79; 95% CI 0.85-3.75) [33]. However, the CYCLOPS study was powered and designed
to compare induction of remission and not to evaluate relapse frequency. Th us, we should 
consider pulse therapy in patients without immediate life-threatening disease to be equal to 
oral cyclophosphamide in terms of effi  cacy for induction of remission. However, the search 
for alternative induction strategies continues. We are coordinating a multi-center study 
comparing mycophenolate mofetil (MMF) as a less toxic but non-inferior induction therapy 
with cyclophosphamide in patients with a relapse of AAV. One previous smaller randomized 
trial on renal vasculitis found similar induction rates between mycophenolate mofetil and 
cyclophosphamide [34]. Other eff orts include a multinational multi-center study comparing 
anti-CD20 therapy (rituximab) with cyclophosphamide for induction of remission in AAV 
(RAVE) [35].
Previously, the CYCAZAREM study showed that cyclophosphamide can be safely 
replaced by azathioprine aft er induction of remission without increased relapse rate [2]. 
However, this study was limited by a follow-up of 18 months only, and did not show any 
short-term signifi cant diff erences between cyclophosphamide and azathioprine toxicity. 
We retrospectively studied outcome of all patients diagnosed with AAV from 1990 at our 
center. Initially, from 1990 until 1996, these patients were treated with cyclophosphamide 
both for induction and maintenance. From 1996 on, aft er induction of stable remission on 
cyclophosphamide, treatment was switched to azathioprine maintenance. Also during long-
term follow-up we found that azathioprine maintenance is not inferior to cyclophosphamide 
maintenance in prevention of relapses. As we also did not detect diff erences in infectious 
complications, malignancies and damage score, so far the preference of azathioprine over 
cyclophosphamide in AAV is not supported by head to head comparisons. Also methotrexate 
(MTX) has been proven eff ective as maintenance therapy. A recent study comparing 
side-eff ects of MTX and azathioprine maintenance did not fi nd signifi cant diff erences in 
treatment toxicity and showed similar relapse rates [36]. Th us, azathioprine and MTX seem 
to have similar effi  cacy as maintenance treatment in AAV, but MTX is contra-indicated in 
patients with renal failure. One should take into account that a considerable proportion of 
patients will develop an adverse reaction to azathioprine or MTX. Th e active metabolite 
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of azathioprine is 6-mercaptopurine, which levels are dependent on the enzyme thiopurine 
methyltransferase (TPMT). Previously, Stassen et al did not fi nd a relation between TPMT 
activity and the occurrence of relapses and adverse eff ects, in particular hepatotoxicity and 
leukopenia [37]. For patients intolerant to azathioprine or MTX mycophenolate mofetil 
might be an alternative [38]. So far, no prospective studies have evaluated optimal duration 
of maintenance therapy with azathioprine or MTX. Most relapses occur aft er therapy has 
been stopped, so prolongation might be an eff ective means to prevent relapses. Nevertheless, 
also during low-dose maintenance with azathioprine patients can experience relapses. Long-
term studies comparing maintenance regimens are eagerly awaited, and individualization of 
immunosuppressive regimens according to cummulative risk-factors for relapse might be the 
way to go. Currently, we are undertaking a prospective randomized multi-center trial adapting 
therapy according to C-ANCA status at switch from azathioprine to cyclophosphamide in 
PR3-ANCA positive patients. Patients who are C-ANCA positive at stable remission are 
randomized to standard azathioprine therapy, with tapering of dosage from 12 months aft er 
diagnosis, and long-term azathioprine therapy which is continued until 48 months aft er 
diagnosis.
MMPs in renal vasculitis
In part 2 of the thesis we focused on renal markers of disease activity and damage. Expression 
of matrix metalloproteinases (MMPs) by infi ltrating and intrinsic renal cells is increased in 
infl ammatory conditions, and may correlate with disease activity of glomerulonephritis [39,
40]. Th e gelatinases (MMP-2 and MMP-9) are a subfamily of MMP that are able to degrade 
basement membrane type IV and V collagen, aggrecan, elastin and gelatins [39]. However,
substrate specifi city is not completely equal, with MMP-9 being signifi cantly more active 
against basement membrane type IV and V collagen. Furthermore, expression diff ers as 
MMP-9 is tightly regulated by many cytokines and growth factors, and, in contrast, MMP-2 
is constitutively expressed [41].
Previously, Urushihara et al detected that MMP-9 expression was increased and 
corresponded to the level of glomerular cell proliferative changes in renal biopsies of 
patients with mesangial proliferative glomerulonephritis (IgA nephritis, Henoch-Schönlein 
nephritis, mesangial proliferative GN and class II lupus nephritis). In contrast, MMP-2 was 
not detected in normal renal tissue or in renal biopsies of patients with IgA nephropathy, 
mesangial proliferative glomerulonephritis and lupus nephritis [42]. We detected increased
glomerular and interstitial expression of MMP-2, -3, -9, and TIMP-1 in renal biopsies of 
patients with active ANCA-associated glomerulonephritis and their expression co-localized 
and correlated with infl ammatory activity.
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Th e critical targets of MMPs in acute kidney injury have still not been elucidated. Because 
MMP-2 and MMP-9 degrade basement membrane compounds, they can cause damage to 
the glomerular basement membrane. MMPs infl uence the behavior of glomerular cells, either 
directly or by regulating growth factors [43]. In vitro production of MMP-2 by mesangial cells 
resulted in a proliferative, highly infl ammatory phenotype, whereas latent MMP-2 or MMP-
9 showed no eff ect on mesangial cells [44]. Additionally, data from ischemia-reperfusion 
animal models show that MMPs mediate acute kidney injury via changes in the vascular 
endothelium and tubular epithelial cells [45]. In experimental glomerulonephritis increased 
expression of MMPs is associated with disease activity and infi ltration by infl ammatory cells. 
Inhibition of MMPs in Th y 1.1 nephritis in rats reduces glomerular lesions, proteinuria and 
matrix accumulation [46]. However, in a model of anti-GBM nephritis, MMP-9 defi cient 
mice showed more severe disease than control mice, implying that MMP-9 can have anti-
infl ammatory properties [47]. 
Our observation that hardly any MMP-activity was present in normal glomeruli is 
consistent with the correlation between normal glomeruli in renal biopsies of patients with 
AAV at diagnosis and subsequent renal recovery. Also active renal lesions like fi brinoid 
necrosis and cellular crescents correlated with GFR 18 months aft er diagnosis in mild to 
moderate renal involvement [48]. However, in more severe renal involvement these active 
glomerular lesions had no predicitive value for GFR 18 months aft er diagnosis [49]. In our 
study glomerular MMP-9 expression was signifi cantly higher in PR3-ANCA positive than 
MPO-ANCA positive patients which might refl ect underlying diff erences in presentation 
and course of the disease [50].
Several previous studies examined renal, urinary and plasma levels of cytokines, among 
others MCP-1 and IL-8, but not MMPs and TIMPs [51]. Here we studied plasma and urinary 
levels of MMP-2, MMP-9 and TIMP-1. We hypothesized that plasma and urine levels of 
these infl ammatory markers refl ect local expression. However, locally increased MMP-2, -9 
and TIMP-1 were not refl ected by increased urinary levels, although urinary MMP-2 and 
TIMP-1 refl ected tubular damage. As the tubulo-interstitium is the major renal compartment 
this might explain the correlation between tubule-interstitial damage and urinary levels of 
MMP-2 and TIMP-1. As discussed previously MMPs have been shown to release or activate 
several growth factors that have been associated with tubular cell proliferation, and renal 
fi brosis, such as pro-transforming growth factor-β [52]. In several other renal disorders a role 
for MMP-2 has been shown in the pathway leading to chronic renal disease [53, 54]. In vitro, 
MMP-2 is necessary and suffi  cient for the transformation of renal tubular epithelium to the 
myofi broblastic phenotype, an essential step in the process leading to interstitial fi brosis [55]. 
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Th us, instead of a refl ection of acute glomerular infl ammation, elevated MMP-2 and TIMP-
1 in the urine of patients with AAV appear to be markers of the common pathway leading 
to chronic renal damage. In the near future new and combined markers of infl ammation 
and damage might provide more detailed information about both glomerular and interstitial 
infl ammation and fi brosis in the diff erent stages of disease. However, for now the renal 
biopsy remains pivotal both at diagnosis and during follow-up when detailed information 
about disease development in the diff erent renal compartments is considered necessary.
CONCLUSIONS
In conclusion, AAV are nowadays chronic diseases with a major disease burden. Although 
treatment has progressed over the last decades and is considered less toxic, both therapy and 
disease related morbidity and mortality have not improved signifi cantly (chapter 6). A major 
determinant regarding outcome is the occurrence of relapse (chapter 2 and 6). However, the 
prediction of relapses in AAV is still imperfect. Several strong predictors have been identifi ed 
and confi rmed, among others PR3-ANCA positivity at diagnosis (chapter 2). In addition we 
report that patients with PR3-ANCA-associated vasculitis who remain C-ANCA positive 
during and aft er induction of remission are at increased risk for relapse (chapter 3). Th is 
might refl ect ongoing smoldering immune activation including T cell activity (chapter 4). 
Th e challenge ahead is whether adaptation of treatment according to risk factors will result 
in a better outcome. Part two of the thesis focused on monitoring kidney disease in AAV. 
We report the increased presence of MMP-2, -3, -9 and TIMP-1 in patients with renal 
AAV (chapter 7). However, locally increased MMP-2, -9 and TIMP-1 were not refl ected 
in increased urinary levels, although urinary MMP-2 and TIMP-1 refl ected tubular damage 
(chapter 8). So, we and others are still searching for better and more specifi c markers of renal 
infl ammation and damage.
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Dit proefschrift  gaat over ANCA-geassocieerde vasculitis. Bij deze zeldzame ziekte zijn de 
kleinste bloedvaten ontstoken. Bloedvaten door het hele lichaam kunnen betrokken zijn, 
maar meestal betreft  het de nieren en luchtwegen. Het is nog onduidelijk wat de eerste 
aanzet geeft  tot het ontstaan van de ontsteking. De ontsteking zelf is het gevolg van een 
ontsporing van het afweerapparaat ook wel immuunsysteem genoemd. Normaal beschermt
het afweerapparaat tegen indringers van buitenaf (bacteriën, virussen, parasieten). Hiervoor 
heeft  het afweerapparaat de beschikking over verschillende onderdelen met verschillende 
tactieken. Er is een snelle algemene reactie en een langzamere meer specifi eke respons. Bij een 
aantal zogenaamde auto-immuun ziekten wordt het eigen lichaam door het afweerapparaat 
als “vreemd” herkend. Een van deze auto-immuun ziekte is ANCA-geassocieerde vasculitis. 
Deze ziekten zijn verder opgedeeld in een viertal aandoeningen die enigszins van elkaar 
verschillen. Dit zijn de ziekte van Wegener, microsopische polyangiitis, tot de nier beperkte 
vasculitis en Churg-Strauss syndroom. 
ANCA
Kenmerkend voor de ziekten is de aanwezigheid van ANCA, antistoff en gericht tegen 
een specifi eke groep witte bloedcellen, de neutrofi ele granulocyten. Antistoff en worden 
normaliter gemaakt als langzame reactie tegen een specifi ek onderdeel van indringers van 
buitenaf. ANCA antistoff en zijn echter gericht tegen specifi eke onderdelen van het eigen 
lichaam. Er zijn verschillende soorten ANCA. De twee belangrijkste ANCA zijn gericht 
tegen respectievelijk proteinase 3 (PR3) en myeloperoxidase (MPO). Proteinase 3 en 
myeloperoxidase zijn beide eiwitten die opgeslagen zijn in neutrofi ele granulocyten. De 
neutrofi ele granulocyt is van groot belang in de snelle algemene reactie van het lichaam tegen 
met name bacteriën. Om deze aan te vallen en te doden maakt de neutrofi ele granulocyt 
gebruik van opgeslagen eiwitten, waaronder proteinase 3 en myeloperoxidase. Het vrijkomen 
van deze eiwitten beschadigt niet alleen de bacteriën maar ook de omgeving, leidend tot een 
ontsteking. Bij vasculitis verzamelen neutrofi ele granulocyten zich in de vaatwand en storten 
hun schadelijke stoff en uit wat leidt tot beschadiging van de bloedvaten. Door ANCAs 
wordt de ontstekingsreactie in de bloedvaten verder verhevigd.
De ontdekking van ANCA is belangrijk gebleken voor het groeperen en herkennen van 
ANCA-geassocieerde vasculitis. Het aantonen van ANCA in het bloed van een patiënt 
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met vaatontsteking maakt de diagnose ANCA-geassoceerde vasculitis heel waarschijnlijk. 
ANCA tegen PR3 komen met name voor bij patiënten met de ziekte van Wegener, ANCA 
tegen MPO komen vaker voor bij microscopische en tot de nier beperkte vasculitis. 
BEHANDELING
Dankzij een betere behandeling zijn de ANCA-geassocieerde vasculitiden tegenwoordig 
chronische ziekten, met variatie in activiteit. Er zijn perioden waarbij de ziekte in rustig 
vaarwater is en patiënten nauwelijks klachten hebben, maar ook perioden van nieuwe ziekte-
activiteit, zogenaamde opvlammingen of recidieven. Opvlammingen van de ziekte leiden tot 
nieuwe schade en vergen intensivering van de toxische therapie. In de voorgaande decennia 
is onderzoek gedaan naar het beloop van ANCA en het beloop van de ziekte. Dit heeft  tot 
tegengestelde resultaten geleid. In ieder geval kan gesteld dat een patiënt die eerder ANCA 
positief was en negatief is geworden op dat moment waarschijnlijk geen actieve ziekte heeft . 
Ook moet een patiënt die ANCA negatief was en ANCA positief wordt nauwkeurig in 
de gaten worden gehouden op verschijnselen van ziekte-activiteit. Echter behandeling op 
geleide van ANCA in plaats van ziekte-activiteit is niet eff ectief gebleken.
Bij actieve ziekte worden patiënten behandeld met medicijnen die het afweersysteem 
sterk onderdrukken: cyclofosfamide (merknaam endoxan) en prednisolon. Deze medicijnen 
zijn erg eff ectief, maar ook schadelijk. Deze schade betreft  onder mee vatbaarheid voor 
infecties en het ontstaan van kanker. Daarom wordt er tegenwoordig voor gekozen als de 
ziekte een tijd in rustig vaarwater is de cyclofosfamide te vervangen door azathioprine 
(merknaam imuran). In een grote Europese studie was deze therapie gelijkwaardig aan het 
doorzetten van de cyclofosfamide.
HET PROEFSCHRIFT
In het eerste deel van het proefschrift  zijn risicofactoren van opvlammingen onderzocht. 
Hoofdstuk 2 beschrijft  de risicofactoren die samenhangen met het optreden van een
opvlamming. Het is gebleken dat patiënten met ANCA gericht tegen PR3 een groter risico 
op opvlammingen hebben dan patiënten met ANCA tegen MPO. In hoofdstuk 3 richtten
we ons dan ook op patiënten met PR3-ANCA geassocieerde vasculitis en de relatie tussen 
PR3-ANCA en het optreden van opvlammingen. Patiënten bij wie PR3-ANCA aantoonbaar 
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bleven gedurende het eerste jaar na diagnose ondanks het verdwijnen van ziekte-activiteit 
hadden een verhoogd risico op een opvlamming. In hoofdstuk 4 hebben we andere merkers
van ontstekingsactivatie in het bloed van patiënten met PR3-ANCA geassocieerde vasculitis 
gemeten. Ook deze merkers van ontstekingsactiviteit identifi ceerden patiënten met een 
verhoogd risico op een opvlamming, maar minder goed dan de PR3-ANCA-antistoff en. 
Patiënten die ANCA positief waren of opnieuw werden hadden verhoogde spiegels van 
ontstekingsmerkers in het bloed. Blijkbaar is er bij deze patiënten een aanhoudende 
onderliggende ontstekingsreactie.
In hoofdstuk 5 en 6 werden twee behandelingen vergeleken. Voor 1996 werden patiënten 
met ANCA-geassocieerd vasculitis behandeld met cyclofosfamide en prednisolon. Vanaf 
1996 werden patiënten aanvankelijk behandeld met cyclofosfamide en 3 maanden na het 
bereiken van remissie omgezet naar het minder schadelijk geachte azathioprine. Een eerdere 
Europese studie heeft  aangetoond dat deze behandelingen tot anderhalf jaar na diagnose 
gelijkwaardig waren. Wij vergeleken de uitkomsten op langere termijn van onze patiënten 
die onderhoudsbehandeling kregen met cyclofosfamide met hen die behandeld werden met 
azathioprine. Er waren geen verschillen in het aantal opvlammingen van ziekte-activiteit. 
Er waren ook geen verschillen in bijwerkingen, met name niet in het aantal patiënten met 
kanker en infecties. Onderhoudsbehandeling met azathioprine en cyclofosfamide lijken dus 
gelijkwaardig.
Het tweede deel van het proefschrift  behandelt matrix metalloproteinases. Dit zijn 
eiwitten die bindweefsel afbreken en daarom belangrijk zijn bij ontstekingsreacties. In 
hoofdstuk 7 hebben wij deze eiwitten aangetoond in nierweefsel van patiënten met 
ANCA-geassocieerde vasculitis. Deze matrix metalloproteinases worden geproduceerd door 
ontstekingscellen en de hoeveelheid hangt samen met de ernst van de ontsteking. Vervolgens 
hebben we in hoofdstuk 8 in bloed en urine matrix metalloproteinases en remmers van matrix
metalloproteinases gemeten. In zowel bloed als urine konden we matrix metalloproteinases 
en hun remmers aantonen, maar de hoeveelheid was niet gerelateerd aan de hoeveelheid in
de nier en ook niet aan de mate van ontsteking in de nier. 
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VERDER ONDERZOEK
In vervolg op bovengenoemd onderzoek en binnen de onderzoekslijn “vasculitis” van het 
UMCG zal ook in de toekomst verder onderzoek gedaan worden naar ANCA-geassocieerde 
vasculitis. Onderzoek dat zich richt op het ontstaan van vasculitis, de verschillende 
onderdelen van het afweerapparaat en merkers die duiden op ziekte-activiteit. Daarnaast zijn 
er op dit moment in Nederland een aantal lopende onderzoeken waarin geprobeerd wordt 
de behandeling van patiënten met ANCA-geassocieerde vasculitis verder te verbeteren. Een 
ervan is een studie waarin langdurige behandeling tot vier jaar na diagnose met azathioprine 
in patiënten met PR3-ANCA geassocieerde vasculitis die ANCA positief blijven wordt 
vergeleken met de standaardbehandeling met azathioprine tot anderhalf jaar na diagnose. 
Het doel hievan is het aantal opvlammingen te verminderen. In een andere behandelstudie 
wordt de eff ectiviteit van MMF (merknaam cellcept) bij een opvlamming vergeleken met 
cyclofosfamide. Hopelijk is MMF even eff ectief als cyclofosfamide en minder schadelijk. 
Tenslotte wordt in een internationale studie rituximab dat een specifi eke ontstekingscel 
remt, de zogenaamde B-cel, vergeleken met standaardbehandeling met cyclofosfamide en 
prednisolon. Dit zou een alternatief bieden voor behandeling met cyclofosfamide.
Ik hoop dat mijn onderzoek en bovengenoemd vervolgonderzoek een bijdrage zal leveren 
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